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Abstract 
The mechanisms involved in breast cancer initiation are not well understood. This may in part 
be due to a lack of an in vitro model that faithfully recapitulates the morphology, phenotype 
and in vivo architecture of the normal human mammary gland. Most in vitro models of normal 
breast have relied on the use of reconstituted basement membrane gels to induce luminal 
epithelial cell polarity and have neglected the role of myoepithelial cells and fibroblasts in this 
process. The aim of this thesis was to develop a three dimensional in vitro culture system of 
normal breast which included three of the major functional cell types of breast embedded in a 
more physiologically relevant collagen I matrix. It was then sought to use the system to 
investigate the mechanisms behind breast cancer initiation via genetic manipulation of well-
known oncogenes and tumour suppressors involved in breast cancer progression. 
To achieve this, myoepithelial cells (Myo1089, originally isolated from breast reduction 
mammoplasty sample, gift of Dr Mike O’Hare) and fibroblasts (isolated and immortalised from 
breast reduction mammoplasty samples collected with ethical approval in house) were 
characterised by immunofluorescence to assess their suitability. Following characterisation, 
these were virally transfected with Turbo Green Fluorescent Protein (tGFP) and dsRed protein 
respectively to enable tracking. Three-dimensional tri-cultures were established in collagen I 
and included the non-tumorigenic luminal epithelial cell line HB2 with GFP Myo1089 cells and 
dsRed fibroblasts. Cells were cultured for three weeks in Transwell™ cell culture inserts. 
Following fixation these were analysed by haematoxylin and eosin staining, confocal 
microscopy and immunohistochemistry. Morphology and immunostaining profiles were 
compared to sections of a normal human in vivo breast tissue specimen.  
Immunohistochemical characterisation using the following antibodies: E-cadherin, epithelial 
membrane antigen, vimentin, laminin 5, collagen IV plus luminal and basal cytokeratins, 
demonstrated polarised epithelial structures with lumen formation and basement membrane 
vii 
 
production with a similar immunostaining profile to normal breast tissue. The importance of 
including myoepithelial cells and fibroblasts in maintaining these structures was 
demonstrated. We established this model was amenable to genetic engineering by 
overexpressing HER2 and HER3 in HB2 cells, and knocking out ERβ1 in Myo1089 cells and 
DOCK4 in fibroblast cell lines using siRNA/shRNA techniques respectively. These were included 
in separate models with morphological and phenotypic effects determined by haematoxylin 
and eosin staining, immunohistochemistry and quantification of HB2 structures formed. We 
further investigated the intracellular signalling cascades stimulated by heregulin in order to 
validate our findings upon overexpression of HER2 and HER3 and to investigate the cancer 
initiation potential of heregulin in the breast. 
In summary, an in vitro model of normal breast tissue that includes three of the major 
functional breast cell types cultured in a physiologically relevant three dimensional matrix has 
been developed. The morphology and protein expression profile of the model was validated 
against a human breast tissue specimen and confirmed that it is a suitable model of normal 
breast. The model proved to be reproducible, suitable for experimentation using genetic 
engineering and cell behaviour could be easily visualised using standard laboratory techniques.  
To conclude, this is a robust in vitro model of normal breast tissue offering an alternative cost-
effective method of studying genes and processes involved in breast cancer initiation. 
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1 Chapter 1: Introduction 
1.1 Normal Breast 
1.1.1 Anatomy 
The female human breast is a complex structure with networks of ducts and glands designed 
for lactation (Fig 1.1 & Fig 1.2). These ducts branch out from the nipple and terminate at 
functional units known as terminal ductal lobular units (TDLU). Lobules are comprised of blind 
ended tubules called acini which are capable of milk secretion. Ducts and lobules are 
surrounded by a fibrous tissue known as the stroma. Ducts, lobules and stroma are all 
embedded within an adipose matrix. Normal breast acini are rich in epithelial cells. These 
comprise two distinct cell lineages; luminal and myoepithelial cells which share a common 
stem/basal parentage. Each acinus contains a layer of luminal epithelial cells arranged around 
a central lumen surrounded by a single layer of myoepithelial cells. These are encased by a 
protein rich basement membrane and are embedded in the stroma (Fig 1.2).  
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Fig 1.1 Diagrammatic representation of the gross anatomy of the adult female breast 
Diagram shows branching network of ducts designed for milk delivery to the nipple. Ducts 
terminate with lobule structures containing multiple acini. These are surrounded by fibrous 
stromal tissue (connective tissue) and adipose tissue (fatty tissue). 
Adapted from http://www.my-breast-cancer-guide.com/what-is-breast-cancer.html  
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Fig 1.2 Representative haematoxylin & eosin stained cross section of normal adult human 
breast tissue.  
a) Cross section of normal human adult breast shows two breast lobules containing multiple 
acini situated adjacent to the terminal ducts. These are surrounded by a fibrous stroma and 
adipose fat tissue. Circle highlights the acinus featured in (b). 
b) Cross section of an acinus showing an internal layer of luminal epithelial cells (L). These are 
surrounded by a layer of myoepithelial cells with clear cytoplasm (M) which sit beneath a 
protein-rich basement membrane shown in dark pink (BM). The acinus is embedded in a 
fibrous stroma containing fibroblasts (F).  
Images courtesy of Prof Andrew Hanby (Leeds Institute of Cancer and Pathology). 
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1.1.2 Epithelial cells of the mammary gland 
Luminal epithelial and myoepithelial cells of the mammary gland have distinct functions and 
protein expression profiles. The main function of luminal epithelial cells is to secrete milk 
during lactation. In order to do this, luminal epithelial cells respond to a variety of hormones 
such as estrogen, progesterone and prolactin [1]. Accordingly, estrogen receptor alpha (ERα) 
[2, 3], progesterone receptor (PR) [4] and prolactin receptor (PrlR) [5] are all specific to luminal 
epithelial cells. However, the expression of hormone receptors is highly dependent on the cell 
environment with a loss of expression common upon in vitro culture. For this reason, luminal 
epithelial cells are more commonly distinguished from myoepithelial cells by their expression 
of cytokeratins 8, 18 and 19 [6, 7] and epithelial membrane antigen (also known as MUC-1) [8].  
The function of myoepithelial cells during lactation is to contract around the acinus and eject 
milk into the ducts [9].  These can be distinguished by their expression of cytokeratins 5 and 14 
as well as vimentin and α-smooth muscle actin (α-SMA) [10-12]. Myoepithelial cells also play a 
role in the formation of the basement membrane that surrounds breast acini. This has been 
proven by their expression of basement membrane proteins such as collagen IV and laminin 
[10, 13]. Myoepithelial cells form distinct desmosomes with both themselves and with luminal 
epithelia and unlike luminal epithelia, form hemidesmosomes and attach to the basement 
membrane [14, 15]. The adhesion properties of myoepithelial cells result in the expression of 
proteins which can be used to further distinguish them from luminal epithelial cells. These 
include desmosomal-specific cadherins such as desmocollin 3 and desmoglein 3 [16, 17] and 
integrins such as β4-integrin [18, 19].   
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1.1.3 Mammary stem cells 
Mammary stem cells (MaSCs) give rise to the luminal and myoepithelial cell lineages described 
above via a series of progenitor cell intermediates [20]. MaSCs reside in the basal region of the 
mammary gland alongside myoepithelial cells [21].  The majority of data available on MaSCs 
has been sourced from studies in mice. The most widely used markers to distinguish MaSCs in 
mice are positivity for CD24 and CD61 (β3-integrin), high expression of CD29 and CD49f (β1- 
and α6 integrin respectively) and no expression of stem cell antigen-1 (Sca-1), estrogen 
receptor (ER), PR, human epidermal growth factor receptor 2 (HER2) and haematopoietic cell 
markers known collectively as Lin [22-25]. Transplantation studies in mice have revealed that 
MaSCs are capable of reforming an entire functional mammary gland from a single cell [22]. 
These give rise to both luminal and myoepithelial cell lineages. MaSCs can be distinguished 
from luminal epithelial cell progenitors and differentiated epithelium using CD24. CD24 
expression is lower (but not lacking) in MaSCs compared with luminal cell lineages [26]. 
However, perhaps due to their shared basal location, MaSCs are much more difficult to 
distinguish from myoepithelial cell lineages as these both share high expression of cell surface 
β1- and α6-integrins and gene expression profiles [23].  
In human breast tissue, both bipotent and unipotent progenitor cell populations have been 
identified. Bipotent progenitors typically have a CD49f high and EpCAM low expression profile 
and are EMA, CD24, and CD133 negative. Unipotent luminal epithelial progenitors are positive 
for CD49f, EpCAM, EMA, CD24, and CD133 [27, 28]. Through serial passaging of bipotent 
progenitors, Stingl et al identified a myoepithelial-restricted progenitor population [27]. More 
recently, a profile for these cells has been identified which is negative for keratins 5 and 19 
with low expression of claudins [29].  
The signalling mechanisms that drive this stem cell hierarchy are largely unclear. Few signalling 
pathways have been identified to induce differentiation down the myoepithelial cell lineage. 
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However, expression of genes such as Gata-3, Elf5, Notch and PML have all been implicated in 
driving a luminal epithelial cell fate [25, 28, 30, 31].  
1.1.4 Stromal cells of the mammary gland 
The stroma is defined as the supportive tissue of an epithelial organ consisting of connective 
tissue and blood vessels [32]. In the breast, the stroma surrounds the ductal-lobular unit and 
contains a variety of cell types. These include vascular endothelial cells lining blood vessels, 
lymphocytes, macrophages and adipocytes [33]. The most abundant cell type within breast 
stroma is fibroblasts. The main function of fibroblasts is to provide structural support to 
epithelial structures. Fibroblasts produce a scaffold of extracellular matrix (ECM) proteins 
which include collagen I [34], fibronectin, and like myoepithelial cells, collagen IV and laminin 
[35]. Due to these apparent overlapping functions of myoepithelial cells and fibroblasts, there 
are few immunohistochemical markers that can distinguish between these cells. Like 
myoepithelial cells, fibroblasts express vimentin. Although fibroblast-specific protein-1 has 
been identified to be specific to fibroblasts [36], it appears that this is a marker of “active” 
fibroblasts [37] and may not be applicable to normal breast. 
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1.2 Breast cancer  
1.2.1 Statistics 
Breast cancer is one of the most commonly diagnosed cancers in the world with an estimated 
1.38 million cases diagnosed worldwide in 2008 [38]. In 2010, over 49,500 women were 
diagnosed with breast cancer in the UK alone with approximately 80% of those aged 50 or 
over. Over the last decade, the incidence of breast cancer in the UK has increased by 
approximately 6% and it is now estimated that a woman has a 1 in 8 risk of developing breast 
cancer in her lifetime. This disease is not limited to women however with approximately 400 
men diagnosed with breast cancer in the UK in 2010 [39]. 
1.2.2 Heterogeneity 
Breast cancer is a highly heterogeneous disease and is categorised into subtypes based on 
morphological features. The World Health Organisation have reported 18 different histological 
subtypes of invasive breast cancer [40]. These can fall into two main categories. Those which 
exhibit unique and easily identifiable morphological features are known as “special type” and 
include invasive lobular, mucinous, tubular and medullary carcinomas. Those which do not 
show any classical morphological features and which vary considerably from case-to-case are 
known as “no special type” and comprise infiltrating ductal carcinomas of no special type (IDC-
NST). It is the IDC-NST group of breast tumours that are the most common form of breast 
cancer and have received the most research interest to date.  
Although these morphologic features correlate with patient prognosis [41], classification of 
breast cancers in this way have been shown to be poorly reproducible with limited clinical 
value by the National Health Service breast cancer screening programme (UK). Breast cancers 
are therefore further classified based on their differentiation and mitotic activity.  The current 
classification system used in the UK is derived from work by Page, Elston and Ellis [42] and is 
based on three parameters. These assess tubular/acinar/glandular formation, nuclear 
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pleomorphism and number of mitotic bodies. Each of these is scored from one to three, a 
summary of how these scores are assigned are summarised below in Table 1.1. 
Score Tubule/Acinar 
Formation 
Nuclear 
Pleomorphism 
Mitotic Index 
(example field 
diameter of 
0.6mm) 
1 >75% of tumour 
exhibit tubular or 
acinar structures 
Small nuclei, little 
variation in size, 
uniform chromatin 
≤10 mitotic bodies 
per field of view 
2 10-75% of tumour 
exhibit tubular or 
acinar structures 
Open vesicular 
nuclei, visible 
nucleoli, variable size 
and shape 
11-20 mitotic 
bodies per field of 
view 
3 <10% of tumour 
exhibit tubular or 
acinar structures 
Vesicular nuclei, 
marked variation in 
size and shape, large 
bizarre forms 
≥22 mitotic bodies 
per field of view 
Table 1.1 Summary of how scores are assigned to the grading parameters outlined by the 
National Health Service breast cancer screening programme for breast tumours 
The scores for tubule formation, nuclear pleomorphism and mitotic index are then added 
together to obtain a total score and overall grade of the tumour as outlined below:  
 Total score of 3-5 = Grade 1 tumour (low grade) 
 Total score of 6-7 = Grade 2 tumour (intermediate grade) 
 Total score of 8-9 = Grade 3 tumour (high grade) 
In addition to the morphologic features discussed, heterogeneity has also been demonstrated 
at a molecular level. The earliest of these studies by Perou et al in 2000 [43] and Sorlie et al in 
2001 [44] identified five main subtypes of IDC-NST based on their gene expression profiles 
(Table 1.2). These subtypes are defined by the expression of the receptors HER2, ER and PR. 
Sorlie et al [44] found that patient outcome significantly correlated with the expression 
patterns of these receptors with Basal and HER2 cancers associated with shortest patient 
survival and Luminal A and B the longest survival time. This classification has enabled more 
efficient pathological diagnosis of breast cancers and is still used to date. 
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Tumour 
Subtype 
Receptor 
Expression 
Tumour 
Characteristics 
Targeted 
Therapies 
Luminal A HER2-, ER+ & PR+/- Low grade, non-
aggressive 
Hormone therapy 
Luminal B HER2+, ER+ & PR+/- Low grade, non-
aggressive 
(worse than 
Luminal A) 
Hormone therapy 
and Trastuzumab 
Basal HER2 –, ER- & PR- High grade, 
aggressive 
None 
HER2 HER2+, ER- & PR- High grade, 
aggressive 
Trastuzumab 
Normal Variable- High 
expression of basal 
and adipose 
markers, low 
expression of 
luminal markers 
Variable None 
Table 1.2 Summary of the Perou classification of IDC-NST based on their receptor expression 
profiles and their correlation with grade and treatment 
Abbreviations: Positive (+), negative (-) 
Recently this heterogeneity has been recognised further with breast cancer now classified into 
at least 10 molecular subtypes [45]. Though this heterogeneity is observed in the epithelial 
component of breast cancers with the majority of breast cancers arising in the luminal 
epithelium, it is becoming increasingly apparent that the surrounding stroma may contribute 
to this [46].   
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1.3 Role of the stroma in breast cancer 
As early as 1975, DeCosse et al demonstrated that an embryonic tissue microenvironment had 
the capacity to cause differentiation of murine mammary carcinomas [47]. The role of the 
tumour stroma has since become a major focus for breast cancer research. This saw the 
advent of several in vitro studies highlighting the role of stromal cells in the enhancement of 
tumour growth and invasion [48, 49]. Conversely, the ability of the normal breast stroma to 
induce malignant cells to take on a non-neoplastic phenotype [50] as well as direct cells from 
foreign organs into a mammary epithelial fate [51, 52], has also been reported.  
Studies using human tissue have reinforced this concept. In 2008, Finak et al identified that the 
surrounding stroma from different breast cancer specimens had different gene expression 
signatures and proved to be a powerful predictor of patient outcome [53]. In addition, the 
expression of ECM related genes has also been linked to patient survival [46].  
Multiple changes in the stroma have been identified and proven to facilitate tumour 
progression. These include: changes in collagen density and mechanical tension [54, 55], 
altered levels of ECM proteins associated with wound healing such as collagens, proteoglycans 
and glycosaminoglycans [33], changes in proteolytic enzymes such as matrix 
metalloproteinases (MMPs) [56, 57] and genetic changes such as loss of heterozygosity [58] 
and somatic mutations [59] exclusive to the stromal component. Although these indicate a 
clear role for the stroma in the progression of breast cancer, these have largely studied the 
stroma as a whole with the roles of each cell type remaining unclear. However, of central 
importance is the role of the fibroblasts which is the main component of the tumour stroma. 
The epithelial cell to fibroblast ratio in normal breast has been estimated at between 2:1 and 
3:1 [60] whereas this is altered in breast tumour stroma with an epithelial cell to fibroblast 
ratio of up to 1:5 reported [61, 62].  
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1.3.1 Fibroblasts and breast cancer 
Many of the changes mentioned above are due to the actions of activated fibroblasts within 
the tumour stroma known as carcinoma associated fibroblasts (CAFs). There are multiple 
theories as to the origin of CAFs. These are that resident fibroblasts are activated by paracrine 
signalling from tumour cells, that mesenchymal stem cells are recruited to the tumour stroma 
and differentiate into fibroblasts [63], or that adipocytes revert to a fibroblast-like phenotype 
in response to paracrine signalling from tumour cells [64]. It is possible that CAFs originate 
from a combination of these sources and may be dependent on the subtype of breast tumour.  
CAFs are a heterogeneous population of cells. A subset of CAFs expressing α-SMA akin to 
fibroblasts associated with wound healing [65] are known as myofibroblasts. Other sub-
populations of CAFs include those that express fibroblast activation protein, Thy-1 and Desmin 
[66]. Significant expression differences have also been reported in CAFs derived from different 
breast tumour subtypes [67].  
It is now well documented that CAFs promote tumour progression. It is widely accepted that 
CAFs mainly exert this influence through secretion of a variety of tumour promoting factors 
which either promote epithelial-mesenchymal transition (EMT) of tumour epithelial cells or 
induce increased vascularisation of tumours. These include hepatocyte growth factor (HGF) 
[68], transforming growth factor receptor-β (TGFβ) and stromal cell derived factor-1 (SDF-1) 
[69]. In addition to CAF influence via paracrine signalling, CAFs also have the capacity to induce 
the changes to the ECM of tumours mentioned in section 1.3 above through production of 
ECM proteins, remodelling collagen fibrils and release of MMPs.   
1.3.2 The importance of myoepithelial cells in breast cancer 
One key feature of progression from the non-obligatory benign precursor lesion ductal 
carcinoma in situ (DCIS, discussed in section 1.4.2) to invasive cancer is the loss of the 
myoepithelial cell layer. This has indicated that myoepithelial cells may play a tumour 
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suppressor role. Both in vitro and in vivo studies have demonstrated that myoepithelial cells 
have the capacity to inhibit tumour growth. Hu et al showed that co-injection of myoepithelial 
cells with MCFDCIS.com cells in a xenograft mouse model suppressed the transition of DCIS 
lesions to invasive carcinoma [70]. One of the hallmarks of breast cancer progression is the loss 
of normal tissue architecture and polarity. Myoepithelial cells are proven to maintain normal 
luminal epithelial polarisation and architecture and do so via production of laminin [17, 71]. In 
addition to their effects on cell arrangement, myoepithelial cells express a number of tumour 
suppressor proteins such as maspin, structural ECM proteins such as fibronectin, proteinase 
inhibitors such as tissue inhibitor of metalloproteinase-1 (TIMP1) and angiogenic inhibitors 
such as thrombospondin-1 [72, 73]. The result of this is to counteract the tumour promoting 
effects of the surrounding stroma, to build ECM rather than degrade it and thus have a 
“containment” effect on malignant cells within ducts. Myoepithelial cells derived from DCIS 
containing breast tissue have an impaired ability to polarise luminal epithelial cells [71] and 
differ in their gene expression pattern [74]. It is clear from these studies that myoepithelial 
cells are a vitally important component in the prevention of tumour invasion. Surprisingly, 
these cells are largely understudied and the mechanisms leading to obliteration of the 
myoepithelial cell layer during invasion is unknown.  
13 
 
1.4 Benign breast disease  
The vast majority of lesions that arise in the breast are benign. The term benign breast disease 
encompasses a heterogeneous group of lesions which exhibit unique morphological features. 
The most frequent subgroup of benign lesions is termed fibrocystic changes (FCCs). These are 
detected in nearly all of the female breast reduction mammoplasty samples examined 
[personal communication, Prof Andrew Hanby, Leeds Institute of Cancer and Pathology] with 
the majority not incurring increased risk of breast cancer. There are a variety of subtypes of 
FCCs. Historically, these have been categorised as non-proliferative lesions, proliferative 
lesions without atypia and proliferative lesions with atypia [75]. For the purpose of this thesis, 
only proliferative benign lesions will be discussed. 
The most common proliferative benign lesions of the breast occur in the epithelium. The use of 
terminology such as “hyperplasia” clouds the understanding of the biology of these lesions. For 
example, usual ductal hyperplasia consists of a polyclonal benign proliferation of cells which 
are not neoplastic while lobular hyperplasia represents a monoclonal neoplastic proliferation. 
For purpose of discussion here, proliferative benign lesions will therefore be categorised into 
non-neoplastic and neoplastic for clarification. Example images of these lesions can be found 
in Fig 1.3. 
1.4.1 Non-neoplastic benign lesions 
Usual Type Ductal Hyperplasia  
As discussed, in the normal breast, ducts are lined by a single layer of secretory luminal 
epithelium surrounded by a contractile layer of myoepithelium. Historically, epithelial 
hyperplasia has been defined as an increase in number of cells within the ductal space. 
Aberrant proliferation of the luminal epithelium (usually in response to environmental cues 
such as systemic hormones) can occur resulting in lumen filling within the ducts. When these 
proliferating cells do not induce distortion of architecture of the ductal space, these are 
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denoted usual ductal hyperplasia (UDH). These can be graded as mild whereby the luminal cell 
layer is three to four cells thick, moderate if the layer is more than four cells thick or florid if 
the lumen is considerably distended or obliterated. Historic works have implied a neoplastic 
character to these lesions; however, there is little evidence to confirm this. Typically, 
immunohistochemistry for cytokeratin markers will show a mixture of cells with both luminal 
and myoepithelial phenotype [76]. This is uncharacteristic of “true” neoplasia which consists of 
a uniform cell population. Cytogenetic analysis of these lesions have demonstrated 
abnormalities such as loss of heterozygosity and chromosomal alterations such as losses at 1p, 
16p, 17q and 22q as well as amplification in 20q [77-79], some of which are also conserved in 
atypical ductal hyperplasia (ADH) [80]. However, these genomic alterations are usually rare 
and randomly distributed. 
Columnar cell lesions  
Columnar cell lesions are characterised by dilation of the acini of TDLUs lined by columnar 
epithelial cells. These can be divided into two broad subgroups: columnar cell change which is 
non-neoplastic and columnar cell hyperplasia which are neoplastic (discussed in section 1.4.2). 
Both these subgroups are further classified by the presence or absence of cytological atypia 
[81]. Lesions classified as columnar cell change feature one or two layers of columnar epithelial 
cells with ovoid nuclei orientated perpendicular to the acini basement membrane. These cells 
may feature “snouts” and lesions sometimes feature calcification [82]. Unlike UDH, cells of 
columnar cell change are predominantly luminal in phenotype, are ER and PR positive but 
negative for myoepithelial cytokeratins and HER2 [76]. Albeit with a limited sample size, in 
2006, Dabbs et al demonstrated that columnar cell change lesions show no loss of 
heterozygosity [83]. Patients with columnar cell change lesions are considered to have a low 
risk of developing breast cancer and it is generally recommended that patients with these 
lesions require no clinical intervention [84].  
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1.4.2 Neoplastic benign lesions 
Flat Epithelial Atypia  
Flat epithelial atypia (FEA) are a type of columnar cell hyperplasia that exhibit cytological 
atypia. These generally consist of more than two layers of columnar epithelial cells and unlike 
columnar cell change lesions, lining epithelia have an increased nuclear-cytoplasmic ratio with 
round nuclei not orientated perpendicular to the basement membrane [85]. These may form 
small micropapillae and commonly form snouts with luminal secretions and calcification. Like 
columnar cell change lesions, FEA lesions have luminal characteristics, express ER and PR and 
do not feature cells with a myoepithelial phenotype or that express HER2 [81]. These 
commonly feature a loss of heterozygosity at chromosomes 16q, 17p and X and gains on 15q, 
16p and 19 [58, 76]. FEA lesions are reported to be associated with only a slight increase in risk 
of developing breast cancer [86] and thus their clinical management is still under intense 
debate.   
Atypical ductal hyperplasia  
Unlike UDH, atypical ductal hyperplasia (ADH) usually features a uniform population of luminal 
type proliferative cells [87, 88]. Like FEA, these are usually ER positive, negative for 
myoepithelial markers and tend to only occupy small ducts of <2mm [89]. Women who have 
ADH are four to five times more likely to develop breast cancer and usually do so 10 to 15 
years post diagnosis [90]. This risk is one-two times for UDH [91]. In 2008, Xu et al 
demonstrated that ADH lesions feature up to five times more chromosomal alterations than 
UDH [92]. These share many of the chromosomal alterations with FEA with loss of 16q being 
the most characteristic and most reported alteration [76, 78]. Chromosome 16q contains the 
E-cadherin gene CDH1 [93] but does not always correlate with a loss of E-cadherin protein 
expression [94].  
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Ductal carcinoma in situ 
Ductal carcinoma in situ (DCIS) is defined as the proliferation of cells with features of 
malignancy with no evidence of basement membrane penetration [95]. Like ADH, proliferation 
of cells occurs within lumen of ducts and acini and results in the loss of a hollow lumen and 
distortion in duct and acini architecture. The morphological differences between ADH and 
some cases of DCIS are subtle and are often only distinguished by the size of the lesion.  
DCIS can be categorized into seven groups based on their morphologic features: cribriform 
(malignant cells oriented to leave a glandular lumen), papillary (malignant cells form large 
papillations into luminal space), micropapillary (malignant cells form smaller finger-like 
protrusions into luminal space) and solid (malignant cells fill the ductal space), apocrine 
(consist of large cells with abundant eosinophilic cytoplasm and large nuclei), flat and other. In 
the UK, these are further classified as high, intermediate or low grade based on cytonuclear 
features and the presence of comedo necrosis. High grade DCIS feature highly mitotic cells 
with large irregularly spaced pleomorphic nuclei cells and often contain areas of necrosis and 
calcification. Low grade DCIS are much more similar to ADH featuring uniform small and 
rounded cells with small nuclei, few mitoses with little necrosis. Intermediate grade DCIS show 
moderate pleomorphism of nuclei which are larger than in low grade DCIS with a high nuclear 
to cytoplasmic ratio [96].  
Examination of biologic features can distinguish DCIS from other benign breast lesions. These 
include chromosomal imbalances with loss of heterozygosity reported in more than 70% of 
high grade DCIS cases as opposed to 42% in ADH [78]. The presence of molecular markers such 
as HER2 also differentiates DCIS from ADH.  Overexpression of the HER2 protein has been 
identified in up to 50% of DCIS cases [97] with no evidence of overexpression in cases of ADH 
[98]. Diagnosis of DCIS confers a strong risk of developing breast cancer in the future. 
Retrospective studies have shown that 30% of DCIS lesions will progress to breast cancer [99, 
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100]. Current thinking is that cells within DCIS lesions acquire further genetic abnormalities 
conducive to cell migration and invasion such as loss of E-cadherin [101]. These become 
capable of penetrating through the basement membrane and invading into the surrounding 
stroma. This process is aided by proteinases such as MMPs [102] and is associated with a loss 
of the myoepithelial cell layer [13]. This theory is supported by the fact that greater than 95% 
of breast cancers are of luminal epithelial origin. In addition, DCIS lesions have been 
demonstrated to exhibit some of the heterogeneity of IDC and can often be categorised into 
the Perou subtypes of breast cancer discussed in section 1.2.2.  
Lobular Lesions 
Unlike ductal lesions, lobular epithelial lesions are less heterogeneous exhibiting a similar 
morphology and are collectively termed lobular neoplasia. Like ductal hyperplasia, epithelial 
cells proliferate uncontrollably to fill luminal spaces but do so in the acini of the lobules. In 
1941, Foote and Stewart defined lobular neoplasia as a monomorphic population of cells that 
arise from and expand the TDLU and spread through the ductal system [103]. Lobular 
neoplasia can be subdivided into atypical lobular hyperplasia (ALH) and lobular carcinoma in 
situ (LCIS) (see Fig 1.3 for examples). These have very subtle differences and are generally only 
distinguished by the extent of epithelial cell proliferation and distension of the lobular unit. 
When less than one half of the acini of a given lobule are affected, the term ALH is used. When 
more than half are affected, this is classed as LCIS. The cells within these lesions as mentioned 
are uniform, usually small and round and have a high nuclear-cytoplasmic ratio. They may also 
contain clear vacuoles [104].  The risk of developing breast cancer differs with these lesions as 
women with ALH are four to five times more likely to develop breast cancer whereas this 
increases to eight to ten times more likely with LCIS [105].  
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Fig 1.3 Histology of benign lesions of the breast 
Example images of H & E stained breast tissue specimens containing benign lesions.  
(a-b) Non-neoplastic benign lesions include usual ductal hyperplasia and columnar cell change. 
Usual ductal hyperplasia lesions (UDH, a) consist of lumens filled with small rounded cells. 
Non-neoplastic columnar cell change lesions feature two layers of columnar shaped epithelial 
cells with ovoid nuclei orientated perpendicular to the basement membrane (arrow, b).  
(c-g) Neoplastic benign lesions include flat epithelial atypia, atypical ductal hyperplasia and 
DCIS. Flat epithelial atypia lesions feature multiple layers of epithelial cells with rounded nuclei 
not perpendicular to the basement membrane (arrow, c). Atypical ductal hyperplasia lesions 
contain uniform populations of proliferative epithelial cells (d). Example of an intermediate 
grade cribriform ductal carcinoma in situ (DCIS) lesion without comedo necrosis which feature 
multiple layers of epithelial cells with pleomorphic nuclei (PN, e) surrounded by spindle-
shaped myoepithelial cells (M, e) and an intact basement membrane (BM, e). Example of a 
high grade solid pattern DCIS lesion with comedo necrosis which feature pink necrotic material 
(necrosis, f) and multiple layers of epithelial cells which are large, irregularly spaced and highly 
pleomorphic (inset, f). Lobular carcinoma in situ lesions consist of small rounded epithelial cells 
with a high nuclear-cytoplasmic ratio (g).  
Images courtesy of Prof Andrew Hanby (Leeds Institute of Cancer and Pathology)  
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1.5 Evolution of breast cancer from preinvasive lesions 
Histological and epidemiological evidence over the last century has resulted in the proposal of 
a linear model of breast cancer progression. This is that an initiating event occurs in the 
luminal epithelium of normal breast and results in FEA. This therefore proposes that FEA is the 
earliest stage of preinvasive ductal carcinoma. A growth advantage of the cells of FEA is then 
thought to result in the development of ADH which then spreads and is classified as DCIS. 
When these cells gain the ability to breach the basement membrane, this gives rise to IDC 
[106]. Genomic and transcriptomic analysis of benign breast lesions largely support this 
hypothesis but have also proposed that this may be specific to the progression of low grade 
IDC.  It is now thought that low grade IDC and high grade IDC have distinct pathways of 
progression which has led to the categorisation of low grade neoplasia and high grade 
neoplasia families.  
FEA, ADH and DCIS have been reported to occur in the same breast [107]. This has indicated 
that these lesions are related and may represent an evolutionary continuum. This is supported 
by the fact that FEA, ADH and low grade DCIS all have overlapping morphological and 
immunohistochemical features [108, 109]. All these lesions share an ER positive, PR positive 
and HER2 negative profile [110, 111]. Perhaps the most striking evidence for the existence of a 
low grade neoplasia “family” has been gained through genomic and transcriptomic analysis. All 
these lesions have shared genomic alterations, the most frequently reported of which are a 
gain in 16p and 17q and a loss in 16q and 17p [58, 76, 83]. These alterations have been shown 
to correlate with low grade IDC and coupled with the ER/PR/HER2 profile suggest that FEA, 
ADH and low grade DCIS are precursor lesions for low grade luminal IDC [43, 76].  
Until recently, it was thought that there was no precursor lesion to high grade DCIS. However, 
it is now proposed that microglandular adenosis (MGA) may be a precursor to high grade DCIS 
and IDC. These lesions often occur in association with IDC [112, 113]. The vast majority of 
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these lesions are ER, PR and HER2 negative [114] and share genetic aberrations with high 
grade DCIS and IDC such as loss of 17q [115, 116]. High grade DCIS and IDC possess uniquely 
different gene expression patterns to the low grade neoplasia family. These profiles are 
associated with mitotic activity and are generally ER and PR negative and may be HER2 positive 
or negative [76, 109]. Chromosomal alterations of high grade DCIS and IDC also differ from the 
low grade neoplasia family with gains in 8q and 17q and loss of 13p reported [77]. 
 Regardless of the specific pathway, the concept that DCIS is a non-obligatory precursor for IDC 
is widely accepted. Nearly all breast cancers are accompanied by DCIS [117] and progression of 
DCIS to IDC has been demonstrated in mouse models [118]. 
A summary of the low grade and high grade pathways to IDC is provided in Fig 1.4 
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Fig 1.4 Summary schematic of the proposed low grade and high grade pathways to breast cancer 
Low grade pathway involves a linear progression through the benign breast lesions flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), low grade 
DCIS and results in luminal type invasive ductal carcinoma (IDC). These are estrogen receptor (ER) and progesterone receptor (PR) positive (+ve). The high 
grade pathway may initiate with microglandular adenosis (MGA) leading to high grade DCIS which if are human epidermal growth factor receptor 2 (HER2) 
positive leads to HER2 IDC but if are HER2 negative (-ve) leads to basal IDC. These are ER and PR negative.
FEA 
Low grade 
DCIS 
ADH 
Luminal A/B 
IDC 
Normal Breast 
 MGA 
High grade 
DCIS 
HER2 IDC Basal IDC 
Low Grade Pathway High Grade Pathway 
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1.6 Cell of origin of breast cancer 
The origin of aberrant epithelium in all these conditions is still under debate. Two theories 
have been suggested. These are the sporadic clonal evolution model and the cancer stem cell 
model.  
The sporadic clonal evolution model proposes that any epithelial cell can acquire genetic 
mutations and those which confer a growth advantage are selected over time and contribute 
to tumour progression [119]. Since epithelia of normal breast are known to harbour genetic 
changes also, it is plausible that a random combination of these may sporadically induce 
aberrant proliferation and tumorigenesis [120, 121].  
The cancer stem cell model proposes that the self-renewal properties of stem cells and their 
propensity to remain in the tissue for long periods of time means that they are more likely to 
accumulate genetic and epigenetic modifications [122, 123]. It is thought that these cells 
undergo asymmetric division to both self-renew and produce progenitor cells that give rise to 
different breast cancer subtypes [124, 125]. An alternative hypothesis is that it is the 
progenitor cells that are the cell of origin for certain subtypes of breast cancer. Luminal 
progenitors have been shown to have a similar genetic signature to HER2 and BRCA1 basal 
breast tumours [126-128]. In this scenario, it is thought that the mature differentiated luminal 
epithelia give rise to the less aggressive luminal subtypes of breast tumours.  
1.7 Preclinical in vitro models of breast cancer 
The highly heterogeneous nature of breast cancer poses a challenge to researchers when 
attempting to model it in the laboratory, with one single experimental system unlikely to be 
able to recapitulate this. As a result, a variety of models are used to fully dissect the complex 
signalling pathways involved in breast cancer initiation and metastasis. One of the biggest 
challenges researchers face is finding a relevant model that allows manipulation of genes and 
proteins in a controlled laboratory environment while accurately reflecting the characteristic 
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features of human breast tissue and tumours. Numerous models have been developed which 
have aided our understanding of breast disease progression. These range from simple cell lines 
grown in two dimensions used to aid discovery of cell signalling pathways, to complex in vivo 
systems, typically mouse, used for validation of drug response and metastasis studies. With 
the amount of different models available for breast cancer research increasing (each with their 
own advantages and disadvantages), choosing the right model to address specific biological 
questions becomes increasingly complex. For the purpose of this thesis, only in vitro models 
will be discussed. However, it is recognised that in vivo mouse models play an integral role in 
breast cancer research. A summary of their suitability to different areas of breast cancer 
research can be found in our published review book chapter of pre-clinical models of breast 
cancer [129]. 
1.7.1 Two dimensional (2D) in vitro models 
The simplest and most commonly used method of investigating breast cancer biology is the 
use of cell lines grown in vitro in 2D on tissue culture plastic. Several different cell lines 
representing the molecular subtypes of breast cancer defined by Perou et al [43] are available, 
a selection of which are summarized in Table 1.3. Cell lines representative of DCIS include 
SUM225 [130] and MCF10DCIS.com [131] have enabled studies of early breast lesions. In 
addition, advances have been made in the isolation of breast cancer stem cells offering 
researchers good models to understand stem cell biology [Reviewed in 132]. It is yet to be 
established whether existing breast cancer cell lines can represent the heterogeneity of breast 
cancer highlighted by Curtis et al [45]. Cell lines have many advantages in that they are readily 
available, easy to propagate and are amenable to genetic manipulation. Further details on 
their biology and provenance can be found in some excellent reviews [Reviewed in 133, 134, 
135]. However, it is increasingly acknowledged that a major problem with 2D culture is a loss 
of polarity and the lack of extracellular cues known to regulate breast tissue architecture in 
vivo [136]. While convenient, 2D culture cannot recapitulate in vivo conditions. Cells are highly 
25 
 
sensitive to their environment and even defining the appropriate culture media to retain their 
in vivo phenotype remains a challenge. For this reason, more sophisticated systems are 
required to assess cell behaviour that take into account the surrounding cell 
microenvironment. 
Cell Line Biomarker 
Expression 
Representative 
Breast Cancer 
Sub-group 
MCF-7 ER+,HER2-, 
ki67Lo 
Luminal A 
ZR-75 ER+,HER2+, 
ki67Hi 
Luminal B 
MDA-MB-468 ER-,PR-, HER2-
, ki67Hi 
Basal 
SKBR3 ER-,PR, 
HER2+, ki67Hi 
HER2 
MDA-MB-231 ER-,PR-, HER2-, 
ki67Lo, ClaudinLo,   
E-CadherinLo 
Claudin-low 
Table 1.3 Examples of breast cancer cell lines and their molecular classification 
Abbreviations: positive (+), negative (-), high expression (Hi) and low expression (Lo) 
 
1.7.2 Three dimensional (3D) in vitro models 
As discussed, the cell microenvironment plays a pivotal role in maintaining epithelial cell 
morphology and phenotype. This has led to a move towards developing methods of culturing 
cells in 3D. For several decades, a simple approach has been taken whereby single cell types 
have been cultured in 3D but have proven remarkably similar to aspects of differentiated 
tissues [137, 138]. The simplest form of 3D in vitro model developed takes advantage of the 
fact that many cell types have the propensity to aggregate together. This can be achieved 
through various methods including rotary cell culture [139] and hanging drop cell culture [140] 
and typically results in cell spheroids. These can be mono- or multicellular depending on the 
research question. Typically, these are used for modelling growth and invasion of solid 
tumours [141, 142]. These are advantageous in that they are easily applied to high-throughput 
screens [143] and are thus valuable for anti-cancer drug screening and testing [144]. The use of 
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spheroids has also revolutionised research into mammary stem cell biology which are easily 
analysable and quantifiable [145-147]. However, spheroid cultures lacks influence from the 
surrounding ECM and may not accurately reflect tissue in vivo.   
Alternatively, cells can be cultured in 3D in the presence of an in vivo-like ECM. Two methods 
are commonly used to generate 3D acini-like structures. The “embedding” technique involves 
completely embedding epithelial cells in an ECM. Epithelial cells are pre-aggregated through 
centrifugation or rotary culture and then suspended in liquid ECM solution and then gels left to 
set or, single cells can be suspended in the ECM solution before setting permitting organisation 
of the cells in 3D matrix. Once embedded, gels are layered with culture media and can either 
be left fixed to the bottom of the cell culture plastic, or, be freed and allowed to float in 
culture media [148] or suspended using Transwell® inserts [149]. Another commonly used 
method is the “overlay” technique whereby cells are seeded onto a bed of ECM gel and may 
be layered with culture media with diluted ECM [150]. The types of ECM material available and 
the choice of cells to include in models such as these will be discussed in Chapter 3.  
There are several advantages to culturing cells in a 3D ECM. A comprehensive study by Kenny 
et al [151] demonstrated that the culture of different breast tumour cell lines in ECM to some 
extent mimicked the heterogeneity of breast cancers in vivo. The phenotypes of these cultures 
even correlated with the different sub-groups of breast cancer highlighted in Table 1.2. 
Mammary luminal epithelial cells respond to ECM by forming acini-like structures [152] which 
resemble in vivo breast. Changes in polarisation and disruption of these acini-like structures 
are factors that can be used to distinguish between non-transformed and transformed cells 
which are not apparent in 2D [153, 154]. The use of 3D in vitro cultures enables the researcher 
to tightly control the condition of the surrounding microenvironment and tailor the cultures to 
address specific hypotheses. By culturing tumour cells with specific ECM constituents, in vivo 
cell-cell and cell-ECM interactions can be represented in the laboratory [155]. Such studies 
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have shed light on the various cell surface molecules important for cell-ECM interactions such 
as Tetraspanin CD151 [156] and α6, β1- and β4-Integrins [50]. Another benefit of culturing 
cells in 3D ECM is the ability to study cell migration and locomotion in a physiologically 
relevant context. 3D in vitro cultures in ECM have helped elucidate novel mechanisms of cell 
migration such as collective cell migration [157] with ECM proving to control motile properties 
of cells [158]. These have also facilitated the discovery of key cell surface signalling proteins 
important for cell invasion. These include desmosomal cadherins, e-cadherin and 
carcinoembryonic antigen-related cell adhesion molecule 1 [17].  These interactions can be 
studied in conjunction with intracellular signalling pathways to better our understanding of the 
link between extracellular environment and cell transformation. Signalling molecules such as 
PI3K and PTEN have been studied in this manner [159]. What’s more, like 2D cultures, 3D in 
vitro cultures are amenable to genetic manipulation. These have identified novel mechanisms 
of action for various tumour suppressors and oncogenes. Examples include the tumour 
suppressors NM23-H1 [160, 161], retinoblastoma [162], AZU-1 [163] and dystroglycan [164] 
and oncogenes such as HER2 [165]. 3D cultures also have the potential for genetic 
manipulation via RNAi techniques facilitating further study of complex signalling pathways. 
New technologies being developed are also providing platforms to study processes such as 
breast cancer metastasis in a complex 3D in vitro tri-culture context through the use of 
microfluidics [166]. The resemblance of 3D in vitro cultures to mammary acini morphology and 
biology provides new opportunities to study cancer initiation mechanisms which may not have 
been possible with 2D cultures. The establishment of culture systems that accurately resemble 
disease-free breast tissue architecture hold the key to investigating the subtle changes that 
occur during the early stages of tumorigenesis. This is a field that is largely unexplored but has 
recently been recognised internationally by panel of expert breast cancer scientists and 
healthcare professionals to be of great importance to our understanding of breast cancer 
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progression and the development of preventative treatments [167]. The current disease-free 
3D in vitro models available will be further discussed in Chapter 3.  
Potential disadvantages of 3D cultures include difficulty in tracking different cell populations in 
models consisting of multiple cell types. Labelling individual cell types with tracker dyes prior 
to incorporation into 3D culture allows cells to be tracked, but many of the cell tracker 
reagents available for this purpose are only stable for relatively short periods of time [149]. For 
longer term experiments, this can be overcome by stable transduction with proteins such as 
Enhanced Green Fluorescent Protein. However, this aside, including just one or two cell types 
still does not account for influences imposed by adipose cells, immune infiltrates and cues 
from vascular endothelium which exists in vivo.  
One of the biggest challenges with the use of 3D in vitro cultures is the subsequent analysis 
and quantification of observations. Biochemical analysis is problematic due to difficulties in 
separating cells from the surrounding ECM [168]. Imaging of these cultures requires 
specialised and often not readily available equipment due to the necessity of an excellent 
signal to noise ratio, optical sectioning ability, good spatial resolution and ample penetration 
of thick specimens [169]. In addition, collagen ECM causes considerably background 
fluorescence making visualisation of collagen based cultures even more challenging [170]. This 
can be overcome by the use of multiphoton microscopy [171] or optical coherence/projection 
tomography [172, 173] but can be both expensive and time consuming. However, recent 
technological advances have been made and have proven that 3D co-culture models can not 
only be cultured for long periods of time (up to 23 days) but can also be imaged in real time to 
observe cell to cell interactions [174].  
The obvious limitation of all 3D in vitro models is the lack of a complex in vivo system complete 
with blood supply, immune infiltrates and regulation by hormonal cues. This limits these 
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models to the study of cell interactions and signalling pathways. In order to study tumour 
progression and metastasis, animal models are required.  
1.7.3 Ex vivo culture 
An alternative in vitro approach developed more recently employs small fragments of breast 
tumours embedded in collagen I and grown in 3D [175]. This has allowed tamoxifen-sensitivity 
to be determined [176] suggesting that the model could prove valuable in assessing drug 
responses of individual patients. Allied to this is the tissue slice model [177], in which we have 
shown that 250µm tissue slices can be maintained in a viable native state for up to seven days 
post-surgery [178]. The ability to culture intact human tissue as outlined in these two models 
could provide an opportunity to validate new drugs on human tissue with fewer ethical 
implications which are associated with animal models. One could foresee the benefits of pre-
testing patient samples with a range of drug therapies via ex vivo culture enabling a more 
accurate and individual treatment regime to be developed. Models such as these could 
improve current 3D models and start to bridge the gap between laboratory research and 
clinical practice.  
1.7.4 Summary of pre-clinical in vitro models of breast cancer 
Due to the complexity and heterogeneity of breast cancer there is no single model that can 
fully recapitulate all aspects of the breast microenvironment. Given this diversity, it is likely 
that not only different models will be required to simulate breast tumours, but that multiple 
different cell types with a variety of genetic aberrations will need to be included. While cell 
lines grown in 2D have contributed much to our understanding of breast cancer biology, it is 
now clear that 3D systems are more biologically relevant. However there is still a need to 
refine current 3D in vitro models to encompass multiple components of the breast 
microenvironment. 3D in vitro models of normal breast in particular are limited and often omit 
key functional cell types of normal breast. This will be discussed further in Chapter 3.  
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Hypothesis & Aims 
A three-dimensional in vitro model of normal breast can be achieved in the laboratory that 
includes three of the major functional cell types of breast in a physiologically relevant matrix 
and accurately reflects the morphology and phenotype of normal human in vivo breast tissue. 
Such a model could be used as a tool to study breast cancer initiation.  
Specific aims were to: 
 Optimise a three dimensional in vitro breast culture system that contained normal 
luminal epithelial cells, myoepithelial cells and fibroblast cell lines in the physiologically 
relevant matrix collagen I 
 Validate the model by comparing morphology and phenotype to a human breast 
reduction mammoplasty specimen 
 Prove that the model was amenable to cancer initiation studies by genetic engineering 
in both the luminal epithelium and the stromal components  
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2 Chapter 2: Materials and Methods 
This chapter details methods used throughout this project that are common to all or more 
than one results chapter. Chapter specific methods can be found in the corresponding chapter. 
2.1 Cell Culture 
A list of all the cell types used throughout this project, where they were obtained, appropriate 
references (if applicable) and how they were maintained and passaged are summarised in 
Table 2.1. All cells were maintained at 37oC in humidified incubators and 95% air and 5% CO2 
and passaged when 70-80% confluent. All cells were cultured using vented cap cell culture 
flasks (Corning). Multiple cryovials (Nuncbrand) of cells at earliest possible passage were 
frozen down as stocks in liquid nitrogen. These were frozen in 90% heat inactivated foetal calf 
serum (HI-FCS) with added 10% dimethyl sulphoxide (Sigma). Cells that were cultured beyond 
20 passages from their first use were discarded and replaced with a new stock vial. All cells 
were regularly tested for mycoplasma infection (Lonza mycoplasma test kit) and no cells used 
in this project tested positive. With the exception of fibroblasts isolated in house, all cell types 
used were Short Tandem Repeat (STR) profiled courtesy of the in house Genomics facility 
(Leeds Institutes of Molecular Medicine) to confirm identity of cell lines used and no cellular 
cross-contamination was detected. Phase contrast images were taken using an Olympus CKK41 
microscope with an Olympus Camedia C-7070 camera attached. Details of the microscope 
used to take fluorescent images will be provided in appropriate results chapters.    
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Cell Type Source and reference Medium Used Passage Protocol 
HB2 ECACC (Cat No. 10081201) 
Ref: [179] 
DMEM+GlutaMAX
TM
 I  (Invitrogen)  
+ 10% HI-FCS 
+ 10µg/mL Insulin 
+ 5µg/mL Hydrocortisone 
Cells washed with DPBS (Invitrogen), 0.1% EDTA in DPBS added for 5 
mins. 0.5% Trypsin/EDTA (Invitrogen) added for ~2mins and cells 
resuspended in medium. Cells were centrifuged at 290 x g for 3 mins, 
pellet resuspended in medium and replated at a 1:25 dilution 
HER2 and HER3 
overexpressing 
HB2 cells  
Gift of Dr Fedor Berditchevsky 
(University of Birmingham) 
Unpublished. 
As per HB2 As per HB2 
Myo1089 Gift of Prof Mike O’Hare 
(Ludwig Institute, London) 
Ref: [149] 
Nutrient Mixture HAM F-12 (Sigma) 
+ 10% HI-FCS 
+ 5µg/mL Hydrocortisone 
+ 10µg/mL Insulin 
+ 10ng/mL Epidermal Growth Factor 
As per HB2. Cells replated at 1:10 dilution. Regularly purified using β4-
Integrin coated Dynabeads (see section 2.2) 
GFP Myo1089 & 
dsRed Myo1089 
Generated in house from 
Myo1089 (see Chapter 3) 
As per Myo1089 As per Myo1089 
MCF10A ATCC (Cat No. CRL 10317) 
Ref: [180] 
Advanced DMEM F12 (Invitrogen) 
+ 5% Horse Serum 
+ 5µg/mL Hydrocortisone 
+ 10µg/mL Insulin 
+ 10ng/mL Epidermal Growth Factor 
+ 50µg/mL Cholera Toxin 
As per HB2. Cells replated at 1:4 dilution. 
HMFU19 Gift of Prof Mike O’Hare 
(Ludwig Institute, London) 
Ref: [181] 
DMEM+GlutaMAX
TM
 I  (Invitrogen)  
+ 10% HI-FCS 
 
Cells washed with DPBS, 0.5% Trypsin/EDTA added for ~2mins and 
cells resuspended in medium. Cells were centrifuged at 290 x g for 3 
mins, pellet resuspended in medium and replated at a 1:10 dilution 
SkBr3 ATCC (Cat No. HTB-30) 
Ref: [182] 
As per HMFU19 As per HMFU19. Cells replated at a 1:3 dilution 
Primary and 
hTERT fibroblasts 
Isolated in house (see Chapter 
3) 
As per HMFU19 As per HMFU19. Cells replated at a 1:4 dilution 
Table 2.1 Details of source, media conditions and maintenance of cells used throughout this study
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Table 2.1 Abbreviations: HI-FCS- Heat-inactivated foetal calf serum, DPBS- Dulbeccos Phospho 
Buffered Saline, EDTA- Ethylenediaminetetraacetic Acid 
2.2 Purification of Myo1089 and MCF10A cells using β4-Integrin 
coated beads 
Pan Mouse IgG Dynabeads (1.5 x 105, Invitrogen) were washed in 1mL sterile filtered 
Dulbeccos Phospho Buffered Saline (DPBS, Invitrogen) + 0.1% bovine serum albumin (BSA) and 
pulled out of solution via a Magnarack (DRI Ltd). Wash was repeated twice before Dynabeads 
were resuspended in 0.5mL DPBS + 0.1% BSA. β4-Integrin antibody (5µg/mL, Clone 3E1, 
Millipore) was added to the resuspended Dynabeads before solution was rotated for 18 hours 
at 4oC. Cells were trypsinised as per Table 2.1, counted using a haemocytometer and 1.5 x 105 
cells centrifuged at 290 x g for 3 mins.  Cells pellet was resuspended in 1mL DPBS + 0.1% BSA. 
β4-Integrin coated Dynabeads were washed 3x with 1mL DPBS + 0.1% BSA using a Magnarack. 
β4-Integrin coated Dynabeads were pulled out solution and resuspended in 1mL of cell 
solution. Cells were rotated with the β4-Integrin coated Dynabeads for 30 mins at 4oC. β4-
Integrin coated Dynabeads were pulled out of solution using a Magnarack and supernatant 
containing β4-Integrin negative cells was retrieved. β4-Integrin coated Dynabeads were 
resuspended in 1mL DPBS + 0.1% BSA and process repeated twice to separate β4-Integrin 
negative and positive cell populations. β4-Integrin coated Dynabeads were resuspended in 
3mL DPBS + 0.1% BSA and both β4-Integrin negative (if required) and positive cell populations 
centrifuged at 290 x g for 3 mins. Cells were resuspended in appropriate medium (see Table 
2.1) and plated out into vented cap cell culture flasks (Corning) before incubation at 37oC and 
95% air and 5% CO2.  
2.3 3D gel culture 
Rat Tail Collagen I (BD Biosciences) was diluted with DPBS to achieve a 2mg/mL collagen 
concentration (previously optimised [149]) and mixed with the following: eight parts of 
collagen solution (2mg/mL) was added to one part 10x Hanks Buffered Salt Solution (HBSS, 
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Sigma). The pH of the gel mixture was neutralised by adding sodium hydroxide drop-wise until 
a pink-orange colour was achieved. Cells were trypsinised as per Table 2.1, counted using a 
haemocytometer and appropriate number of each cell type (as indicated in relevant chapters) 
mixed together and centrifuged at 290 x g for 3 mins. Cell pellet was resuspended in 
appropriate medium (as indicated in relevant chapters) to a volume that constituted one part 
of the final gel volume. These were added to achieve a total cell density of 4x105 cells /mL of 
gel mixture. The gel-cell mixture (200µl) was added to 12-well plate cell culture inserts with a 
PET membrane with 8.0µm pore size (Falcon) and these placed within wells of a 12-well 
culture plate (Costar, Corning Inc). Gels were left to solidify for 20 mins before 500µl of 
appropriate medium (as indicated in relevant chapters) was added on top of each gel within 
the insert and 1mL added to the bottom of each well in the cell culture plate. Gels were 
cultured at 37oC and 95% air and 5% CO2 for 21 days unless otherwise specified with 50% of 
the medium being replaced every three days during this time. Gels were fixed in 10% Formalin 
(Sigma) for five hours before being processed in a Leica ASP 200 tissue processor (Leica 
Microsystems), paraffin embedded and 5µm sections taken using a Leica RM2235 microtome 
(Leica Microsystems) ready for analysis.  
2.4 Preparation of conditioned medium 
The non-tumorigenic fibroblast cell line HMFU-19 and tumour epithelial cell line SkBr3 were 
passaged (Table 2.1) and allowed to recover in normal growth conditions for 24 hours. Cells 
were rinsed in DPBS and incubated for 48 hours in serum-free medium. Medium was aspirated 
and cell debris removed by centrifugation at 290 x g for 3 mins before being stored at -80˚C 
until used.  
2.5 Haematoxylin and Eosin (H & E) staining  
Gel sections (5µm) were dewaxed with xylene (VWR International, 4 x 3 mins) and rehydrated 
with 100% ethanol (4 x 3 mins) and graded ethanols of 75%, 50% and 25% diluted in water (3 
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mins each). Sections were rinsed in water for 2 mins and stained with Mayers Haematoxylin 
(11.4mM haematoxylin, 2mM sodium iodate, 3mM citric acid, 173mM chloral hydrate, 61mM 
aluminium potassium sulphate, 2% ethanol, 12% glycerol, prepared from reagents from Sigma 
in house courtesy of the Histopathology team, Leeds Institute of Cancer and Pathology) for 2.5 
mins. Sections were rinsed in water for 2 mins and then counterstained with eosin (14mM 
eosin-Y in distilled water, prepared from powder from BDH in house courtesy of the 
Histopathology team, Leeds Institute of Cancer and Pathology) for 2 mins. Sections were rinsed 
in water for 1 min and then dehydrated in 100% ethanol (10 secs, 30 secs and 2 x 5 mins) and 
xylene (3 x 3) mins before being mounted onto coverslips with DPX (CellPath).  
2.6 Immunohistochemistry (IHC) 
Gel sections (5µm) were dewaxed with xylene and rehydrated with ethanol (as for H & E 
above) before incubating in 10% H2O2 (VWR International) in methanol at room temperature 
for 10 mins to block any endogenous peroxidase. For proteolytic digestion antigen retrieval, 
sections were incubated at 37oC for 20 mins in 20µg/mL Proteinase K (Fungal, Invitrogen) in 
Phosphate Buffered Saline (PBS, 137 mM NaCl, 2.7 mM KCl and 10 mM phosphate buffer 
solution pH 7.4, prepared from ready-made tablets, Sigma). For heat-induced antigen retrieval, 
sections were placed in boiling distilled water containing 0.9% Antigen Unmasking Solution 
(Vector Laboratories Inc) in a pressure cooker. Once full pressure was achieved, antigen 
retrieval was timed for 2 mins before cooling sections. Sections were placed in Sequenza 
coverplates (Shandon) and rinsed with PBS. Non-specific binding sites for all sections were 
blocked with 1 x Casein (Vector Laboratories Inc) diluted 1:10 in PBS for 20 mins at room 
temperature. Where extra blocking steps were required, sections were rinsed twice with 2% 
BSA (Sigma) in PBS before adding 100µl 20% goat serum (Dako) in PBS and incubating at room 
temperature for 20 mins. All sections were rinsed with PBS before the addition of 100 µl of 
primary antibodies (Table 2.2) diluted in Antibody Diluent (Invitrogen). Primary antibody was 
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omitted to serve as negative controls. Sections were incubated either overnight at 4oC or for 2 
hours at room temperature (see Table 2.2), rinsed twice in PBS and stained using Dako 
Envision Detection System according to manufacturer’s instructions. Sections were incubated 
in Copper Sulphate for 2 mins, rinsed in water and counterstained with Mayer’s Haematoxylin 
(Sigma) for 1 min, before incubation in Scotts Tap Water Substitute (Sigma) for 2 mins. 
Sections were subsequently dehydrated in 100% Ethanol and Xylene (as per H & E) before 
being mounted onto coverslips with DPX (CellPath).  
2.7 Image acquisition of gel and tissue sections  
Throughout this study, digital images of H & E and IHC stained gel and human tissue sections 
were acquired through slide scanning courtesy of the in house Virtual Pathology facility (Leeds 
Institute of Cancer and Pathology). Glass slides were scanned using Aperio CS and Aperio AT 
scanners (Aperio Technologies Inc) using x20 and x40 objectives producing images with a final 
resolution of 0.23 and 0.43µm per pixel respectively. Images were acquired using Aperio 
Imagescope software version 11 (Aperio Technologies Inc).  
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Table 2.2 Details of antibodies, their dilutions and methods used for IHC
Antibody Against 
(abbreviation) 
Manufacturer Clone Type Dilution  Antigen 
Retrieval 
Method 
Extra blocking 
step used 
Incubation time 
Collagen IV  
(Coll IV) 
Sigma COL-94 Mouse 
Monoclonal 
1:1000 Proteolytic 
Digestion 
Yes- Goat serum Overnight at 4
o
C 
Tenascin-C  
(TN-C) 
Sigma BC-24 Mouse 
Monoclonal 
1:1000 Proteolytic 
Digestion 
Yes- Goat serum Overnight at 4
o
C 
Vimentin 
(Vim) 
Dako Vim 3B4 Mouse 
Monoclonal 
1:200 Heat 
induced 
No Overnight at 4
o
C 
Epithelial 
Membrane Antigen 
(EMA) 
Dako E29 Mouse 
Monoclonal 
1:5000 Heat 
induced 
No Overnight at 4
o
C 
α-Smooth Muscle 
Actin (αSMA) 
Dako 1A4 Mouse 
Monoclonal 
1:200 Heat 
induced 
No Overnight at 4
o
C 
E-Cadherin 
(E-Cad) 
Dako NCH-38 Mouse 
Monoclonal 
1:100 Heat 
induced 
No Overnight at 4
o
C 
Ki67 Dako MIB-1 Mouse 
Monoclonal 
1:1000 Heat 
induced 
No Overnight at 4
o
C 
M30 Roche M30 Mouse 
Monoclonal 
1:50 Heat 
induced 
No Overnight at 4
o
C 
Turbo GFP (tGFP) Pierce N/A Rabbit 
Polyclonal 
1:500 Heat 
induced 
Yes- Goat serum 2 hours room 
temperature 
dsRed Clontech N/A Rabbit 
Polyclonal 
1:200 Heat 
induced 
Yes- Goat serum 2 hours room 
temperature 
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2.8 Isolation of primary fibroblasts from clinical specimens 
Breast tissue that was surplus to histopathological diagnosis was selected from reduction 
mammoplasty samples after patients provided informed consent. All samples were collected via 
the Leeds Breast Tissue Bank following ethical approval (Rec: 09/H1306/108, Leeds Teaching 
Hospital Trust R+D No. HTA 11_0001). Samples were selected on the condition that patients had 
received no prior chemotherapy and that samples were received no later than 6 hours after 
operation was carried out.  
Primary fibroblasts were isolated using a method adapted from one used by Gomm et al 
previously [183]. Tissue was minced with a scalpel before being placed in a vented cap cell culture 
flask (Corning) with 5mL RPMI-1640 (Gibco) + 5% HI-FCS containing 2.5µg/mL of Fungizone and 
100U/mL of Penicillin/Streptomycin antibiotics (both Invitrogen). Tissue was incubated overnight 
at 37oC and 95% air and 5% CO2 in a humidified incubator. Tissue was digested the following 
morning with 10mg/mL of Collagenase IA (Sigma) with gentle shaking and monitoring every 30-60 
mins. If required, another 10mg/mL of collagenase IA was added to ensure thorough digestion of 
sample. Once tissue was digested, sample was diluted with 25mL DPBS (Invitrogen) and passed 
through a 70µM Nylon BD Falcon cell strainer (BD Biosciences) to harvest fibroblasts. Fibroblast-
rich solution was centrifuged for 3 mins at 290 x g and cell pellet resuspended in 15mL DPBS to 
wash. This was repeated twice to give a total of 3x DPBS washes. Fibroblasts were plated out onto 
vented cap cell culture flasks coated with 20µg/mL Fibronectin (Sigma) in DMEM-GlutaMAXTM-I + 
10% HI-FCS, 2.5µg/mL Fungizone and 100U/mL Penicillin/Streptomycin antibiotics and incubated 
at 37oC and 95 % air and 5% CO2 in a humidified incubator. Antibiotics were removed following 
one week in culture. Stocks of cells were frozen as per section 2.1 between passages 0 and 2.   
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2.9 Lentiviral Transduction 
Lentiviral transduction was carried out using the 2nd generation calcium phosphate method 
developed by Prof Didier Trono [184]. This was performed in a Genetically Modified Category II cell 
culture facility that was approved for viral work under permission obtained by Dr Georgia Mavria 
(Leeds Institute of Cancer and Pathology).  Details of lentiviral expression plasmids used will be 
detailed in relevant chapters. 
2.9.1 Production of expression and packaging plasmids 
Lentiviral expression plasmids, pMD2.G envelope plasmid (gift from Dr Georgia Mavria, Fig 2.1) 
and psPAX2 packaging plasmids (gift from Dr Georgia Mavria, Fig 2.2) were transformed into XL1-
Blue Supercompetent bacterial cells (Agilent) and cultured on LB-agar plates (prepared using 
Lennox LB Broth with Agar powder as per manufacturer’s instructions, Sigma) containing 
100µg/mL of Ampicillin (Sigma). Colonies were picked and plasmid DNA purified using Qiagen 
Plasmid Maxi-Prep Kit (Qiagen) following manufacturer’s instructions.  
2.9.2 Production of lentiviral particles 
Replication-deficient lentiviral particles containing expression or shRNA constructs were generated 
using Lenti-X 293T cells for lentiviral packaging (Clontech). Lenti-X 293T cells were maintained in 
DMEM-GlutaMAX-1™ medium (Invitrogen) + 10% HI-FCS at 37oC and 95 % air and 5% CO2 in a 
humidified incubator. For routine passage, cells were washed with DPBS, 0.5% Trypsin/EDTA 
added for ~2mins and cells resuspended in medium. Cells were centrifuged at 290 x g for 3 mins, 
pellet resuspended in medium and replated at a 1:10 dilution.  
Lenti-X 293T cells were seeded into 15cm round cell culture dishes (Corning) with a seeding 
density of 2.5 x 106 cells and left to recover for 48 hours until ~70% confluent. Medium was 
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replaced 2 hours prior to transfection. The following transfection solution was prepared in a 50 mL 
centrifuge tube (Falcon®, Corning) with each of the components added in order:- 
 22.5µg lentiviral expression plasmid 
 7.9µg pMD2.G envelope plasmid  
 14.6µg psPAX2 packaging plasmid  
 660µl 0.1 x Tris EDTA (1mM Tris, 0.1mM EDTA, pH 8.8) 
 350µl molecular biology grade water (Calcium Phosphate Transfection kit, Sigma) 
 113µl 2.5M Calcium phosphate (Calcium Phosphate Transfection kit, Sigma) 
The transfection solution was mixed briefly by pipetting. 1.14mL of 2 x Hepes Buffered Saline 
(Calcium Phosphate Transfection kit, Sigma) was added dropwise under agitation by vortexing and 
solution left to incubate at room temperature for 20 mins. Transfection solution was then added 
dropwise to Lenti-X 293T cells and rocked gently to mix. Cells were left to incubate for 16 hours at 
37oC and 95 % air and 5% CO2 in a humidified incubator. Medium was then replaced and cells left 
to incubate for 8 hours. Medium containing lentiviral particles was then harvested, centrifuged at 
290 x g for 3 mins to remove cell debris and passed through a 0.45µm sterile filter (Sartorius). 
Virus supernatant was then stored at -80oC until ready to use.  
2.9.3 Transduction of cells with lentiviral particles 
Target cells were cultured in 25cm3 vented cap cell culture flasks (Corning) until 60% confluent. 
Medium was replaced with viral supernatant either neat (pFURW expression vector), or, diluted 
1:5 in DMEM-GlutaMAX-1™ medium (Invitrogen) + 10% HI-FCS (pGIPZ expression vectors) 
containing 8µg/mL Polybrene (Sigma). Cells were incubated in viral supernatant for 5 hours before 
washing 3 x DPBS and medium replaced with appropriate target cell medium. Cells were left to 
recover for 72 hours and growth monitored daily. The transduction efficiency was determined by 
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assessing the percentage of fluorescent cells using an EVOS fl microscope (Advanced Microscopy 
Group). This was performed by counting the number of fluorescent cells from three separate fields 
of view at 10 x magnification and expressing as a ratio of the total number of cells counted from 
the corresponding phase contrast fields of view at 10 x magnification. In the event that less than 
~90% of the cells were fluorescent, fluorescent cell populations were enriched using Fluorescence-
activated cell sorting (FACS) courtesy of the in house flow cytometry facility (Leeds Institutes of 
Molecular Medicine). Un-transduced cells were used as negative controls to define the flow-
cytometry gates.  
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Fig 2.1 Simplified plasmid map of pMD2.G envelope plasmid 
Diagram represents key elements contained within the pMD2.G envelope plasmid (gift from Dr 
Georgia Mavria, Leeds Institute of Cancer and Pathology) used for lentiviral transduction. Key 
elements are as follows:- Cytomegalovirus promoter (CMV), β-Globulin Intron, G glycoproteins of 
the vesicular stomatitis virus gene (VSV-G), β-Globulin polyadenylation sequence (PolyA).  
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Fig 2.2 Simplified plasmid map of psPAX2 packaging plasmid 
Diagram represents key elements contained within the psPAX2 packaging plasmid (gift from Dr 
Georgia Mavria, Leeds Institute of Cancer and Pathology) used for lentiviral transduction. Key 
elements are as follows:- Cytomegalovirus promoter (CMV), Group Antigen polyprotein gene 
(gag), Viral Protease gene (Pro), reverse transcriptase gene (Pol), Regulator of Expression of Virion 
Protein gene (Rev), Trans-activator of Transcription gene (Tat),  β-Globulin polyadenylation 
sequence (PolyA), Simian Vacuolating Virus 40 origin of replication (SV40 Ori) and Ampicillin 
resistance gene (AmpR).  
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2.10 Retroviral transduction 
Retroviral transduction was carried out by Dr Euan Baxter, Leeds Institute Cancer and Pathology. 
This was performed in a Genetically Modified Category II cell culture facility that was approved for 
viral work under permission obtained by Prof Margaret Knowles (Leeds Institute Cancer and 
Pathology).  Viral supernatant comprised of retroviral particles containing pBabe-neo-hTERT 
plasmid expression constructs in DMEM-GlutaMAX-1™ medium (Invitrogen) + 10% HI-FCS (see Fig 
2.3 for plasmid map) was provided courtesy of Dr Julie Burns, Leeds Institute Cancer and 
Pathology.  
Target cells were cultured in 25cm3 vented cap cell culture flasks (Corning) until 60% confluent. 
Medium was replaced with viral supernatant diluted 1:5 in DMEM-GlutaMAX-1™ medium 
(Invitrogen) + 10% HI-FCS containing 1µg/mL Polybrene (Sigma). Cells were incubated in viral 
supernatant overnight before washing 3 x DPBS and medium replaced with DMEM-GlutaMAX-1™ 
medium (Invitrogen) + 10% HI-FCS containing 500µg/mL Geneticin (G418, Sigma). Cells were 
maintained and passaged using this medium for 10 days before G418 was removed. Cell growth 
was monitored daily thereafter. 
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Fig 2.3 Plasmid map of pBabe-neo-hTERT retroviral plasmid used to insert the hTERT gene into 
primary fibroblasts 
Diagram represents key elements contained within the pBabe-neo-hTERT plasmid used for 
retroviral transduction of primary fibroblasts with the hTERT gene. Key elements are as follows:- 
5’-long terminal repeats (5’-LTR), truncated gag gene (truncated gag), human Telomerase Reverse 
Transcriptase gene (hTERT), Simian Vacuolating Virus 40 promoter (SV40 IEP),Neomycin resistance 
gene (Neo), 3’-LTR, origin of replication (Ori), Ampicillin resistance gene (AmpR) and restriction 
enzyme sites for EcoRI and SalI.  
Diagram adapted from [185]. 
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2.11 Protein extraction and quantification 
Cells for protein extraction were cultured in vented cap cell culture flasks until 60% confluency was 
reached with any treatments performed in situ before protein extraction was carried out. Lysis 
buffer used contained 1x modified RIPA buffer (300mM NaCl, 4mM EDTA, 2% NP40 (Sigma) and 
0.5% Na deoxycholate (Sigma)), with 1x protease inhibitor (Roche mini protease cocktail tablet 
made up to 1ml in nuclease-free water, Ambion). Cells were washed with ice cold PBS and flask 
placed on ice.  Pre-chilled lysis buffer (500µl per T25 flask) was applied and incubated on ice for 4 
mins with intermittent swirling of flask. Cells were scraped with a cell scraper and lysate 
transferred to a chilled eppendorf tube and left on ice for 20 minutes.  Lysate was centrifuged in a 
microcentrifuge at 15682 x g for 15 minutes and the supernatant transferred to a new chilled 
tube.  Protein extracts were ideally used fresh or stored at -80°C. 
Protein concentration was determined using the colorimetric DC protein assay according to 
manufacturer’s instructions (BioRad). Briefly, 5 µl of BSA protein standards ranging from 2 - 
0.1875mg/ml as well as 5 µl of protein samples were added to separate wells of a flat-bottomed 
96 well microtitre plate (Corning). A solution of alkaline copper tartrate solution was prepared 
(Reagent A + Reagent S) and 25µl added to each of the wells containing standards and samples. 
This was followed by addition of 200µl of Folin’s reagent (Reagent B) to each sample. Colour 
change was allowed to develop for 15 minutes before optical density was measured at 670nm 
using an Opsys MRTM microplate reader (Dynex Technologies Ltd). The protein concentration was 
calculated using the standard curve from BSA protein standards. 
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2.12 Western Blotting 
All protein samples were diluted to ensure equal concentrations using deionised water and 20µl of 
sample transferred to a new pre-chilled eppendorf tube. To each sample, 7.5µl of 4x NuPAGE® LDS 
sample buffer (Life Technologies) and 2.5µl of beta-mercaptoethanol (Sigma) was added to make a 
final volume of 30µl. Samples were denatured for 5 mins at 105oC using a Grant QBD2 dry block 
heater, vortexed and allowed to cool on ice. Precast NuPAGE® Novex® 4-12% Bis-Tris Gels were 
used with Xcell SureLock™ Mini-Cell system and submerged in 1 x NuPAGE® MOPS SDS Running 
Buffer (all Invitrogen). 20 µl of the samples and 7 µl of the BioRad Dual Color Protein Plus protein 
standard (BioRad) were loaded into the gels and electrophoresis was performed for 1 to 1.5 hours 
at 150V. 
Proteins were transferred to a Polyvinylidene difluoride membrane (Amersham). Briefly, 
membrane was activated with methanol for 30 secs, and soaked in 1 x NuPAGE® Transfer buffer 
diluted with distilled water and 10% methanol. Proteins were transferred in transfer buffer using 
the Xcell II Blot Module SureLock™ system (Invitrogen) overnight at 4oC at 13v.  
Membrane was blocked with 5% skimmed milk in TBST (10mM Tris-HCl, pH 8.5, 150mM NaCl, 
0.1% Tween-20) for 8 hours at 4oC with gentle rocking. Membrane was then incubated with 
primary antibody diluted in blocking buffer overnight at 4oC with gentle rocking. Membrane was 
washed 3 x 10 mins with TBST before incubating with secondary antibody diluted in blocking 
buffer for 1 hour at room temperature. Following 3 x 10 min washes in TBST, membrane was 
developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and 
visualised using ChemiDoc® MP imaging system.  
Primary antibodies used:  anti-HER2 IgG (Rabbit Polyclonal, Cell Signalling Technology, dilution 
1:1000), anti-HER3 IgG (Mouse monoclonal, Clone 2F12, Millipore, dilution 1:1000), anti-β-actin 
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IgG (Clone AC-15, Sigma, dilution 1:10000), anti-DOCK4 IgG (Rabbit polyclonal, Bethyl Laboratories 
Inc, dilution 1:500), anti-phospho-Akt Ser473 IgG (Rabbit monoclonal, Clone 193H12, Cell 
Signalling Technology Inc, dilution 1:1000), anti-phospho-PLCγ1 Ser1248 IgG (Mouse monoclonal, 
Clone D25A9, Cell Signalling Technology Inc, dilution 1:1000). 
Secondary antibodies used: HRP-conjugated polyclonal goat anti-rabbit antibody (Santa Cruz 
Biotechnology, dilution 1:10000), HRP-conjugated polyclonal goat anti-rabbit antibody (Santa Cruz 
Biotechnology, dilution 1:10000). 
2.13 Quantification of H & E stained 3D HB2 structures  
The method used for quantification of 3D in vitro HB2 co-cultures was developed in house 
courtesy of Dr Darren Treanor (Virtual Pathology facility, Leeds Institute of Cancer Pathology). Gels 
were serial sectioned, H & E stained and 20x magnified digital images acquired as per sections 2.5, 
2.6 and 2.7. For the purpose of optimisation, 10 serial sections encompassing a total depth of 
50µm were taken. Quantification thereafter was based on sections taken from a depth between 
15µm and 40µm (see Chapter 3 for validation).  
Quantification was performed using Aperio Imagescope software version 11. Annotation tools 
were used to outline the perimeters of the whole gel section, any holes within the gel section and 
around HB2 units manually using a computer equipped with a Wacom Cintiq touchscreen monitor. 
Example annotations are shown in Fig 2.4. A viable HB2 unit was defined as a cohesive cluster of 
four or more cells with discernible nuclei. To ensure that units quantified were comprised of HB2 
cells and not Myo1089 and fibroblast cells, IHC was performed alongside H & E of the gels as per 
sections 2.5 and 2.6 to confirm that the structures being annotated did not contain tGFP or dsRed 
positive cells. HB2 units on the periphery of the gel section or holes were excluded as they were 
not representative of the majority of HB2 structures within the gels. Aperio Imagescope software 
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calculated the area of each annotation in µm2 and the number of units was based on the number 
of annotations drawn. Lumen formation was defined as a space within HB2 units that was 
enclosed by a continuous chain of cells and was counted manually. Any HB2 units that contained 
spaces with breaches in the surrounding cells were excluded. Example images of what was defined 
as a viable lumen and a non-viable lumen are shown in Fig 2.5. 
 The area of the gel section was calculated by subtracting the area of holes in the gel from the total 
area of the gel section. Due to the inherent variation between the size of gel sections and 
therefore the number of units within each gel, the area of HB2 units were normalised by 
expressing the area of the unit per µm2 of gel. This was calculated by taking the area of each HB2 
unit and dividing by the area of the gel section (µm2). 
For each experiment, one section from three replicate gels for each variable was quantified. Raw 
data obtained from Aperio Imagescope was inputted into GraphPad Prism 6 software where the 
mean and standard error of the mean (SEM) was calculated along with any statistical analysis was 
performed.  
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Fig 2.4 Representative images of annotations drawn in Aperio Imagescope software used for 
quantification of HB2 units in 3D in vitro culture  
a) Example image showing representative annotations drawn to calculate the total area of each 
gel section (Gel, green), any holes within gel sections (Hole, yellow) and of HB2 cell units (HB2 
Unit, Red). 
b) Example image at 20x magnification showing representative annotations drawn around HB2 
units. 
a) 
b) 
Gel 
Hole 
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Fig 2.5 Representative images to demonstrate what constituted a viable and a non-viable lumen 
for quantification 
a) Example of a HB2 unit containing a luminal space that was considered viable for quantification. 
Unit contains a luminal space (L) that is surrounded/enclosed by a continuous chain of rounded 
HB2 cells (Cell chain) that contains no breaches. b) Example of a HB2 unit containing a luminal 
space that was considered not viable for quantification. Unit contains a luminal space (L) that is 
not fully enclosed by a chain of HB2 cells. HB2 cell layer surrounding the space is discontinuous 
featuring breaches (B).  
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3 Chapter 3: Optimisation of a 3D in vitro tri-culture model of 
normal breast 
3.1 Introduction 
The basic principle of 3D in vitro culture is to incorporate either single or multiple cell types into a 
3D matrix in order to recapitulate an in vivo tissue environment. Therefore, there are two main 
considerations when developing a 3D in vitro model of normal breast; choice of an appropriate 
matrix and selection of cells to include. 
3.1.1 Choice of Matrix 
Natural ECM materials isolated from murine sources are preferred for 3D models. Various 
techniques using natural ECM materials have been extensively reviewed [186-188] and under the 
right conditions, support cell growth in 3D. The most commonly used ECM material is the 
commercially available compound MatrigelTM. Matrigel is derived from the Engelbreth-Holm-
Swarm mouse sarcoma and is rich in the basement membrane proteins laminin and collagen IV, as 
well as several extracellular growth factors [189]. Culture of breast epithelial cells in 3D MatrigelTM 
has seen the formation of acini-like structures [190] with evidence of milk protein expression 
[152]. However, materials such as MatrigelTM should be used with caution. Levels of growth factors 
within MatrigelTM can vary, and components such as collagen IV can differ in subunit composition 
to in vivo components [191] potentially increasing susceptibility to remodelling and proteolysis not 
commonly found in vivo. MatrigelTM may also provide tumour cells with additional survival and 
proliferative signals facilitating tumorigenesis [192]. Although these caveats can be overcome by 
the use of growth factor reduced MatrigelTM, there are alternative ECM materials to MatrigelTM 
that may be more appropriate for the culture of breast cells in vitro. 
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As demonstrated by our group in Fig 3.1 and reported by Parmar and Cunha [193], the main 
constituent of normal breast stroma consists predominantly of collagen I. The remodelling and 
mechanical tension of collagen I has been proven to influence breast tumour cell invasion [54] and 
the morphology of breast cells [194, 195]. An increase in collagen density has also been linked to 
increased risk of breast cancer [196, 197]. It therefore seems prudent that the influence of 
collagen I matrix be accounted for in 3D in vitro models of breast and may provide a more 
physiologically relevant environment for culture of breast cells. Production of successful acini- and 
duct-like structures akin to those cultured in MatrigelTM has already been achieved [198, 199] 
through culture of mammary epithelial cells in collagen I perhaps making collagen I a viable and 
more appropriate choice of ECM matrix for 3D models of breast.
 
Fig 3.1 Sirius red staining of collagen I in normal breast tissue 
Example of a normal breast tissue sample stained with Sirius Red highlighting the abundance of 
collagen I fibrils in the breast stroma (S). Image courtesy of Prof Valerie Speirs (Leeds Institute of 
Cancer and Pathology).  
S 
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3.1.2 Choice of Cells 
Despite the vast amount of breast cancer cell lines available, there is a scarcity of normal breast 
epithelial cell lines. The MCF10A cell line has customarily been chosen as a representative of 
normal luminal breast epithelium. MCF10A cells are a spontaneously immortalised mammary 
epithelial cell line derived from a patient with fibrocystic change. They are non-tumorigenic as 
don’t exhibit anchorage-independent growth and they exhibit features of normal luminal cells 
such as ultrastructural similarities to breast luminal epithelial cells and expression of breast 
epithelial cytokeratins and sialomucins, [180, 200]. Culture in MatrigelTM has yielded some 
impressive acini-like structures which are polarised, contain hollow lumens and produce basement 
membrane proteins [154, 190]. This has also been recapitulated in collagen I matrix [201]. Another 
less commonly used representative for normal luminal breast epithelium is the HB2 cell line. HB2 
cells are a sub-population of the MTSV1-7 cell line [202] which have luminal epithelial 
characteristics and were originally isolated from breast milk. Branching 3D duct-like structures 
have been achieved through culture of HB2 cells in collagen I [199].  
While culture of these cells in 3D matrix has resulted in structures akin to in vivo breast acini and 
ducts which cannot be achieved through culture in 2D, in vivo breast architecture is much more 
complex including a variety of other cell types that influence epithelial architecture. This has led to 
a rise in 3D co-culture with stromal cells with co-culture with fibroblasts most commonly reported 
[149, 195, 201] and examples of combinations of fibroblasts and adipocytes also demonstrated 
[203, 204]. As previously discussed (Chapter 1), it has emerged that fibroblasts regulate epithelial 
cell invasion [205] secreting various growth factors such as MMPs [206] which have been proven 
through use of 3D co-cultures. Markedly, some of these effects are only evident upon culture in 
collagen I [207]. As previously discussed in Chapter 1, myoepithelial cells also play a key role in 
normal in vivo breast. Given their tumour suppressive nature [72, 208] and their capacity to 
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maintain luminal cell polarity [71], it seems apt to include these cells in normal in vitro models of 
breast, however, to date studies incorporating these cells are lacking.  
It stands to reason that luminal epithelial organisation is maintained by a delicate balance 
between the opposing functions of fibroblasts and myoepithelial cells. It seems apt that both 
these cell types are included in a 3D in vitro model of normal breast with luminal epithelial cells to 
accurately reflect the in vivo environment. Only one such tri-culture model has been achieved 
previously by Holliday et al [149] but this used aberrant luminal epithelial cells thus representing 
DCIS. A 3D in vitro tri-culture model of normal breast has not been achieved and could prove 
valuable for cancer initiation studies and for better understanding of how different cell types 
within the breast interact and communicate with each other. 
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3.2 Aims 
To develop a 3D in vitro model in physiologically relevant collagen I matrix that includes luminal 
epithelial, myoepithelial and fibroblast cell lines. The model was validated by characterising and 
comparing to normal breast tissue specimens. This was achieved by :- 
 Stable transduction of the myoepithelial cell line Myo1089 with tGFP protein to enable 
tracking in culture 
 Optimisation of culture conditions in collagen I with GFP Myo1089 and either HB2 or 
MCF10A cells 
 Isolation of fibroblasts from a breast reduction mammoplasty primary sample and their 
stable transduction with human Telomerase Reverse Transcriptase (hTERT) to increase 
longevity in culture and with dsRed fluorescent reporter to enable tracking in a tri-culture 
model 
 Characterising the phenotype and immunoprofile by IHC and compared profile to a normal 
breast tissue specimen 
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3.3 Materials and Methods 
3.3.1 Immunofluorescence  
Cells were trypsinised as per Chapter 2, Table 2.1 and seeded onto glass coverslips (Scientific 
Laboratory Supplies Ltd) which had been sterilised with 70% ethanol in water. These were left to 
recover in normal growth conditions until 60% confluency was reached. Cells were rinsed in PBS at 
4°C and fixed in 4% paraformaldehyde in PBS for 10 minutes. Cells were permeabilised for 5 mins 
with 0.1% Triton X-100 (Sigma) in PBS, rinsed in PBS and processed for immunofluorescence (IF), 
or stored for up to 2 weeks at 4°C.  Fixed cells were rinsed in PBS and blocked with 1% BSA in PBS 
for 30 mins. Cells were washed in PBS (3 x 5 mins) and then incubated with primary antibody 
diluted in blocking solution (Table 3.1) by inversion on to the solution on parafilm (M Lab 
supplies). Primary antibody was omitted to serve as a negative control. Following 3 x 5 mins PBS 
washes, secondary antibody conjugated to a fluorescent dye was applied and incubated in the 
dark for 40 mins. Coverslips were washed and mounted on a microscope slide (VWR International) 
using Vectashield hard-set mountant containing 4', 6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories Inc). Slides were stored at 4oC in the dark until imaged. Fluorescent images were 
captured within 2 weeks of staining using microscopes detailed in relevant figures. Secondary 
antibodies used: Goat anti-mouse IgG Texas Red ®-X (Invitrogen, diluted 1:400), goat anti-rabbit 
IgG (H+L) Alexa Fluor® 594 (Invitrogen, diluted 1:400) and goat anti-mouse IgG FITC conjugated 
(Dako, diluted 1:500). 
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Antibody Against Manufacturer Clone Type Dilution 
β4-Integrin Millipore 3E1 Mouse 
Monoclonal 
1:25 
Cytokeratin 14 AbD Serotec LL002 Mouse 
Monoclonal 
1:100 
Cytokeratin 5/6 Dako D5/16 B4 Mouse 
Monoclonal 
1.100 
Cytokeratin 18 Sigma CM-90 Mouse 
Monoclonal 
1:500 
α-Smooth Muscle Actin Dako 1A4 Mouse 
Monoclonal 
1:100 
Vimentin Dako Vim 3B4 Mouse 
Monoclonal 
1:200 
Epithelial Membrane Antigen Dako E29 Mouse 
Monoclonal 
1:200 
Table 3.1 Details of antibodies and dilutions used for immunofluorescence  
 
3.3.2 Lentiviral transduction for cell tracking 
Lentiviral transduction was carried out as per Chapter 2. In order to produce Myo1089 cells that 
stably expressed green fluorescent protein, the pGIPZ-tGFP empty lentiviral expression vector was 
used (see Fig 3.1, Thermo Scientific).  In order to produce LS11-083 hTERT fibroblast cells that 
stably expressed dsRed fluorescent protein, the pFURW empty lentiviral expression vector was 
used (unpublished, gift from Dr Mihaela Lorger, Leeds Institute of Cancer and Pathology). This 
expression construct was generated by Dr Mihaela Lorger by splicing out the DsRed gene from 
pDsRed-express1 plasmid via BamHI/HpaI restriction enzyme sites. The fragment was then blunted 
and ligated into the HpaI restriction site of the pFUW vector [209]. See Fig 3.2 for a plasmid map of 
the pFURW vector. 
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Fig 3.2 Simplified plasmid map of pGIPZ lentiviral expression plasmid 
Diagram represents key elements contained within the expression plasmid used to lentivirally 
transduce cells with TurboGFP protein. Key elements are as follows:- Human Cytomegalovirus 
promoter (hCMV), TurboGFP gene (tGFP), internal ribosome entry site (IRES), Puromycin 
resistance gene (PuroR), Woodchuck hepatitis virus post-transcription regulatory element (WPRE), 
3’- self inactivating long terminal repeat (3’-SIN LTR), Simian Vacuolating Virus 40 origin of 
replication (SV40 Ori), pUC origin of replication (pUC), Ampicillin resistance gene (AmpR), 5’-LTR, 
psi packaging sequence (ψ) and Rev Response Element (RRE).  Adapted from [210]. 
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Fig 3.3 Simplified Plasmid map of pFURW lentiviral expression plasmid 
Diagram represents key elements contained within the expression plasmid used to lentivirally 
transduce cells with dsRed protein. Key elements are as follows:- Cytomegalovirus promoter 
(CMV), 5’-long terminal repeats (LTR), psi packaging sequence (ψ), Rev Response Element (RRE), 
human ubiquitinC promoter, restriction enzyme site for HpaI, dsRed gene, Woodchuck hepatitis 
virus post-transcription regulatory element (WPRE), 3’-LTR, Simian Vacuolating Virus 40 origin of 
replication (SV40 Ori), Bleomycin resistance gene (BleoR) and Ampicillin resistance gene (AmpR).  
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3.4 Results 
3.4.1 Production and characterisation of a GFP positive myoepithelial cell line 
The cell line Myo1089 (gift from Dr Mike Allen, Barts Cancer Institute, Queen Mary, University of 
London) was selected as a representative myoepithelial cell line for our study. Following 
recommended purification using β4-integrin coated Dynabeads, in 2D culture, these cells formed a 
cobblestone-like monolayer consisting of elongated stellate-shaped cells characteristic of 
myoepithelial cells in culture [211]. To enable the tracking of Myo1089 cells in 3D culture, 
Myo1089 cells were lentivirally transduced with pGIPZ-tGFP empty vector plasmid (courtesy of Dr 
Georgia Mavria, Leeds Institute of Cancer and Pathology). FACS courtesy of in house flow 
cytometry facility (Leeds Institutes of Molecular Medicine), produced a cell population which 
retained a stellate-shaped morphology in which >99% of cells were GFP positive (Fig 3.4). These 
were termed GFP Myo1089 cells throughout the study.  
In order to assess GFP Myo1089 cell phenotype, immunofluorescence was carried out using a 
panel of antibodies containing markers of luminal and myoepithelial cell populations with 
representative images from three biological replicate experiments presented (Fig 3.5). While GFP 
Myo1089 cells stained uniformly for the myoepithelial associated markers β4-integrin and αSMA, 
cells were negative for the myoepithelial markers cytokeratin 14 and vimentin. Only approximately 
1% of cells exhibited staining for EMA however all cells demonstrated strong cytoplasmic staining 
for cytokeratin 18 which are both luminal epithelial markers. This indicates that GFP Myo1089 cells 
may consist of a mixed population of cells.  
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Fig 3.4 GFP Myo1089 cells imaged using phase contrast and fluorescence microscopy 
Phase contrast microscopy of GFP Myo1089 cells demonstrate formation of a cobblestone 
monolayer (a, original magnification 4x) consisting of elongated stellate-shaped cells (b, arrows, 
original magnification 20x). Fluorescence microscopy shows >99% GFP positivity of GFP Myo1089 
cells in green with DAPI stained nuclei in blue (c, original magnification 63x taken with a Nikon C1 
confocal microscope).  
  
a) 
c) 
b) 
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Fig 3.5 Characterisation of GFP Myo1089 cells 
GFP Myo1089 cells were characterised by immunofluorescence staining with a panel of antibody 
markers and visualised using Texas Red (red) with nuclei visualised using DAPI (blue). 
Representative images from three biological replicate experiments presented. Primary antibody 
was omitted to serve as a negative control (a). Over 95% of GFP Myo1089 cells exhibited positive 
staining for β4-Integrin concentrated at cell membranes (arrows, b). Cells were negative for 
cytokeratin 14 but staining artefacts were detected thought to be staining of Dynabeads following 
purification (arrows, c). All cells exhibited strong cytoplasmic staining for cytokeratin 18 (d) while 
approximately 1% of cells displayed epithelial membrane antigen positivity (e). Over 95% of cells 
demonstrated cytoplasmic α-smooth muscle actin staining (f) while cells were negative for 
vimentin (g). All images taken at 63x magnification with a Nikon A1R confocal microscope.    
a) b) c) 
d) e) f) 
g) 
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3.4.2 Characterisation of luminal epithelial cell line MCF10A 
The MCF10A cell line was assessed for its suitability as a representative luminal epithelial cell line 
for study (Fig 3.6). In 2D culture, MCF10A cells demonstrated varying cell morphologies. Sub-
populations of MCF10A cells were detected with either an elongated spindle-shaped morphology 
akin to myoepithelial cells as well as smaller, rounded and cohesive cells that form a cobblestone 
monolayer. MCF10A cell phenotype was examined by immunofluorescence with representative 
images from three biological replicate experiments presented. MCF10A cells largely exhibited a 
myoepithelial cell phenotype with all cells displaying strong positive staining for cytokeratin 5/6 
and αSMA with some positive staining for cytokeratin 14. In addition, approximately 30% of cells 
were positive for the myoepithelial specific marker β4-integrin and although EMA staining was 
detected in these cells, the majority of cells were negative.  
3.4.3 Morphology and phenotype of 3D in vitro dual-culture models containing 
MCF10A cells with myoepithelial cells 
Due to the apparent plasticity of MCF10A cells and basal nature of sub-populations of cells, 
purification with β4-integrin coated Dynabeads was attempted in order to separate basal and 
luminal epithelial cell populations. Original MCF10A cells were designated MCF10A wildtype 
(MCF10A WT), β4-integrin positive MCF10A cells were designated MCF10A basal (MCF10A Basal) 
and β4-integrin negative MCF10A cells were designated MCF10A luminal (MCF10A Luminal). 
MCF10A WT, MCF10A Basal and MCF10A Luminal were cultured in 3D collagen gels for up to 14 
days with GFP Myo1089 cells in a 1:1 cell ratio with a total cell density of 4x105 cells/ml of collagen 
gel (Fig 3.7). Representative images from three biological replicate experiments presented. 
Visualisation by H & E staining demonstrated that in the presence of GFP Myo1089 cells, all sub-
types of MCF10A cells formed cohesive cell structures after 7 days in culture with the appearance 
of spindle-shaped cells loosely distributed throughout the collagen gels. MCF10A WT cells 
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displayed a combination of small cohesive rounded units and larger elongated units indicative of 
mixed populations of MCF10A structures. MCF10A Luminal cell structures were uniformly small, 
cohesive and rounded in comparison to MCF10A WT structures. Surprisingly, it was MCF10A Basal 
cells that formed structures most representative of in vivo breast acini which were larger with 
evidence of lumen formation unlike other MCF10A sub-types.  After 14 days in culture, regardless 
of MCF10A sub-type, all cohesive structures were lost with cells loosely scattered throughout the 
collagen gels.   
Distribution of GFP Myo1089 cells was visualised by IHC using anti-tGFP (Fig 3.8). tGFP staining was 
observed in cells associated around the edges of all MCF10A units and remained un-changed with 
different populations of MCF10A cells. This confirmed the spheroid units observed by H & E 
staining consisted of MCF10A cells and not GFP Myo1089 cells.  
Characterisation by IHC demonstrated a mixed phenotype of MCF10A WT cells and a largely basal 
phenotype of MCF10A Luminal and MCF10A Basal cells regardless of segregation using β4-integrin 
coated beads (Fig 3.9 & 3.10, representative images from three biological replicate experiments 
presented). A combination of both positive and negative staining for E-cadherin (E-Cad) was 
detected in MCF10A WT units as well as some units proving positive for EMA while some were 
negative. Both MCF10A Luminal and MCF10A Basal units were uniformly positive for E-Cad at cell-
cell junctions and strong cytoplasmic EMA staining was detected in all units. M30 staining was 
detected in centres of MCF10A WT and MCF10A Basal units only and was negative in MCF10A 
Luminal units suggesting only MCF10A WT and MCF10A Basal cells were capable of lumen 
formation. All sub-populations of MCF10A cells formed units that were positive for 
basal/myoepithelial markers α-SMA and vimentin (Vim) as well as accompanying GFP Myo1089 
cells. All MCF10A sub-populations showed ability to produce basement membranes distributed on 
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the outer edges of MCF10A units as demonstrated by positive staining for collagen IV (Coll IV) and 
tenascin-C (TN-C). Therefore, despite attempts to separate a sub-population of MCF10A cells using 
β4-integrin coated beads to represent the luminal epithelium of our in vitro model of normal 
breast, all sub-populations of MCF10A cells displayed basal/myoepithelial characteristics in this 
culture system deeming MCF10A cells an inadequate luminal epithelial cell line for study. This 
highlighted a need to identify another luminal epithelial cell line for the model. 
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Fig 3.6 Morphology and characterisation of MCF10A cells using phase contrast microscopy and 
fluorescence microscopy 
Phase contrast microscopy of MCF10A cells displayed a mixed population of cells consisting of 
longer spindle-shaped cells (SC) and cohesive rounded cells (RC) in a cobblestone monolayer (i, 
original magnification 20x). MCF10A cells were characterised by immunofluorescence (ii) staining 
with a panel of antibody markers and visualised using Texas Red (red) with nuclei visualised using 
DAPI (blue). Representative images from three biological replicate experiments presented. Primary 
antibody was omitted to serve as a negative control (a). ~30% of cells exhibited positive staining 
for β4-Integrin concentrated at cell membranes (arrow, b). Majority of cells displayed weak 
cytoplasmic cytokeratin 14 staining (WS, c) with ~1% of cells exhibiting strong staining (SS, c). All 
cells exhibited cytoplasmic staining for cytokeratin 5/6 (d) while a mixture of weak membranous 
staining (WS) and strong cytoplasmic staining (SS) was detected for epithelial membrane antigen 
(e). All cells displayed strong cytoplasmic staining for α-smooth muscle actin staining (f). All images 
taken at 63x magnification with a Zeiss AxioPlan II microscope.  
RC 
SC 
b) a) c) 
WS 
SS 
d) e) 
WS 
SS 
f) 
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Fig 3.7 H & E staining of 3D in vitro dual-culture models of different populations of MCF10A cells 
with myoepithelial cells 
Wildtype (MCF10A WT), β4-integrin negative (MCF10A Luminal) and β4-integrin positive (MCF10A 
Basal) MCF10A cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) in 3D 
collagen gels for 7 and 14 days. 5µm sections of gels were stained with H & E. Representative 
images from three biological replicate experiments presented. After 7 days in culture, MCF10A WT 
(a) formed a combination of compact rounded units (RU) and more elongated units (EU). Both 
MCF10A Luminal cells (c) and MCF10A Basal cells (e) formed compact rounded units but these 
appeared larger with MCF10A Basal cells and demonstrated possible lumen formation (L) in their 
centres. All gels featured spindle-shaped cells (SC) loosely distributed throughout the collagen gel. 
After 14 days, all MCF10A structures were lost regardless of type of MCF10A cell (b, d & f). Original 
magnification 20x, scale bars = 100µm. 
a) b) 
c) d) 
e) f) 
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Fig 3.8 Immunohistochemical labelling of myoepithelial cells in 3D in vitro dual-culture model 
with different sub-populations of MCF10A cells 
Wildtype (MCF10A WT), β4-integrin negative (MCF10A Luminal) and β4-integrin positive (MCF10A 
Basal) MCF10A cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) in 3D 
collagen gels for 7 days. 5µm sections of gels were stained with anti-tGFP by IHC to visualise 
distribution of myoepithelial cells within gels. Representative images from three biological 
replicate experiments presented. All gels display positive staining for tGFP in cells distributed 
around the outer edges of HB2 cell units (arrows, a-c). Original magnification 20x, scale bars = 
100µm. 
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Fig 3.9 Immunohistochemical characterisation of 3D in vitro dual-culture model with different 
sub-populations of MCF10A cells A 
In vitro dual-culture model containing GFP Myo1089 cells with MCF10A wildtype (MCF10A WT), 
β4-integrin negative MCF10A cells (MCF10A Luminal) or β4-integrin positive MCF10A cells 
(MCF10A Basal) were characterised by IHC. Representative images from three biological replicate 
experiments presented. Primary antibody was omitted to serve as negative (Neg) controls (a, b, & 
c). A combination of E-cadherin (E-Cad) positive MCF10A units (+ve) with staining between cell-cell 
junctions of MCF10A cells and E-Cad negative MCF10A units (-ve) were detected with MCF10A WT 
cells (d). All units with MCF10A Luminal and MCF10A Basal displayed strong E-Cad positivity at cell-
cell junctions of MCF10A cells (e & f respectively). A combination of strong staining (SS) and weak 
staining (WS) for epithelial membrane antigen (EMA) was detected in units with MCF10A WT cells 
(g) whereas MCF10A Luminal (h) and MCF10A Basal (i) displayed strong uniform EMA staining 
across all units. M30 staining was detected both in the centre and in cells at the periphery of 
MCF10A WT units (arrows, j). MCF10A Luminal units were negative for M30 (k) and MCF10A Basal 
units also stained positive for M30 in the centres of units (l). Original magnification 20x, scale bars 
= 100µm.
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Fig 3.10 Immunohistochemical characterisation of 3D in vitro dual-culture model with different 
sub-populations of MCF10A cells 
In vitro dual-culture model containing GFP Myo1089 cells with MCF10A wildtype (MCF10A WT), 
β4-integrin negative MCF10A cells (MCF10A Luminal) or β4-integrin positive MCF10A cells 
(MCF10A Basal) were characterised by IHC. Representative images from three biological replicate 
experiments presented. All MCF10A units were uniformly positive for α-smooth muscle actin 
(αSMA) as well as GFP Myo1089 cells regardless of sub-population (a-c). Similarly, all MCF10A 
types of units were positive for vimentin (Vim) as well as GFP Myo0189 cells (d-f). Collagen IV (Coll 
IV) was found concentrated at the outer edges of all types of MCF10A units (arrows inset, g-i) and 
similarly tenascin-C (TN-C) was found at outer edges of all types of MCF10A units (arrows inset, j-
l). Original magnification 20x, scale bars = 100µm. 
 
  
74 
 
3.4.4 Characterisation of luminal epithelial cell line HB2 
As mentioned, the cell line HB2 has been used by other research groups as a representative of 
normal luminal breast epithelium. We therefore selected HB2 cells as an alternative to MCF10A 
cells and assessed their suitability to represent the luminal epithelium in the model (Fig 3.11). In 
2D culture, HB2 cells demonstrated a more uniform cell morphology than MCF10A cells consisting 
of rounded and cohesive cells that formed clusters in a monolayer. When examined by 
immunofluorescence, HB2 cells exhibited a luminal epithelial cell phenotype with cells displaying 
strong staining for the luminal epithelial markers EMA and cytokeratin 18 and were negative for 
the myoepithelial markers cytokeratin 5/6 and αSMA. The myoepithelial vimentin marker was 
detected in these cells but was considerably weaker than the staining for luminal markers tested. 
Representative images from three biological replicate experiments presented. 
3.4.5 Optimisation of culture media in 3D in vitro dual-culture model with 
myoepithelial and HB2 luminal cells  
Though not necessary for culture using MCF10A cells due to the similarities in media requirements 
of MCF10A cells and GFP Myo1089 cells, composition of culture media for co-culture of HB2 cells 
and GFP Myo1089 cells was optimised. HB2 cells were cultured in 3D collagen gels for 7 days with 
GFP Myo1089 cells in a 1:1 cell ratio with a total cell density of 4x105 cells/ml of collagen gel in 
different media conditions with representative images from three technical replicates presented 
(Fig 3.12). Medium 1 consisted of 100% HB2 cell specific culture medium (DMEM Glutamax + 10% 
FCS, 10µg/ml insulin & 5µg/ml hydrocortisone). Medium 2 consisted of 50% HB2 cell culture 
medium with 50% fibroblast conditioned medium (FCM, DMEM Glutamax + 10% FCS collected 
from normal fibroblast cell line HMFU-19 after 48 hours in culture). Medium 3 consisted of 50% 
GFP Myo1089 cell specific culture medium (HAMF12 Nutrient mixture + 10% FCS, 10ng/ml EGF, 
10µg/ml insulin & 5µg/ml hydrocortisone) with 50% FCM. Visualisation by H & E staining 
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demonstrated culture in medium 1 yielded small compact cell units which were sparsely 
distributed throughout the collagen gel. Addition of fibroblast conditioned medium, as 
demonstrated by culture in medium 2, did not affect the morphology of structures which had a 
similar appearance to structures in medium 1. Inclusion of GFP Myo1089 specific medium in the 
culture system, as demonstrated by culture in medium 3, dramatically changed the morphology of 
structures formed as larger, compact and more numerous structures were observed with evidence 
of some lumen formation. Spindle-shaped cells were also detected in medium 3 loosely 
distributed throughout the collagen gels. Therefore, the presence of GFP Myo1089 cells specific 
medium was necessary to produce structures more reflective of in vivo breast acini.  
3.4.6 Optimisation of cell ratios in 3D in vitro dual-culture model with myoepithelial 
and HB2 luminal cells  
In order to yield more HB2 structures with a breast acini-like morphology, the ratio of GFP 
Myo1089 cells to HB2 cells was altered in order to identify an appropriate number of GFP 
Myo1089 cells to use in culture with representative images from three technical replicates 
presented (Fig 3.13). HB2 cells were cultured in 3D collagen gels for 14 days with GFP Myo1089 
cells in different ratios.  A ratio of 1 part GFP Myo1089 cells to 1 part HB2 cells (1:1) was compared 
to a ratio of 3 parts GFP Myo1089 cells to 1 part HB2 cells (3:1) with a total cell density of 4x105 
cells/ml of collagen gel in both cases. Visualisation by H & E staining demonstrated that a 1:1 ratio 
produced structures that were elongated, branched and in some cases appeared discohesive. 
Lumen formation was detected in a small number of these structures but was rare and therefore 
not shown. An excess of myoepithelial cells in a 3:1 ratio yielded structures which were more 
rounded and which consisted of more lumen formation than 1:1 ratio. In both cases, spindle-
shaped cells were detected loosely distributed throughout collagen gels. Therefore, an excess of 
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myoepithelial cells produced more structures that better resemble the rounded and hollow 
architecture of in vivo breast acini. 
3.4.7 Distribution of myoepithelial cells in 3D in vitro dual-culture model with HB2 
cells 
Distribution of GFP Myo1089 cells in dual-cultures with HB2 cells was visualised by IHC using anti-
tGFP representative images from three technical replicates presented (Fig 3.14). tGFP staining was 
observed in rounded cells attached around the edges of HB2 units under optimised conditions. 
This confirmed the spheroid units observed by H & E staining consisted of HB2 cells and not GFP 
Myo1089 cells.  
3.4.8 Optimisation of time in culture of 3D in vitro dual-culture model with 
myoepithelial and HB2 luminal cells 
In order to determine the maximum length of time in culture that could sustain the production of 
HB2 acini-like structures under optimum media and cell ratio conditions described above, HB2 
cells were cultured in 3D collagen gels for up to 35 days with GFP Myo1089 cells and examined at 
7 day intervals (Fig 3.15). Representative images from three technical replicates presented. 
Visualisation by H & E staining demonstrated that after 7 days, small cohesive rounded structures 
were formed with no lumen formation detected. After 14 days, structures appeared larger with 
evidence of some lumen formation in their centres and after 21 days in culture, wide and cleared 
lumens were detected within structures surrounded by a thinner layer of epithelial cells. However, 
culture for longer than 21 days saw a loss in cohesive architecture of HB2 structures with 
remaining structures consisting of discohesive cells and containing large breaches. Therefore, 21 
days was deemed the maximum length of time for culture and yielded structures that most 
resembled breast in vivo breast acini architecture.   
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To summarise, the optimal conditions for co-culture of HB2 cells with GFP Myo1089 cells in the 3D 
in vitro model determined through these experiments were as follows:-  
 Culture medium: 50% GFP Myo1089 cell specific medium with 50% FCM 
 Cell ratios: 3 parts GFP Myo1089 cells: 1 part HB2 cells 
 Maximum length of time in culture: 21 days  
3.4.9 Characterisation of 3D in vitro dual-culture model with HB2 cells 
Characterisation of the 3D dual-culture model cultured under optimised conditions above was 
assessed by IHC with representative images from three technical replicates presented (Fig 3.16). 
Under optimal conditions, HB2 cells formed units that expressed E-Cad at cell-cell junctions and 
EMA was concentrated at the apical-lumen interface of HB2 cells. Cell apoptosis was limited to 
central lumens of HB2 units as demonstrated by M30 staining. Vim and  αSMA was specific to GFP 
Myo1089 cells and HB2 cells remained negative. Basement membrane protein production was 
evident in GFP Myo1089 cells only around the outer edges of HB2 units as demonstrated by Coll IV 
and TN-C staining. Overall, HB2 cells exhibited a luminal epithelial phenotype and GFP Myo1089 a 
myoepithelial phenotype in 3D culture in collagen I. 
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Fig 3.11 Morphology and characterisation of HB2 cells using phase contrast microscopy and 
fluorescence microscopy 
Phase contrast microscopy of HB2 cells demonstrated formation of an adhesive cell monolayer 
arranged in clusters (arrow a, original magnification 4x) consisting of rounded and cohesive cells 
(b, arrows, original magnification 20x). HB2 cells were characterised by immunofluorescence 
staining with a panel of antibody markers and visualised using Texas Red (red) with nuclei 
visualised using DAPI (blue). Representative images from three biological replicate experiments 
presented. Primary antibody was omitted to serve as a negative control (a).100% of cells stained 
positive for the luminal epithelial markers EMA (d) and CK18 (e) and negative for the myoepithelial 
markers CK5/6 (f) and αSMA (g). Vim staining was detected in all cells (h) but was weaker than for 
the luminal markers tested. All images taken at 63x magnification.    
c) d) e) 
f) g) h) 
a) b) 
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Fig 3.12 H & E staining of 3D in vitro dual-culture models of HB2 cells with myoepithelial cells in 
different cell culture media conditions 
HB2 cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) in 3D collagen gels 
for 7 days in Medium 1 (100% DMEM + 10% FCS, 10µg/ml Insulin & 5µg/ml Hydrocortisone), 
Medium 2 (50% Medium 1: 50% fibroblast conditioned medium) or Medium 3 (50% HAMF12 
Nutrient mixture + 10% FCS, 10ng/ml EGF, 10µg/ml Insulin & 5µg/ml Hydrocortisone: 50% 
fibroblast conditioned medium). 5µm sections of gels were stained with H & E and representative 
images from three technical replicates taken. Culture in either medium 1 (a) or medium 2 (b), 
yielded small compact units which were sparse throughout the collagen gels. Upon culture with 
medium 3 (c), much larger units were detected with evidence of some lumen formation (L) and 
spindle-shaped cells (SC) loosely distributed throughout the collagen gel. Original magnification 
20x, scale bars = 100µm. 
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Fig 3.13 H & E staining of 3D in vitro dual-culture models comparing different cell ratios of HB2 
cells with myoepithelial cells  
HB2 cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) in 3D collagen gels 
for 14 days in a 1:1 (1 part GFP Myo1089 cells to 1 part HB2 cells) or a 3:1 (3 parts GFP Myo1089 
cells to 1 part HB2 cells) cell ratio. 5µm sections of gels were stained with H & E and representative 
images from three technical replicates taken. With a 1:1 cell ratio (a), large elongated units were 
observed consisting in some cases of discohesive cells (DC) with some evidence of branching (B). 
With a 3:1 cell ratio (b), cell units appeared more rounded with more evidence of lumen formation 
(L). Spindle-shaped cells (SC) were detected loosely distributed throughout the collagen gel in both 
cases. Original magnification 20x, scale bars = 100µm. 
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Fig 3.14 Immunohistochemical labelling of myoepithelial cells in 3D in vitro dual-culture model 
with HB2 cells under optimal conditions 
HB2 cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) in 3D collagen gels 
for 21 days. 5µm sections of gels were stained with anti-tGFP by IHC to visualise distribution of 
myoepithelial cells within gels. Representative images from three technical replicates presented. 
tGFP staining was detected in rounded cells distributed around the outer edges of HB2 cell units 
(arrows). Original magnification 20x, scale bars = 100µm. 
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Fig 3.15 H & E staining of 3D in vitro dual-culture models of HB2 cells with myoepithelial cells at 
different time-points in culture 
HB2 cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) in 3D collagen gels 
for up to 5 weeks and examined at 1 week intervals. 5µm sections of gels were stained with H & E 
and representative images from three technical replicates taken. Culture for 1 week (a) yielded 
small cohesive rounded units (RU). After 2 weeks in culture (b), units appeared much larger with 
evidence of lumen formation (L). Culture for 3 weeks (c) produced units with much wider cleared 
lumens (L). After 4 (d) and 5 (e) weeks, units were less compact and consisted of discohesive cells 
(DC).  Spindle-shaped cells (SC) loosely distributed throughout the collagen gels featured at all 
time points. Original magnification 20x, scale bars = 100µm. 
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Fig 3.16 Immunohistochemical characterisation of 3D in vitro dual-culture model with HB2 cells 
In vitro dual-culture model containing GFP Myo1089 cells with HB2 cells were characterised by 
IHC. Representative images from three technical replicates presented. Primary antibody was 
omitted to serve as a negative control (Neg). E-cadherin (yellow arrow, inset, E-Cad) staining was 
detected between cell-cell junctions of all HB2 units. Epithelial membrane antigen (yellow arrow, 
inset, EMA) staining was concentrated at the apical-lumen interface of HB2 cells and M30 staining 
was specific to lumens of HB2 units (arrow, M30). α-smooth muscle actin (arrow, αSMA) and 
vimentin (arrow, Vim) was specific to GFP Myo1089 cells. Collagen IV (arrow, Coll IV) and similarly 
tenascin-C (arrow, TN-C) was found concentrated at the outer edges of HB2 units. Original 
magnification 20x, scale bars = 100µm. Inset images for E-Cad and EMA magnified using to 
Microsoft Word to highlight areas of interest. 
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3.4.10 Characterisation of fibroblast cell line HMFU19 
As discussed, a major functional component of in vivo breast is stromal fibroblasts and inclusion of 
which in our 3D in vitro model was deemed essential in accurately representing normal breast 
tissue architecture. We first considered the use of the cell line HMFU19 as a representative 
fibroblast component for our study and assessed their suitability via examination of their 
morphology and phenotype (Fig 3.17). In 2D culture, HMFU19 cells displayed an elongated 
spindle-shaped morphology and formed a discohesive monolayer. HMFU19 cell phenotype was 
examined by immunofluorescence with representative images from three biological replicate 
experiments presented. HMFU19 cells exhibited a mixed phenotype as all cells displayed both 
positive staining for epithelial-associated cytokeratins 14 and 18 and strong staining for fibroblast 
associated vim. Strong αSMA staining was also detected in ~25% of cells. On inspection of 
immunofluorescence staining it was also noted that cells exhibited a mixed morphology with some 
fibroblast-like elongated spindle-shaped cells and some fatter rounded cells with lamellipodia 
formation. Overall, it appeared that these fibroblasts represent a myofibroblast/activated cell 
population presenting a need to source a more appropriate fibroblast cell line for the model.  
3.4.11 Isolation and hTERT transduction of fibroblasts from primary breast reduction 
mammoplasty tissue 
Following appropriate ethical approval as described in Chapter 2, a breast reduction mammoplasty 
sample was selected in order to produce a normal fibroblast cell line to include in the 3D tri-
culture model of normal breast. The breast reduction mammoplasty tissue was digested and 
processed as described in Chapter 2 and yielded a monolayer of dispersed cells with an elongated 
spindle-shaped morphology characteristic of breast fibroblasts (Fig 3.18). To produce a fibroblast 
cell population that could be cultured longer term, fibroblasts at passage 2 were engineered to 
overexpress hTERT via retroviral transduction with pBabe-hTERT-neo vector by Dr Euan Baxter 
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(Leeds Institute of Cancer and Pathology) and designated LS11-083 hTERT fibroblasts. Both 
primary and LS11-083 hTERT fibroblasts were cultured for 21 days to assess their longevity in 
culture. Over 21 days, primary fibroblasts underwent 5 passages. Following passage 5, primary 
fibroblasts were lost demonstrated by a lack of adherent cells and the appearance of rounded 
floating bodies in the culture medium. In this time, LS11-083 hTERT fibroblasts underwent 12 
passages and retained an elongated spindle-shaped morphology and grew in characteristic 
“whorls” reminiscent of cultured breast fibroblasts.  
3.4.12 Production and characterisation of a dsRed positive fibroblast cell line 
To enable the tracking of LS11-083 hTERT fibroblasts in 3D tri-culture with GFP Myo1089 and HB2 
cells, LS11-083 hTERT fibroblasts were lentivirally transduced with pFURW-dsRed empty vector 
plasmid. FACS was used to sort cells and produced a 100% dsRed positive LS11-083 hTERT 
fibroblast population which retained an elongated spindle-shaped morphology (Fig 3.19). These 
were termed LS11-083 dsRed Fibs throughout the study. 100% of LS11-083 dsRed Fibs stained 
uniformly for vim and were 100% negative for cytokeratin 14, cytokeratin 18 and EMA epithelial 
markers. LS11-083 dsRed Fibs were also negative for αSMA indicating that these fibroblasts do not 
represent a myofibroblast/activated fibroblast population. Representative immunofluorescence 
images from three biological replicate experiments presented. 
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Fig 3.17 Morphology and characterisation of HMFU19 cells using phase contrast microscopy and 
fluorescence microscopy 
Phase contrast microscopy allowed visualisation of HMFU19 cells cultured in 2D (a). HMFU19 cells 
grew in a discohesive monolayer (i, original magnification 4x) consisting of elongated spindle-
shaped cells (ii, original magnification 20x). HMFU19 cells were characterised by 
immunofluorescence (b) staining with a panel of antibody markers and visualised using Texas Red 
(red) with nuclei visualised using DAPI (blue). Representative images from three biological 
replicate experiments presented. Primary antibody was omitted to serve as a negative control 
(Neg). 100% of cells stained positive for cytokeratin 14 (CK14) with over 90% of cells also positive 
for cytokeratin 18 (CK18) which are both epithelial markers. While all cells were positive for the 
fibroblast marker for vimentin (Vim), cells with a more rounded morphology with evidence of 
lamellipodia formation (RC) were detected as well as fibroblast-like spindle-shaped cells (SC). α-
smooth muscle actin staining (αSMA) was detected in ~25% of cells and further demonstrated cell 
populations with a lack of characteristic fibroblast morphology. All immunofluorescence images 
taken at 63x magnification using a Nikon C1 confocal microscope. 
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Fig 3.18 Morphology of primary fibroblasts compared to hTERT transduced fibroblasts 
Phase contrast microscopy of primary fibroblasts shows a mono layer of dispersed cells (a, original magnification 4x) which consist of an 
elongated spindle-shaped morphology (b, original magnification 10x). Cell death of primary fibroblasts at passage 5 is demonstrated by lack of 
adhered cells and appearance of rounded floating bodies in the medium (arrow, c) whereas virally transduced hTERT fibroblasts at passage 12 
(d) are spindle-shaped, adherent and grow in characteristic whorls typical of fibroblasts populations (original magnification of c & d, 4x).  
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Fig 3.19 dsRed lentiviral transduction and immunofluorescence characterisation of LS11-083 
hTERT fibroblasts  
LS11-083 hTERT fibroblasts were lentivirally transduced with dsRed protein and FACS sorted to 
produce a 100% dsRed positive fibroblast population and termed LS11-083 dsRed Fibs. Phase 
contrast microscopy demonstrated LS11-083 dsRed Fibs retained an elongated spindle-shape 
morphology (a) and showed >99% positivity for dsRed with fluorescence microscopy (b). 
Original magnification for (a) and (b) 10x. LS11-083 dsRed Fibs were characterised by 
immunofluorescence staining with a panel of antibody markers and visualised using FITC 
(green) with nuclei visualised using DAPI (blue). Representative images from three biological 
replicate experiments presented. Primary antibody was omitted to serve as a negative control 
(c). 100% of cells exhibited positive staining for vimentin (d) demonstrating an elongated 
spindle-shape. All cells were negative for fibroblast activation marker α-smooth muscle actin 
(e), for myoepithelial marker cytokeratin 14 (f) and for luminal epithelial markers cytokeratin 
18 (g) and epithelial membrane antigen (h). All images taken at 63x magnification with a Nikon 
A1R confocal microscope.  
c) d) e) 
f) g) h) 
a) b) 
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3.4.13 Optimisation of number of fibroblasts in 3D in vitro tri-culture model with 
myoepithelial and HB2 luminal cells 
In order to determine an appropriate number of LS11-083 dsRed Fibs to co-culture in a 3D tri-
culture in collagen I which does not disrupt the acini-like HB2 architecture with lumen 
formation, GFP Myo1089 and HB2 cells were cultured together according to previously 
optimised ratios with the addition of varying numbers of LS11-083 dsRed Fibs for 21 days (Fig 
3.20). Representative images from three technical replicates presented. Due to the inclusion of 
fibroblasts in the culture system and their propensity to thrive in epithelial-associated 
medium, 50% HB2 medium (DMEM Glutamax + 10% FCS, 10µg/ml insulin & 5µg/ml 
hydrocortisone) to 50% GFP Myo1089 medium (HAMF12 Nutrient mixture + 10% FCS, 10ng/ml 
EGF, 10µg/ml insulin & 5µg/ml hydrocortisone) was used for the tri-culture system.  FCM, 
included in the dual-culture system, was omitted. In all culture conditions, elongated, spindle-
shaped cells were detected spread throughout collagen gels and appeared to increase with 
increasing numbers of LS11-083 dsRed Fibs. Culture with 0.1x105 LS11-083 dsRed Fibs retained 
HB2 structures with lumens which consisted of cohesive cells as seen in dual-cultures. Similar 
results were attained upon culture with 0.25x105 LS11-083 dsRed Fibs with lumen formation 
within HB2 units, however, units appeared less cohesive featuring discohesive cells. Culture 
with 0.5x105, 1x105 and 2x105 LS11-083 dsRed Fibs resulted in disorganised and discohesive 
HB2 structures with little evidence of lumen formation. In addition, only culture with 1x105 and 
2x105 LS11-083 dsRed Fibs caused extensive contraction of gels in some cases leaving gels 
unanalysable. Therefore, 0.1x105 was considered an appropriate number of LS11-083 dsRed 
Fibs to include in the tri-culture model with which to retain acini-like HB2 features observed in 
dual-culture conditions. 
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3.4.14 Distribution of myoepithelial cells and fibroblasts in 3D in vitro tri-culture 
model 
Distribution of GFP Myo1089 cells and LS11-083 dsRed Fibs in tri-cultures with HB2 cells was 
visualised by IHC using anti-tGFP and anti-dsRed respectively (Fig 3.21). Representative images 
from three technical replicates presented. tGFP staining was observed in rounded cells 
associated around the edges of HB2 units. dsRed staining was detected in long spindle-shaped 
cells in all HB2 gels. These were loosely distributed throughout the collagen gels and on 
occasions, associated with edges of HB2 units. This confirmed units observed by H & E staining 
still consisted predominantly of HB2 cells and not GFP Myo1089 cells or LS11-083 dsRed Fibs.  
3.4.15 Characterisation of 3D in vitro tri-culture model and comparison to normal 
breast tissue 
Immunohistochemical characterisation of the 3D tri-culture model optimised above 
demonstrated a phenotype strikingly similar to that of the normal breast (Fig 3.22 & 3.23). 
Representative images from three technical replicates presented. With the addition of LS11-
083 dsRed Fibs, HB2 units retained a phenotype as shown in dual-culture with GFP Myo1089 
cells. Briefly, E-Cad was expressed at HB2 cell-cell junctions with EMA at apical membranes. 
Mixtures of proliferative and non-proliferative HB2 cells were identified via Ki67 staining, with 
cell apoptosis detected within central lumens of units via M30 staining. αSMA was found to be 
specific to GFP Myo1089 cells while basement membrane production was detected around 
outer edges of HB2 units via Coll IV expression. Vim expression was detected in both GFP 
Myo1089 cells and LS11-083 dsRed Fibs. Comparison of these features to normal breast 
demonstrated strong similarities to breast acini. E-Cad expression was specific to luminal 
epithelium with EMA sequestered to the apical-lumen interface of acini. Apoptosis featured 
within the lumens of breast acini as demonstrated by M30 expression and αSMA staining was 
specific to the myoepithelial layer of breast acini. Coll IV staining was detected in basement 
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membranes surrounding breast acini with Vim expression seen in both myoepithelial cells and 
fibroblasts within the breast tissue.  
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Fig 3.20 H & E staining of 3D in vitro tri-culture models of HB2 cells with myoepithelial cells 
and different numbers of fibroblasts 
HB2 cells were cultured with GFP positive myoepithelial cells (GFP Myo1089) and dsRed 
positive fibroblasts (LS11-083 dsRed Fib) in 3D collagen gels for 21 days. 5µm sections of gels 
were stained with H & E and representative images from three technical replicates taken. 
Regardless of number of LS11-083 dsRed Fibs, all gels featured HB2 units (HU) and spindle-
shaped cells (SC) loosely distributed throughout the collagen. Culture with 0.1x105 LS11-083 
dsRed Fibs (a) yielded HB2 units with lumens (L) consisting of cohesive cells (CC). HB2 units 
with 0.25x105 LS11-083 dsRed Fibs (b) similarly contained lumens (L) but featured discohesive 
cells (DC) compared with 0.1x105 LS11-083 dsRed Fibs. HB2 units cultured with 0.5x105 (c), 
1x105 (d) and 2x105 (e) LS11-083 dsRed Fibs all featured discohesive cells (DC) an appeared less 
organised with no lumen formation. Original magnification 20x, scale bars = 100µm. 
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Fig 3.21 Immunohistochemical labelling of myoepithelial cells and fibroblasts in 3D in vitro 
tri-culture model  
HB2 cells were co-cultured in 3D collagen gels with GFP positive myoepithelial cells (GFP 
Myo1089) and dsRed positive fibroblasts (LS11-083 dsRed Fibs) for 21 days. 5µm sections of 
gels were stained with anti-tGFP and anti-dsRed by IHC to visualise distribution of 
myoepithelial cells and fibroblasts within gels. Representative images from three technical 
replicates presented. Positive staining for tGFP was detected in GFP Myo1089 cells distributed 
around the outer edges of HB2 cell units (arrows, a). dsRed staining highlighted LS11-083 
dsRed Fibs loosely distributed throughout collagen gels (arrows, b). Original magnification 20x, 
scale bars = 100µm. 
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Fig 3.22 Immunohistochemical characterisation of 3D in vitro tri-culture model compared to 
normal human breast tissue A 
In vitro tri-culture model containing HB2 cells, GFP Myo1089 cells and LS11-083 dsRed Fibs 
were characterised by IHC and compared to normal breast tissue sections. Representative 
images from three technical replicates presented. Primary antibody was omitted to serve as a 
negative control (a & b). E-cadherin (E-Cad) was expressed by HB2 cells at cell-cell junctions 
(arrow, c) in keeping with luminal epithelium of breast acini (arrow, d).  Strong staining was 
concentrated at the HB2 cell-lumen interface of HB2 units (yellow arrow, e) and was specific to 
apical membranes of luminal epithelium of breast acini (arrow, f). The majority of cells within 
HB2 units were positive for Ki67 (g) while few Ki67 positive cells were detected within breast 
acini (arrow, h).  Original magnification for tri-culture model (a, c, e & g) 20x, scale bars = 
100µm. Original magnification for normal tissue (b, d, f & h) 40x, scale bars = 50µm.   
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Fig 3.23 Immunohistochemical characterisation of 3D in vitro tri-culture model compared to 
normal human breast tissue B 
In vitro tri-culture model containing HB2 cells, GFP Myo1089 cells and LS11-083 dsRed Fibs 
were characterised by IHC and compared to normal breast tissue sections. Representative 
images from three technical replicates presented. M30 staining was detected within lumens of 
HB2 units (arrow, a) comparable to M30 staining observed within lumens of breast acini 
(arrow, b). α-smooth muscle actin (αSMA) was observed in rounded myoepithelial cells on the 
outer edges of HB2 units (arrow, c) while a continuous layer of αSMA positive myoepithelial 
cells surround luminal epithelial cells of breast acini (arrow, d). Collagen IV (Coll IV) was 
concentrated around outside edges of HB2 units (yellow arrow, e) and similarly is 
demonstrated encapsulating breast acini (arrow, f). Vimentin (Vim) staining was detected in 
both rounded GFP Myo1089 cells (M) on outer edges of HB2 units and spindle-shaped LS11-
083 dsRed Fibs (F) in the tri-culture model (g) analogous to Vim positivity in myoepithelial cells 
(M) and fibroblasts (F) in normal breast tissue (h). Original magnification for tri-culture model 
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(a, c, e & g) 20x, scale bars = 100µm. Original magnification for normal tissue (b, d, f & h) 40x, 
scale bars = 50µm.  
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3.4.16 Optimisation of quantification methods for number and size of HB2 units  
It was considered necessary to determine a method of quantifying the co-unit structures 
observed in the model in order to make it a more viable model for research, and in order to 
elucidate any changes in structural features in a scientific manner. In order to determine 
whether the depth of an individual gel had an effect on the number and area of HB2 units 
formed and thus to determine an appropriate number of sections to use for quantification, 10 
x 5µm H & E stained serial sections from a single representative 3D tri-culture gel were 
quantified using Aperio Imagescope software (Fig 3.24). Quantification of number of HB2 units 
showed variation between individual serial sections but did not systematically increase or 
decrease when traversing through the gel. No significant correlation between the mean 
number of units to the depth of gel section was observed upon calculation of the Pearson 
product-moment correlation coefficient using GraphPad Prism software (p= 0.1931). The 
coefficient of variation for number of units was calculated as a running coefficient of variation 
and demonstrated that quantification of one section gave a coefficient of variation from the 
mean of 10 sections of 13%. As serial sections were sequentially calculated this steadily 
decreased and dropped to 9.52% upon quantification of 10 serial sections.  
Quantification of area of HB2 units (Fig 3.25) demonstrated no significant correlation between 
the mean area of units to the depth of gel section upon calculation of the Pearson product-
moment correlation coefficient using GraphPad Prism software (p=0.0779).  The coefficient of 
variation for area of units was calculated as a running coefficient of variation and 
demonstrated that quantification of one section gave a coefficient of variation from the mean 
of 10 sections of 11.6%. As serial sections were sequentially calculated this steadily decreased 
and dropped to 9.36% upon quantification of 8 serial sections but then rose to 17.2% upon 
quantification of 10 serial sections. This suggests sections taken from greater than 40µm 
contains units with areas that are not representative of the mean population. The running 
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mean area of HB2 units plotted against the number of units counted demonstrated that the 
mean area taken from 80 measurements or upwards gave a good representation of the mean 
taken from all 10 serial sections. Quantification of the number of units showed that the mean 
number of units per section was between 62 and 90 units which indicated that to get a good 
representation of the mean area of HB2 units from 10 serial sections, one section could be 
quantified. 
Taken together, it was reasoned that by taking one section from the gel at a depth between 
15µm and 40µm would give a sufficient representation of the mean area of HB2 units from 10 
serial sections and would give a count of number of units with an error of 13% and an area of 
units with an error of 11.6%. Therefore, quantifying one section taken from an appropriate 
depth of a gel was reasoned to be a satisfactory method of quantifying area and number of 
HB2 units.  
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Fig 3.24 Quantification of number of HB2 units in 3D tri-culture gels from 10 H&E stained 
serial sections 
10 x 5µm serial sections of one representative 3D tri-culture gel were stained with H&E. 
Number and area (µm2) of HB2 units from each serial section were quantified with Aperio 
Image scope and analysed with Graph Pad Prism 6 software. (a) The total mean number of HB2 
units from all 10 sections was calculated and is denoted by the dashed line. While the number 
of HB2 units did vary between sections, the numbers did not systematically increase or 
decrease when traversing through the gel as demonstrated by quantification of serial sections. 
Correlation analysis for number and depth of gel demonstrated no significant trend when 
traversing through the gel (p=0.1931, Pearsons product-moment correlation coefficient). (b) 
The running coefficient of variation demonstrated that taking one section gives an error of 
13% to the total mean across 10 serial sections. This error falls to 9.52% upon quantification of 
10 serial sections.   
a) 
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Fig 3.25 Quantification of area of HB2 units in 3D tri-culture gels from 10 H & E stained serial 
sections 
10 x 5µm serial sections of 1 representative 3D tri-culture gel were stained with H & E. Area of 
HB2 units (µm2) from each serial section were quantified with Aperio Image scope and 
analysed with Microsoft Excel and Graph Pad Prism 6 software. The total mean area of HB2 
units from all 10 sections was calculated and is denoted by the dashed lines. (a) The running 
mean area of units demonstrated that size of units did not significantly increase or decrease 
mean = 1159 
a) 
b) 
mean = 
1159 
c) 
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when traversing through the gel as demonstrated by quantification of serial sections. 
Correlation analysis for area and depth of gel demonstrated no significant trend when 
traversing through the gel (p=0.0779, Pearsons product-moment correlation coefficient). (b) 
The running coefficient of variation demonstrated that taking 1 section gives an error of 11.6% 
to the total mean across 10 serial sections. This error falls to 9.36% upon quantification of 8 
serial sections. mean of all measurements of HB2 unit area taken across all 10 sections was 
calculated to determine an appropriate sample size for quantification.  This demonstrated that 
the mean area of HB2 units calculated from approximately 80 units and upwards gives a good 
estimate of the mean for the whole population from 10 serial sections. (c) The running mean 
of all measurements of HB2 unit area taken across all 10 sections was calculated to determine 
an appropriate sample size for quantification.  This demonstrated that the mean area of HB2 
units calculated from approximately 80 units and upwards gives a good estimate of the mean 
for the whole population from 10 serial sections.  
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3.5 Discussion 
Traditionally, breast cancer studies have focussed on the transition of luminal epithelial cells 
from a pre-invasive to an invasive state while less emphasis has been put on investigating the 
earlier stages of breast cancer initiation and carcinogenesis. In order to address this, an 
appropriate 3D model of normal breast tissue would be required that incorporates all three of 
the major cell types of breast and that is representative of in vivo breast tissue. Research 
groups striving to elucidate the mechanisms behind luminal epithelial transformation have 
relied on the use of MCF10A cells in 3D basement membrane preparations with either 
fibroblasts or fibroblasts with endothelial cells or adipocytes [201, 204, 212]. While these 
models provide a more sophisticated 3D environment in which cells can propagate, breast 
tissue consists predominantly of collagen I and thus would be a more appropriate matrix for an 
in vitro model of breast. In addition, myoepithelial cells have largely been neglected in these 
studies despite their presence in normal in vivo breast tissue, their loss in the transition from 
DCIS to invasive cancer [213] and despite evidence of their tumour suppressive nature [71, 
214]. While Holliday et al produced a such a model of DCIS, analysis was costly and laborious 
and involved the use of cell tracker dyes which limited culture to 7 days [149].  
Therefore, in this series of experiments we endeavoured to develop a longer term and easily 
analysable 3D in vitro model that included both myoepithelial cells and fibroblasts with luminal 
epithelial cells in the physiologically relevant matrix of collagen I.  By validating against normal 
breast reduction mammoplasty tissue during model development, we aimed to validate that 
the model recapitulated the features and phenotype of in vivo breast acini.  
To produce such a model, the gold standard would have been to use individual cell populations 
isolated from primary breast tissue. However, in order to optimise a model without wasting 
valuable material and without introducing complications such as donor variability, 
representative luminal and myoepithelial cell lines were used to optimise a dual-culture model 
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in the first instance. Both the commonly used cell line MCF10A and less commonly used cell 
line HB2 were used to represent luminal epithelium. The cell line Myo1089 was used to 
represent the myoepithelium.  
One of the first hurdles to overcome in developing this model was distinguishing between 
luminal epithelial and myoepithelial cells in culture due to their similarities in cell morphology. 
Lentiviral vectors are a widely used tool to deliver exogenous genes into cells [215].  These 
genes can be advantageous in that they can assign a specific characteristic to a cell such as 
fluorescence which can be used to track cells in culture [216]. We applied this concept to track 
Myo1089 cells in culture via stable transduction with turbo green fluorescent protein (tGFP) 
using pGIPZ lentiviral vector. Production of GFP Myo1089 cells and identification of a suitable 
tGFP antibody for IHC allowed us to distinguish between GFP Myo1089 cells and either 
MCF10A cells or HB2 cells during longer term culture of these cells in 3D. 
3.5.1 Choice of representative normal luminal epithelial cell for the model 
Since the use of MCF10A cells as a representative of “normal” luminal epithelium is well 
documented, we attempted to incorporate these cells in our 3D co-culture model with GFP 
Myo1089 cells in collagen I. It was first noted that MCF10A cells were plastic in culture with a 
mixture of luminal- and basal-like cell morphologies observed as a 2D monolayer. This was 
confirmed through immunofluorescence characterisation which demonstrated expression of 
luminal markers EMA and cytokeratin 18 as well as basal/myoepithelial markers cytokeratin 
14, β4-integrin and αSMA. The use of immunomagnetic beads to isolate different populations 
of breast epithelial cells has been previously described [183, 217]. Since β4-integrin is a 
transmembrane receptor which is specific to basal/myoepithelial cells of the breast [18], and 
was expressed by a sub-set of our MCF10A cells, we attempted to isolate sub-populations of 
basal-like MCF10A cells from luminal-like MCF10A cells via β4-integrin coated Dynabead 
separation.  The two separate sub-populations were designated MCF10A Luminal (β4-integrin 
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negative) and MCF10A Basal (β4-integrin positive) and these along with MCF10A wildtype cells 
were co-cultured with GFP Myo1089 cells in collagen I in three separate 3D in vitro dual-
culture models and compared. Since fibroblasts are proven to influence arrangement and 
growth of mammary epithelial cells [218] and conditioned media has been validated to serve 
as a substitute for using fibroblast cells in culture [219], MCF10A and GFP Myo1089 cells were 
cultured in 50% MCF10A specific medium and 50% HMFU19 fibroblast conditioned medium. 
Examination of MCF10A wildtype structures by H & E staining and IHC demonstrated variation 
in morphology and a mixed phenotype with only some structures positive for E-Cad and EMA 
reminiscent of the plasticity of these cells in 2D culture. MCF10A Luminal and MCF10A Basal 
were uniformly positive for these two markers. However, regardless of population of MCF10A 
cells, all structures were positive for basal/myoepithelial markers αSMA and vim and evidence 
of basement membrane production was seen in all structures. The propensity of MCF10A cells 
to adopt a basal phenotype has been described by several research groups [180, 220] and are 
reported to be highly sensitive to changes in culture conditions [221]. The inability of these 
cells to maintain expression of luminal epithelial markers in our culture system suggested they 
may not be an appropriate representative of luminal epithelium for our model. In addition, 
despite the successful culture of MCF10A spheroids for up to 26 days in other studies [222], 
MCF10A structures could not be maintained in our culture system beyond 7 days despite the 
presence of fibroblast conditioned medium, preventing any long term experimentation with 
this model. This highlighted a need to identify another cell line to better represent the luminal 
epithelium in our model in order to investigate cancer initiation mechanisms.  
HB2 cells were selected as an alternative representative of luminal epithelium due to their 
proven ability to form branching duct-like structures in collagen I and for their luminal 
epithelial characteristics [199]. In concordance with this, immunofluorescence characterisation 
of these cells as a 2D monolayer demonstrated a luminal epithelial cell phenotype with 
positive staining for cytokeratin 18 and EMA luminal markers and no staining for the 
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myoepithelial markers cytokeratin 5/6 and αSMA.  These were therefore considered viable as 
a luminal epithelial representative for our study. 
It was recognised that co-culturing different cell types together each with their own specific 
media requirements would require optimisation of culture media conditions to ensure survival 
and to maintain phenotype of both GFP Myo 1089 and HB2 cells. Since luminal epithelial cells 
are susceptible to adopting a more basal phenotype [223] which could have been induced by 
using GFP Myo1089 specific medium on HB2 cells, 100% HB2 specific medium was used 
initially when co-culturing HB2 and GFP Myo1089 cells in 3D collagen I. Examination of HB2 
structures by H & E staining demonstrated small, compact and sparse structures using HB2 
specific medium with no evidence of cells with a myoepithelial-like spindle-shaped 
morphology. Addition of fibroblast conditioned medium had no effect on the morphology of 
these structures. However, the use of 50% GFP Myo1089 cell specific medium with 50% FCM 
produced much larger structures which were more abundant, showed evidence of lumen 
formation with appearance of cells with a myoepithelial-like spindle-shaped morphology 
distributed throughout the collagen gel. This suggested that the presence of GFP Myo1089 cell 
specific medium was necessary to retain GFP Myo1089 cell survival and that these cells 
influenced HB2 cell arrangement. We confirmed that these features were mediated by the 
presence of GFP Myo1089 cells in the culture system and not just through the influence of GFP 
Myo1089 cell specific medium through culturing HB2 cells alone in either 50% HB2 cell specific 
medium: 50% FCM or 50% GFP Myo1089 cells specific medium : 50% FCM. This proved that 
HB2 cells are unable to form large units with lumens without the presence of GFP Myo1089 
cells regardless of the GFP Myo1089 cell specific medium being present.  
The importance of GFP Myo1089 cells in HB2 cell arrangement was further demonstrated by 
increasing the number of GFP Myo1089 cells. An excess of GFP Myo1089 cells produced HB2 
units which were more cohesive, rounded, contained lumens and thus more representative of 
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in vivo breast acini. Immunohistochemical analysis of these structures using anti-tGFP antibody 
demonstrated GFP Myo1089 cell distribution around outer edges of HB2 units making physical 
contacts with HB2 cells reminiscent of in vivo breast acini. This indicated that HB2 cells and 
GFP Myo1089 cells could be co-cultured together in 3D collagen I and produce structures that 
were comparable to in vivo breast acini. Furthermore, the quality of these structures were 
retained and even enhanced noted by production of larger “cleared” lumens through 
prolonged culture for up to three weeks allowing this model to be used for longer term 
experimentation.  
It has been previously reported that inclusion of myoepithelial cells with luminal epithelial cells 
in 3D collagen I matrix can abrogate the need for basement membrane preparations such as 
MatrigelTM [71] due to their ability to produce proteins required for basement membrane 
formation [72]. Immunohistochemical characterisation of our dual-culture model of HB2 and 
GFP Myo1089 cells demonstrated such basement membrane deposition around the outer 
edges of HB2 units through coll IV and TN-C expression. All HB2 cell units displayed E-Cad 
expression between HB2 cell junctions indicating these cells did not undergo EMT and all units 
were polarised with EMA situated at the apical-luminal interface of HB2 cells. Furthermore, 
unlike MCF10A dual-cultures, HB2 cells retained a luminal epithelial phenotype with αSMA and 
vim staining restricted to GFP Myo1089 cells. Lumen formation was evidenced through 
apoptosis in the centres of HB2 units. The morphology and phenotype of these structures 
provided confidence that, under the right conditions, HB2 cells in co-culture with GFP 
Myo1089 in 3D collagen I were a better representative of breast acini than MCF10A cells and 
could be cultured for up to three weeks providing a better platform for experimentation of 
cancer initiation events.  
109 
 
3.5.2 Developing a tri-culture model by incorporation of fibroblasts 
Having successfully established a heterotypic 3D in vitro dual-culture model of normal human 
breast, we endeavoured to introduce a stromal fibroblast component to the model to better 
represent the in vivo breast microenvironment.   
Collagen I is a major synthetic product of fibroblasts thus fibroblasts form the structural 
framework for the majority of connective tissues and serve to maintain the ECM environment 
through secretion of factors such as MMPs [206]. Quiescent fibroblasts have the capacity to 
become “activated” during wound healing and fibrosis, synthesise collagen I [224] and 
characteristically acquire contractile stress fibres and express αSMA [225]. Fibroblast influence 
on breast epithelial architecture is well documented [205, 226, 227] and is specifically 
enhanced by culture in 3D in response to an ECM environment [228].  
HMFU19 cells are a breast fibroblast cell line originally isolated from breast reduction 
mammoplasty samples [181]. While these were originally considered for use as the fibroblast 
component of our tri-culture model, characterisation of these cells by immunofluorescence 
demonstrated a loss of a “normal” fibroblast phenotype through expression of αSMA 
suggestive of a myofibroblast phenotype and expression of epithelial-associated cytokeratins 
14 and 18. These cells were therefore deemed an inadequate representative of normal 
fibroblasts and presented a need to obtain a new normal fibroblast cell line.  
Due to lack of commercially available normal fibroblast cell lines, we isolated fibroblasts from 
breast reduction mammoplasty samples to produce a normal primary fibroblast cell 
population. This was based on a technique by Holliday et al [149] whereby digestion of primary 
tissue with collagenase I yielded a fibroblast-rich supernatant fraction from which adherence 
and outgrowth of a cell population with an elongated spindle-shaped morphology was 
achieved. These grew in whorl patterns characteristic of fibroblast monolayer cultures. 
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However, primary cell cultures have a finite life span [229] limiting use of these cells to short 
term experiments and presenting issues with reproducibility. hTERT is the catalytic subunit of 
the telomerase enzyme and catalyses the addition of nucleotides to chromosome telomeres. 
This prevents degradation of chromosome ends and allows multiple rounds of DNA replication 
and thus proliferation and immortalisation of cells [230, 231]. It was reasoned that this 
technique could be applied to our primary fibroblasts to prolong their culture life span 
sufficiently for use throughout our study. Primary fibroblasts were retrovirally transduced with 
pBABE-hTERT-neo vector and compared to non-transduced cells. Previous cultures of primary 
fibroblasts in our laboratory have proven to senesce and apoptose following five passages (Dr 
Deborah Holliday, personal communication). It was therefore deemed unnecessary to select 
hTERT transduced fibroblasts with geneticin as if hTERT transduction was not successful; hTERT 
transduced fibroblasts would also have a finite life span in culture with little cell survival past 
five passages.  As expected, un-transduced primary fibroblasts did not survive more than five 
passages over three weeks while hTERT transduced fibroblasts underwent 12 passages in the 
same time while retaining an elongated spindle-shaped morphology. These also did not show 
evidence of becoming larger and fatter which are phenotypic changes associated with 
fibroblast senescence [232]. All subsequent experiments using these fibroblasts were done so 
with hTERT transduced fibroblasts between passages 12 and 20. hTERT transduced fibroblast 
morphology did not change upon 20 passages suggesting these cells may be immortalised but 
would require further experimentation to confirm this. Satisfied with a representative 
fibroblast population that could be cultured in excess of three weeks and therefore sufficient 
for our experiments, LS11-083 hTERT fibroblasts were lentivirally transduced with pFURW-
dsRed vector to allow tracking in 3D tri-culture. Following FACS, these retained constitutive 
expression of dsRed protein in 100% of the cells with an elongated spindle-shaped morphology 
and were termed LS11-083 dsRed Fibs. Furthermore, characterisation of LS11-083 dsRed Fibs 
by immunofluorescence demonstrated a normal fibroblast phenotype with 100% positivity for 
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vim and lack of luminal and myoepithelial cell markers in all cells. These were also confirmed 
to be non-activated through lack of αSMA expression. LS11-083 dsRed Fibs were therefore 
considered a robust, traceable cell population to represent the normal fibroblast component in 
our model. 
Due to the propensity of fibroblasts to dominate primary cultures [233], their basic media 
requirements to thrive and their ability to maintain their fibroblast phenotype regardless of 
culture in epithelial specific media, we anticipated that LS11-083 dsRed Fibs would flourish in 
both HB2 and GFP Myo1089 medium in a tri-culture model. The introduction of LS11-083 
dsRed Fibs into the tri-culture model negated the need for fibroblast conditioned medium in 
the culture system as previously optimised with HB2 and GFP Myo1089 dual-culture. Since we 
were conscious of inducing a luminal-myoepithelial transition of HB2 cells by using an excess of 
GFP Myo1089 cell specific medium and had also proved 50% GFP Myo1089 cell specific 
medium was sufficient for GFP Myo1089 cell survival, 50% HB2 cell specific medium: 50% GFP 
Myo1089 cell specific medium was used for the tri-culture model. Varying numbers of LS11-
083 dsRed Fibs were incorporated into the culture system with the previously optimised ratio 
of HB2 to GFP Myo1089 cells and assessed through visualisation with H & E. An optimal 
number of 0.1x105/ml of LS11-083 dsRed Fibs was identified that successfully retained the 
acini-like structures seen in the dual-culture system with hollow HB2 units, GFP Myo1089 cells 
associated around outside edges and LS11-083 dsRed Fibs loosely distributed throughout the 
collagen gel. These structures were examined by a consultant breast pathologist (Dr Rebecca 
Millican-Slater) who confirmed that the proportion of each of these three cell types and the 
structures they formed were a good representation of normal in vivo breast. In these 
conditions, a maximum culture period of three weeks was established through time course 
experiments with structural degradation noted after weeks four, five and six. 
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Immunohistochemical analysis of the tri-culture model phenotype under optimised culture 
conditions revealed a strikingly similar staining pattern to breast acini providing confidence 
that this is a robust model of normal breast tissue. Through culture of HB2 cells in the 
presence of both a myoepithelial and a fibroblast component, we have demonstrated the 
production of a basement membrane through coll IV and TN-C expression, the polarisation of 
HB2 cells through EMA and E-cad expression and the presence of lumens cleared via apoptosis 
through M30 expression without the need for MatrigelTM. In addition, we have proved that 
each individual cell type retains a phenotype representative of their corresponding cell type in 
normal breast tissue with vimentin expression detected in GFP Myo1089 and LS11-083 dsRed 
Fibs cells and αSMA found in GFP Myo1089 cells only.  
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3.5.3 Quantification Technique 
Having established a model that we were confident was representative of normal breast 
tissue, we reasoned that this model could be a useful tool for cancer initiation studies through 
manipulation of individual cells prior to culture. In order to analyse and interpret differences in 
structure formation/architecture scientifically upon cell manipulation in future experiments, 
we deemed it necessary to determine a technique of quantifying our observations obtained 
from histological methods. Through collaboration with the Leeds Digital Pathology Team, a 
method of quantifying size and number of HB2 units was developed by annotating digitally 
scanned H & E stained slides using Aperio Image Scope software. Due to the 3D nature of the 
model, it was anticipated that the depth of gel may affect the size and number of HB2 units. 
With this in mind, 10 x 5µm serial sections from one tri-culture gel were taken, H & E stained, 
digitally scanned, annotated and size and number of HB2 units compared. We found that the 
number of HB2 units did not systematically increase or decrease when traversing through the 
gel suggesting that HB2 units were evenly distributed throughout the gel. We demonstrated 
that quantifying one section gave a good estimate of the mean number of HB2 units 
throughout the whole population from 10 sections with an error of 13%.  
Similarly, no significant differences were seen between sections two to eight from the mean 
area of HB2 units from the whole population. Since the quantification of area of approximately 
80 HB2 units gave a good representation of the mean from the whole population and the 
mean number of units per section was between 62 and 90 units, we reasoned that quantifying 
one section, providing it was taken from a depth of between 15 to 40µm, was an acceptable 
method of quantification of area and number of HB2 units.  
Conscious of the fact that there may be variation in diameter and therefore sections between 
gel replicates or gels cultured in different conditions that could influence the number and size 
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of HB2 units, we reasoned that area and number of HB2 units would be expressed as a ratio of 
the total area of the gel section in future experiments. 
3.5.4 Summary 
Current available 3D in vitro models of breast typically incorporate one or two cell types, such 
as MCF10A cells and fibroblasts [149, 195, 201]. Presented here for the first time is a 3D in 
vitro model of normal breast tissue that not only incorporated luminal epithelial cells and 
fibroblasts, but also included myoepithelial cells which are often neglected from other 3D in 
vitro cultures of breast. In addition, unlike other 3D in vitro models of breast which are often 
cultured in basement membrane preparations such as MatrigelTM [190],  this model was 
cultured in the more physiologically relevant matrix of collagen I. Using cells engineered to 
express red and green fluorescent proteins we proved individual cell populations could be co-
cultured and tracked in 3D. Culture in this manner yielded polarised structures with lumens 
that mimic breast acini and that produced basement membrane proteins at their periphery, 
replicating features achieved with other available 3D in vitro models of breast in the literature 
[154, 190]. However, unlike other models, this was achieved by incorporating myoepithelial 
cells and without the need for MatrigelTM and also made the model more representative of 
normal in vivo breast tissue than other available models. This was proven by comparing 
morphology and phenotype to normal in vivo breast. This demonstrated that each individual 
cell type retained an in vivo phenotype and, that combined, shared morphology and 
phenotype with normal breast acini.  
Therefore this model is robust and a good representative model of normal human breast 
tissue. Furthermore, while mimicking features of acini in vivo and replicating key features of 
other available 3D models, our model offers the opportunity to study the role of myoepithelial 
cells in 3D luminal epithelial architecture and the co-operation of these with fibroblasts in this 
process which have not been possible before.  
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However, it is recognised that although our model may be a good representation of normal 
breast acini, it does lack the complete cellular heterogeneity found in in vivo breast tissue. 
Other stromal components such as endothelial cells [234-236], immune cells [237, 238] and 
adipocytes [239] all play key roles in breast cancer progression through release of tumour 
promoting cytokines and growth factors. 3D co-culture models have been achieved which 
include endothelial cells [240] or adipocytes [204, 212] with epithelial cells and fibroblasts but 
neglect the myoepithelial cell component of breast. In order to provide a comprehensive 
model of human breast tissue, cells such as these would need to be incorporated into our 
model. However, tracking cells in a multicellular model such as this may prove challenging.  
This could perhaps be overcome to certain degree by use of cell conditioned media but 
applications of the model would be limited.  
Nevertheless, since our model provided an adequate stromal component, could be analysed 
through standard laboratory techniques and was quantifiable, we feel it has the potential to be 
used as a tool for cancer initiation studies and could be built upon in the future to include 
other aspects of in vivo breast architecture. 
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4 Chapter 4: Assessing the suitability of the model for cancer 
initiation studies via overexpression of HER proteins  
4.1 Introduction 
Having produced a 3D in vitro tri-culture model that accurately recapitulates the normal breast 
environment, we then sought to determine if the model could be used as a tool to study 
cancer initiation processes. By genetic manipulation of the luminal epithelium in the model 
which as discussed in Chapter 1 are the source for the majority of breast cancers, we aimed to 
disrupt the normal architecture of the model to produce a morphology and phenotype akin to 
early stages of breast cancers. To do this we selected HER proteins as a candidate to 
overexpress in HB2 cells. 
4.1.1 HER2 
Human epidermal growth factor receptor-2 (HER2/Neu, c-erbB2) is a member of a family of 
receptor tyrosine kinases (RTKs) known as HERs/ErbBs. The HER family contains three other 
members, epidermal growth factor receptor (HER1/ErbB1/EGFR), HER3 (ErbB3) and HER4 
(ErbB4). Like other RTKs, HER proteins are transmembrane spanning receptors usually 
consisting of a cysteine rich extracellular domain designed for ligand binding, and an 
intracellular kinase domain rich in tyrosine autophosphorylation sites [241]. HER receptors 
exist in a monomeric form until stimulation from ligand binding where dimerization occurs 
forming homodimers or heterodimers with other HER receptors [242]. Heterodimerisation is 
the key to the signal amplification and diversification of HER receptors and is summarised in 
Fig 4.1.  Investigation into the extracellular and intracellular domains of HER receptors has 
revealed that HER2 proteins are incapable of binding ligands [243] while HER3 receptors have 
weaker intrinsic tyrosine kinase activity in comparison to other HER receptors [244]. Without 
heterodimerisation with other receptors, these HER members remain inactive. Since HER2 
exists in an open confirmation [245], it is the preferred heterodimerisation partner for other 
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HER family members. HER2 reduces the dissociation rate of its heterologous ligands [246] and 
can prevent internalisation and thus down-regulation of its binding partners [247]. This results 
in prolonged and more potent signalling, making HER2 containing heterodimers the most 
catalytic heterodimer combinations of the HER family. Due to the ability of HER3 to bind 
multiple PI3K protein substrates at a time [248] and the ability of HER2 to sustain ligand-HER3 
interactions, the HER2-HER3 heterodimer is the most potent and mitogenic heterodimer of the 
HER family. The potential of the HER2-HER3 heterodimer to activate PI3K [249],the ability of 
HER2 to activate the MAPK pathway [250, 251] and Stat transcription factors [252, 253] makes 
HER2 a key regulator of a variety of cell responses such as proliferation, apoptosis and 
differentiation. It could therefore be expected that HER2 would play a role in normal 
mammary development and maintenance of normal breast physiology. 
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Fig 4.1 Diagrammatic representation of HER dimerization combinations and their 
corresponding ligands 
Ligand binding to HER receptors induces formation of homodimers (HER1 and HER4 only) or 
heterodimers leading to activation and phosphorylation (P) of tyrosine residues within the 
intracellular domains. HER ligands belong to the epidermal growth factor family (EGF) and over 
16 different ligands have been identified, selections of which are displayed. These can be 
grouped into three main categories. HER1 binding ligands such as EGF, amphiregulin and 
transforming growth factor α (TGFα), HER1 and HER4 binding ligands such as betacellulin, 
heparin-binding EGF (HB-EGF) and epiregulin, and, the heregulin family (HRG). HRG1 and HRG2 
bind HER2-HER3, HER2-HER4 and HER4-HER4 dimers while HRG3 and HRG4 are HER4 binding 
ligands. The ability of HER receptors to heterodimerize allows the activation of a variety of 
different as well as overlapping downstream signalling pathways from the same the ligand 
making the HER signalling network diverse and complex.  
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However, perhaps due to the variety of signalling pathways that HER2 regulates coupled with 
the lethality of knocking out the HER2 gene in mouse models, the role HER2 plays in mammary 
development remains unclear. Due to overlapping functions of all four HER receptors, and the 
fact that more than one HER receptor has the capacity to respond to the same ligand 
[reviewed in 254], clarifying the role of individual receptors in mammary development is 
challenging. Furthermore, research on this topic to date has been limited to studies with 
murine models which may not be conserved in humans due to physiological differences 
between mice and humans [255]. However, studies in mice and rats have demonstrated a 
need for HER2 in several stages of mammary development. HER2 has proven necessary for 
terminal end bud formation [256], for lactation at parturition [257] and plays a role in 
hormonally controlled pubertal development [258]. The roles of HER2 in these processes are 
largely linked to epithelial cell proliferation and invasion which are key events in breast 
tumorigenesis. Therefore it is logical that this receptor would have oncogenic potential and 
could play a key part in breast cancer progression. 
4.1.2 HER2 and breast cancer 
With this in mind, it is not surprising that HER2 gene amplification and protein overexpression 
is found in approximately 16% of breast cancers [259] with breast cancer cells demonstrating 
as many as 50 copies of the HER2 gene [260]. Overexpression of HER2 is associated with a poor 
prognosis and survival in breast cancer patients and correlates with more invasive tumours 
[261]. The fact that HER2 overexpression also occurs in up to 50% of DCIS [97] suggests a role 
for HER2 in early events of cancer initiation and tumorigenesis. Studies in mice have shown 
HER2 overexpression alone is sufficient to induce transformation of mammary epithelium in a 
single step [262, 263] demonstrating the potency of HER2 as an oncogene. In addition to its 
mitogenic properties, HER2 has been linked to an increase in cancer stem cell populations in 
breast [264] suggesting this receptor may initiate breast tumour formation through a variety of 
mechanisms.  
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The mechanism behind how HER2 can promote cancer initiation still remains unclear. In vitro 
studies using cell lines has provided some insight into the effect HER2 signalling has on already 
established tumorigenic breast cancer cells. Early in vitro studies demonstrate a decrease in 
apoptosis [265], an increase in proliferation [266] as well as an increase in migration [267-269] 
and invasion [270] in breast cancer cell lines in response to HER2. However, this does not 
address the transforming ability of HER2. Limited studies using non-tumorigenic breast 
epithelial cell lines in more sophisticated 3D models have given clues as to how this may occur. 
Studies using the non-tumorigenic breast cell lines HB2 in 3D collagen matrix have 
demonstrated increased branching [271] and MCF10A in 3D Matrigel have demonstrated 
disrupted and invasive structures in response to HER2 overexpression. This suggests a role for 
HER2 in increasing normal mammary epithelial cell migration and inducing an EMT phenotype. 
In addition, increased cell proliferation in luminal spaces of 3D MCF10A acini structures in 
response to HER2 overexpression suggests HER2 may promote a DCIS-like phenotype [165]. 
Although promising, these in vitro models do not take into account the influence of 
surrounding stromal cells on these processes. A more representative model of normal breast 
tissue is needed to investigate the effects of HER2 on normal mammary epithelial cell 
phenotype in the presence of stromal signals to get a more accurate picture of how HER2 
functions in vivo breast. 
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4.2 Aims 
The aim of this series of experiments was to investigate the ability of HER2 and HER3 both 
alone and combined to induce changes in phenotype and morphology of normal luminal breast 
epithelial cells in a physiologically relevant 3D tri-culture in vitro model of normal breast tissue 
described in Chapter 3. In parallel to this we sought to validate the appropriateness of using 
our 3D in vitro model for breast cancer initiation studies. This was addressed by :-  
 Comparing the phenotype of HER2, HER3 and both HER2 and HER3 overexpressing 
HB2 cells to wildtype HB2 cells in a 3D collagen mono-culture model 
 Investigating the effect of adding either myoepithelial cells or fibroblasts to wildtype 
and HER overexpressing HB2 cells in a 3D collagen dual-culture model  
 Investigating the effect of adding a combination of myoepithelial cells and fibroblasts 
on wildtype and HER overexpressing HB2 cells in a 3D tri-culture model  
 Quantifying differences in morphology of HB2 units by measuring area, number and 
lumen formation from sections of 3D gels stained with H & E  
 Characterising the phenotype by IHC   
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4.3 Materials and Methods 
HB2 cells that overexpressed HER2 and HER3 proteins were a gift courtesy of Dr Fedor 
Berditchevsky (University of Birmingham) and were maintained as per Table 2.1 Chapter 2. To 
generate HER2 overexpressing (HB2 HER2OE) and HER3 overexpressing HB2 cells (HB2 
HER3OE), HB2 wildtype cells (HB2 WT) were retrovirally transduced with HER2 and HER3 using 
two separate pSV2-neo plasmids containing HER2 and HER3 genes as previously described 
[272] and FACS was performed to isolate cell populations which were >95% positive for either 
HER2 or HER3. To generate both HER2 and HER3 overexpressing HB2 cells (HB2 HER2/3OE), 
HB2 HER2OE cells were retrovirally transduced with a pSV2-neo plasmid containing the HER3 
gene and double-staining flow cytometry was performed to isolate cell populations which 
were >95% positive for both transgenes. 
4.4 Results 
4.4.1 Confirmation of the overexpression of HER2 and HER3 in HB2 cell lines 
HER2 and HER3 protein expression was assessed in HB2 WT, HB2 HER2OE, HB2 HER3OE and 
HB2 HER2/3OE using western blotting. Fig 4.2 represents results from three biological 
replicates and showed that HER2 protein expression was increased in HB2 HER2OE and HB2 
HER2/3OE cells and HER3 protein expression was increased in HB2 HER3OE and HB2 HER2/3OE 
cells. Quantification data is presented as expression fold difference to HB2 WT for both 
proteins and confirmed a 40-fold increase in HER2 expression in HB2 HER2OE cells and a 13-
fold increase in HB2 HER2/3OE cells. HER3 was increased by 10-fold in HB2 HER3OE cells and 
by 17-fold in HB2 HER2/3OE cells. This confirmed that HB2 cells retained the overexpressed of 
HER2 and HER3 proteins as expected.  
123 
 
Fig 4.2 Western blot for HER2  and HER3 in HB2 cells transduced with HER2, HER3 or both 
HER2 and HER3 expression plasmids in comparison to HB2 wildtype cells. 
a) Anti-HER2 IgG was used to detect total HER2 protein in HB2 wildtype cells (HB2 WT), HB2 
cells overexpressing HER2 (HB2 HER2OE), HB2 cells overexpressing HER3 (HB2 HER3OE) and 
HB2 cells overexpressing both HER2 and HER3 (HB2 HER2/3OE). Bands of ~185kDa were 
observed in HB2 HER2OE and HB2 HER2/3OE cells with HB2 HER2OE displaying a more intense 
band than HB2 HER2/3OE. No bands were detected in HB2 WT and HB2 HER3OE cells. Anti-
HER3 IgG was used to detect total HER3 protein for which bands of ~185kDa were observed in 
HB2 HER3OE and HB2 HER2/3OE cells with HB2 HER2/3OE displaying a more intense band than 
HB2 HER3OE. No bands were detected in HB2 WT and HB2 HER2OE cells. Anti-β-Actin IgG was 
used as a loading control for which bands were observed in all samples at ~42kDa.  
b) Histograms show quantification of HER2 and HER3 expression following densitometry 
analysis using BioRad Image Lab 4.1 software. Expression was calculated as fold difference to 
HB2 WT after normalization to β-Actin for each cell type. Bars denote mean from three 
biological replicates and error bars the standard error of the mean (SEM).  
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4.4.2 The effect of HER protein overexpression on the morphology and phenotype 
of 3D in vitro tri-culture model of normal breast 
In order to determine the effect of HER protein overexpression in HB2 cells in our model, 
morphology of morphology of HB2 WT, HB2 HER2OE, HB2 HER3OE and HB2 HER2/3OE tri-
cultures with LS11-083 dsRed Fibs and GFP Myo1089 cells was assessed by H & E. These were 
analysed following 21 days in culture as it was demonstrated in Chapter 3 that 21 days was the 
optimal culture period for production of representative acini-like structures in our HB2 WT 
control cells.  Results presented are representative images from three technical replicates (Fig 
4.3). This demonstrated that as in Chapter 3, HB2 WT cells formed small rounded units with 
clear lumen formation with spindle-shaped cells loosely distributed throughout the collagen 
gel. Upon HER2 overexpression, HB2 cells appeared to form much larger, elongated units 
which featured distorted lumens and appearance of protrusions from outer edges of units.  
HER3 overexpressing cells also appeared to form larger units containing distorted lumens but 
these remained more rounded. HB2 cells overexpressing both HER2 and HER3 appeared to 
form a combination of smaller rounded units and larger elongated units that were larger than 
HB2 WT and also featured distorted lumens. Quantification of these structures (Fig 4.4) 
supported these observations. A significant increase in size of HB2 units was demonstrated 
upon HER2 and both HER2 and HER3 overexpression compared to HB2 WT units (p=<0.05, 
unpaired t-test). Only overexpression of HER3 alone induced a difference in number of units 
formed showing a significant decrease (p=0.0442, unpaired t-test). Overexpression of HER2, 
HER3 and a combination of HER2 and HER3 caused a decrease in lumen formation compared 
to HB2 WT (p=<0.05, unpaired t-test). 
Distribution of GFP Myo1089 cells and LS11-083 dsRed Fibs in tri-cultures with HER 
overexpressing HB2 cells was visualised by IHC using anti-tGFP and anti-dsRed respectively 
with representative images from three technical replicates presented (Fig 4.5). As per Chapter 
3, GFP Myo1089 cells were observed around outer edges of all HB2 units, and LS11-083 dsRed 
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Fibs were detected loosely distributed throughout all collagen gels and remained un-changed 
upon overexpression of HER2 and HER3. Association of LS11-083 dsRed Fibs with edges of HB2 
HER3OE units was also noted. This confirmed units observed and quantified by H & E staining 
still consisted predominantly of HB2 cells and not GFP Myo1089 cells or LS11-083 dsRed Fibs 
regardless of HER protein overexpression.  
Characterisation of phenotype of HB2 WT, HB2 HER2OE, HB2 HER3OE and HB2 HER2/3OE 3D 
tri-cultures by IHC with representative images from three technical replicates presented (Fig 
4.6 & 4.7) demonstrated that in the presence of both GFP Myo1089 and LS11-083 dsRed Fibs, 
E-Cad expression was observed at cell-cell junctions within all HB2 units regardless of HER2 or 
HER3 overexpression. However, this staining did appear weaker in HB2 HER2/3OE units. Strong 
EMA staining was detected in the single monolayer of cells surrounding a central lumen in HB2 
WT units, and across the entirety of HB2 HER2OE and HB2 HER3OE units. EMA staining 
appeared weaker in HB2 HER2/3OE units but distributed at the cell-lumen interface. Strong 
Ki67 expression was observed largely across the entirety of all HB2 units, however, areas of 
Ki67 negativity were detected within central luminal spaces of HB2 HER2/3OE units. No M30 
expression was detected within HB2 WT units but weak staining was detected in cells loosely 
distributed throughout collagen gel. HB2 HER2OE units contained no M30 expression while 
HB2 HER3OE and HB2 HER2/3OE showed speckles of M30 expression within centre of HB2 
units. Strong coll IV expression was detected neatly distributed around the edges of HB2 units 
regardless of HER2 or HER3 overexpression.  
4.4.3 HER2 overexpressing HB2 tri-cultures resemble DCIS in vivo  
In order to validate whether our HER2 overexpressing tri-culture models were representative 
of in vivo DCIS, we compared H & E stained sections of HB2 HER2OE tri-cultures with a cross 
section of a human in vivo breast tissue specimen that contained areas of both DCIS and 
normal adjacent acini to compare to our HB2 WT controls (Fig 4.8). As per Chapter 3, HB2 WT 
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units were small, rounded and contained clear lumens and were therefore strikingly similar to 
normal breast acini in vivo. Areas of DCIS in vivo featured large elongated ducts and contained 
distorted lumens with necrotic tissue. These also featured enlarged and discohesive cells. HB2 
HER2OE units similarly were elongated in shape and contained discohesive cells and distorted 
luminal spaces thought to be a product of necrosis. This not only confirmed that the normal 
tri-culture model was robust and retained features of normal breast acini, but this also 
confirmed that we could accurately recapitulate features of DCIS through overexpression of 
HER2 in our model.   
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Fig 4.3 H & E staining of 3D in vitro tri-culture models containing HER overexpressing HB2 
cells  
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were co-cultured in 3D 
collagen gels with GFP positive myoepithelial cells (GFP Myo1089) and dsRed positive 
fibroblast cells (LS11-083 dsRed Fib) for 21 days. 5µm sections of gels were stained with H & E 
and representative images from three technical replicates are presented. HB2 WT cells (a & b) 
formed cohesive rounded units (RU) with lumens (L) and gels featured spindle shaped cells (SC) 
loosely distributed throughout collagen matrix. HB2 HER2OE cells (c & d) formed much larger 
more elongated units (EU) with distorted lumens (DL) and featured protrusions (PRO) at edges. 
HB2 HER3OE cells (e & f) formed larger rounded units with distorted lumens.  HB2 HER2/3OE 
cells (g & h) formed a combination of large rounded and elongated units with distorted lumens 
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and gels featured spindle shaped cells loosely distributed in surrounding collagen matrix. 
Original magnification 20x, scale bars = 100µm. 
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Fig 4.4 Quantification of area, number and lumen formation of HER overexpressing HB2 units 
in 3D tri-culture gels from H & E stained sections 
Size, number and lumen formation of wildtype (HB2 WT Tri), HER2 overexpressing (HB2 
HER2OE Tri), HER3 overexpressing (HB2 HER3OE Tri) and both HER2 and HER3 overexpressing 
(HB2 HER2/3OE Tri) HB2 cell units cultured with both GFP Myo1089 and LS11-083 dsRed Fibs 
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were quantified with Aperio Image scope, analysed with Graph Pad Prism 6 and normalized to 
total size of each respective collagen gel section. (a) Overexpression of HER2 and HER2/3 in 
HB2 cells significantly increased the size of HB2 units formed. (b) Number of HB2 HER3OE units 
was significantly decreased only with no significant difference seen with HB2 HER2OE and HB2 
HER2/3OE. (c) Overexpression of HER2, HER3 and HER2/3 in HB2 cells significantly decreased 
lumen formation. Bars denote mean from three technical replicates and error bars standard 
error of the mean (SEM). * indicates significant difference to HB2 WT following unpaired t-test 
(p=<0.05). 
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Fig 4.5 Immunohistochemical labelling of myoepithelial cells and fibroblasts in 3D in vitro tri-
culture model  
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were co-cultured in 3D 
collagen gels with GFP positive myoepithelial cells (GFP Myo1089) and dsRed positive 
fibroblasts (dsRed Fibs) for 21 days. 5µm sections of gels were stained with anti-tGFP and anti-
dsRed by IHC to visualise distribution of myoepithelial cells and fibroblasts within gels and 
representative images from three technical replicates are presented. All gels were positive for 
tGFP in cells distributed around the outer edges of HB2 cell units (arrows, a, c, e & g). HB2 WT, 
HB2 HER2OE and HB2 HER2/3OE were positive for dsRed in cells loosely distributed 
throughout collagen gels (arrows, b, d & h respectively). HB2 HER3OE were positive for dsRed 
in cells loosely associated around outer edges of HB2 units (arrow, f). Original magnification 
20x, scale bars = 100µm.
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Fig 4.6 IHC characterisation of 3D in vitro tri-culture models containing HER overexpressing 
HB2 cells A 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype 
were characterised by IHC to assess cell adhesion and polarisation and representative images 
from three technical replicates are presented. All HB2 units showed E-cadherin (E-Cad) staining 
localised between HB2 cell junctions (yellow arrows, b, e, h & k). Epithelial Membrane Antigen 
(EMA) staining was observed in a single monolayer of HB2 cells surrounding a central lumen 
with EMA negative cells (arrow) loosely associated with the edge of HB2 WT units (c). HB2 
HER2OE and HB2 HER3OE units showed less organised distribution of EMA with no central 
areas of strong staining (f & i respectively). HB2 HER2/3OE cell units showed areas of strong 
EMA staining which appeared at the cell-lumen interface not localised to centre of units 
(yellow arrow, l). Primary antibody was omitted to serve as negative (Neg) controls (a, d, g & j). 
Original magnification, 20x, scale bars = 100µm. 
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Fig 4.7 IHC characterisation of 3D in vitro tri-culture models containing HER overexpressing 
HB2 cells B 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype 
were characterised by IHC to assess proliferation, apoptosis and basement membrane 
production and representative images from three technical replicates are presented. Strong 
Ki67 staining was observed in all cells within HB2 WT, HB2 HER2OE and HB2 HER3OE units (a, d 
& g respectively). HB2 HER2/3OE units also featured Ki67 positive cells but contained negative 
areas in the centre of units (j). While all HB2 units remained largely negative for M30 staining, 
speckles of weak staining was observed in cells outside of HB2 WT units (arrow, b), and within 
HB2 HER3OE and HB2 HER2/3OE units (yellow arrows, h & k). HB2 WT (b), HB2 HER3OE (h) and 
HB2 HER2/3OE (k) units were negative for M30 staining while low levels of M30 expression 
was detected around the edges of HB2 HER2OE units (arrow, e). Collagen IV (Coll IV) 
expression was detected in all gels neatly distributed around outer edges of HB2 units (arrows, 
c, f, i & l). Original magnification 20x, scale bars = 100µm. 
  
136 
 
 
Fig 4.8 Comparison of HB2 wildtype and HB2 HER2 overexpressing tri-culture model to 
normal acini and DCIS in vivo 
a) H & E stained cross section of in vivo breast tissue specimen containing normal acini and 
adjacent DCIS. Normal acini (left) appeared small and rounded in shape and contained a 
central cleared lumen (L, inset).  Areas of DCIS consisted of enlarged, discohesive cells (DC) and 
featured distorted lumens containing necrotic cells (DL). Image courtesy of Prof Andrew Hanby 
(Leeds Institute of Cancer and Pathology). Original magnification 10x. 
b) HB2 wildtype units of the tri-culture model were also small, rounded and featured central 
lumens (L) and therefore strongly resembled normal in vivo acini. Original magnification, 20x, 
scale bars = 100µm. 
c) HER2 overexpressing HB2 units strongly resembled DCIS in both their elongated branched 
shape, the appearance of distorted lumens with possible necrosis (DL) and also consisted of 
discohesive cells (DC) akin to DCIS in vivo. Original magnification, 20x, scale bars = 100µm.  
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4.4.4 Morphology and phenotype of wildtype and HER overexpressing HB2 cells 
cultured in 3D in vitro mono-culture  
In order to validate that HER protein overexpression affected HB2 architecture in a similar 
manner to other published studies, the morphologies of HER overexpressing HB2 cells in 3D 
mono-cultures were examined by H & E with representative images of three technical 
replicates presented (Fig 4.9). This demonstrated that while overexpression of HER2 or HER3 
changed the morphology of the units, HER3 overexpression had the most disruptive effect. 
Although HB2 HER2OE cell units appeared larger, more elongated and less cohesive than HB2 
WT units, overexpression of HER3 alone or in combination with HER2 induced cells to form 
units which appeared larger and more branching than HB2 WT and HB2 HER2OE units. These 
units also featured distorted luminal spaces. Quantification of three technical replicates (Fig 
4.10) supported these observations demonstrating the most significant increase in size of HB2 
units upon HER3 overexpression (p=<0.0001, unpaired t-test). Overexpression of HER3 alone 
or with HER2 also lead to a significant increase in number of units and lumens formed (p=<0.01 
unpaired t-test).  
To determine if these observations were attributed to a change in phenotype, HB2 units were 
characterised by IHC with representative images from three technical replicates presented (Fig 
4.11 & 4.12). HB2 WT units showed the least amount of E-Cad expression suggestive of an EMT 
phenotype but this was not reflected by their morphology. HB2 HER2OE units contained areas 
of no expression or weak expression of E-Cad at cell-cell junctions. HB2 HER3OE displayed 
strong expression of E-Cad at cell-cell junctions while HB2 HER2/3OE units showed very strong 
expression of E-Cad in the cytoplasm of HB2 cells. HB2 WT units showed strong expression of 
EMA in their centre and cells on outer edges of units remained largely negative. 
Overexpression of HER2, HER3, or both HER2 and HER3 caused a loss of organised EMA 
expression in the centre of units with strong EMA expression seen both within and at edges of 
units. HB2 WT units contained a mixture of proliferative and non-proliferative cells which were 
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randomly distributed throughout units as indicated by Ki67 staining. Overexpression of HER2, 
HER3 and HER2 and HER3 caused an increase in proliferative cells with nearly all cells within 
units positive for Ki67 expression. Little evidence of HB2 cell apoptosis was observed in any of 
the units, demonstrated by lack of M30 staining, although speckles of weak staining were 
observed around the outer edges of HB2 HER2OE units. Weak expression of the basement 
membrane marker coll IV was observed in HB2 WT and HB2 HER2OE units and was found 
within units rather than surrounding outer edges. Stronger staining was detected in HB2 
HER3OE and HB2 HER2/3OE units with some distribution noted at the outer edges. 
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Fig 4.9 H & E staining of 3D in vitro mono-culture models of HER overexpressing HB2 cells  
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were cultured in 3D 
collagen gels for 21 days. 5µm sections of gels were stained with H & E with representative 
images from three technical replicates presented. HB2 WT cells (a & b) formed compact 
rounded units (RU) and contained highly cohesive cells (CC). HB2 HER2OE units (c & d) were 
larger less compact and less rounded containing discohesive cells (DC). HB2 HER3OE units (e & 
f) were much larger, elongated (EU), branched (B) and featured protrusions (PRO) at edges. 
These contained discohesive cells with distorted lumens (DL). HB2 HER2/3OE units (g & h) 
were also larger and elongated and contained discohesive cells and distorted lumens. Original 
magnification 20x, scale bars = 100µm.  
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Fig 4.10 Quantification of area, number and lumen formation of HER overexpressing HB2 cell 
units in 3D mono-culture gels from H & E stained sections 
Size, number and lumen formation of wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), 
HER3 overexpressing (HB2 HER3OE) and both HER2 and HER3 overexpressing (HB2 HER2/3OE) 
HB2 cell units cultured alone were quantified with Aperio Image scope, analysed with Graph 
Pad Prism 6 and normalized to total size of each respective collagen gel section. (a) 
Overexpression of HER2, HER3 and HER2/3 in HB2 cells significantly increased size of HB2 units 
formed. (b) Number of HB2 HER3OE and HB2 HER2/3OE units were significantly decreased 
with no significant difference seen with HB2 HER2OE. (c) Overexpression of HER3 and both 
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HER2 and HER3 in HB2 cells significantly decreased lumen formation but not overexpression of 
HER2 only. Bars denote mean from three technical replicates and error bars standard error of 
the mean (SEM). * indicates significant difference to HB2 WT following unpaired t-test 
(p=<0.05). 
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Fig 4.11 IHC characterisation of 3D in vitro mono-culture models of HER overexpressing HB2 
cells A 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotypes 
were characterised by IHC to assess cell adhesion and polarisation with representative images 
from three technical replicates presented. While all HB2 units were positive for E-Cadherin (E-
Cad) staining, differences in E-Cad distribution within units was detected upon HER2 and HER3 
expression. HB2 WT cells expressed E-Cad in localised pockets inside units (yellow arrow, b). 
HB2 HER2OE cell showed patchy distribution of E-Cad staining within units localised at cell 
membranes (arrow, e). HB2 HER3OE cells displayed more uniform expression of E-Cad 
between cell junctions (arrow, h). HB2 HER2/3OE cells showed very strong uniform expression 
of E-Cad within units in both cell membranes and cytoplasm (k). Epithelial Membrane Antigen 
(EMA) staining demonstrated that only HB2 WT units showed a degree of polarisation with 
strong staining localised in the centre of units (arrow, c). HB2 HER2OE and HB2 HER3OE units 
showed less organised distribution of EMA with no central areas of strong staining (f & i 
respectively). HB2 HER2/3OE cell units showed areas of strong EMA staining which were not 
localised to centre of units (black arrow, l) but some cells remained negative at the outer edges 
(yellow arrow, l). Primary antibody was omitted to serve as negative (Neg) controls (a, d, g & j). 
Original magnification b, e, h & k, 40x, scale bars = 50µm. Original magnification of all others, 
20x, scale bars = 100µm. 
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Fig 4.12 IHC characterisation of 3D in vitro mono-culture models of HER overexpressing HB2 
cells B 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype 
were characterised by IHC to assess proliferation, apoptosis and basement membrane 
production with representative images from three technical replicates presented. HB2 WT cells 
expressed Ki67 in patches within units (a) whereas all cells within HER2OE and HER3OE units 
were positive for Ki67 (d & g). HB2 HER2/3OE units contained areas which were negative for 
Ki67 but the majority of cells were positive (inset j). HB2 WT (b), HB2 HER3OE (h) and HB2 
HER2/3OE (k) units were negative for M30 staining while low levels of M30 expression was 
detected around the edges of HB2 HER2OE units (arrow, e). Collagen IV (Coll IV) expression 
was detected in all HB2 units with HB2 WT and HB2 HER2OE units showing expression within 
units (yellow arrows, c & f respectively), while HB2 HER3OE and HB2 HER2/3OE expressed Coll 
IV on outer edges of units (arrows, i & l respectively).  Original magnification 20x, scale bars = 
100µm. 
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4.4.5 The effect of myoepithelial cells on the morphology and phenotype of 
wildtype and HER overexpressing HB2 cells in a 3D in vitro dual-culture 
model 
In order to determine if myoepithelial cells had an effect on the formation of wildtype and HER 
overexpressing HB2 units, we assessed the morphology of HB2 dual-cultures and 
demonstrated that GFP Myo1089 cells induced all HB2 cells to form cohesive rounded units 
regardless of HER overexpression (Fig 4.13) with representative images from three technical 
replicates presented. GFP Myo1089 cells also induced clear lumen formation in HB2 WT units 
and distorted lumen formation in HB2 units with HER3 overexpression, either alone or with 
HER2. In all cases, cells which were loosely distributed throughout the collagen matrix were 
detected and were thought to be GFP Myo1089 cells. Quantification of units from three 
technical replicates (Fig 4.14) demonstrated HER2 and HER3 overexpression still significantly 
increased the size of HB2 units regardless of presence of GFP Myo1089 cells (p=<0.05, 
unpaired t-test). Unlike with mono- and tri-cultures whereby numbers were increased, the 
number of HB2 HER2/3OE units was significantly decreased compared with HB2 WT in the 
presence of GFP Myo1089 cells (p=0.0016, unpaired t-test). Quantification of lumen formation 
reflected observations with only overexpression of HER2 inducing a significantly decreased 
amount of lumen formation compared to HB2 WT in the presence of GFP Myo1089 cells 
(p=0.0017, unpaired t-test). 
Analysis by IHC using anti-tGFP showed an association of GFP Myo1089 cells around the edges 
of all HB2 units as well as distributed throughout the collagen gel which remained un-changed 
upon overexpression of HER proteins (Fig 4.15). Representative images from three technical 
replicates are presented. This confirmed units observed and quantified by H & E staining 
consisted predominantly of HB2 cells and not GFP Myo1089 cells.  
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Characterisation of HB2 unit phenotype by IHC with representative images from three 
technical replicates presented (Fig 4.16 & 4.17) in response to GFP Myo1089 cells 
demonstrated an increase in E-Cad expression between HB2 cell junctions within HB2 WT units 
and a loss of E-Cad expression in HER overexpressing HB2 units. HB2 WT units retained strong 
expression of EMA in their centre with no staining detected in cells on outer edges of units. 
However, with HER3 overexpression alone, strong EMA expression was seen both within and 
at edges of units. GFP Myo1089 cells did not appear to alter proliferation as HB2 WT, HB2 
HER2OE and HB2 HER3OE units contained a mixture of proliferative and non-proliferative cells 
although the majority of the cells within HB2 HER2/3OE units appeared to express Ki67. 
Apoptosis was also largely unaffected with HB2 WT, HB2 HER2OE and HB2 HER3OE units 
negative for M30 staining. However, GFP Myo1089 cells did induce apoptosis within central 
luminal spaces of HB2 HER2/3OE units. GFP Myo1089 cells affected basement membrane 
production in HB2 WT and HB2 HER2OE units only with strong coll IV staining detected around 
outer edges of units while coll IV expression within invaginations and in the centre HB2 
HER3OE and HB2 HER2/3OE units was retained as with mono-cultures.  
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Fig 4.13 H & E staining of 3D in vitro dual-culture models of HER overexpressing HB2 cells 
with myoepithelial cells 
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were cultured with GFP 
positive myoepithelial cells (GFP Myo1089) in 3D collagen gels for 21 days. 5µm sections of 
gels were stained with H & E with representative images from three technical replicates 
presented. All types of HB2 cells formed rounded units with gels featuring spindle shaped GFP 
Myo1089 cells (M) loosely distributed throughout the collagen matrix. HB2 WT units (a) 
contained lumens (L) surrounded by a cohesive cell (CC) layer. HB2 HER2OE units (b) did not 
contain lumens but consisted of cohesive cells. HB2 HER3OE units (c) contained discohesive 
cells (DC) and distorted lumens (DL) while HB2 HER2/3OE units (d) consisted of cohesive cells 
but contained distorted lumens. Original magnification 20x, scale bars = 100µm. 
HB2 
WT 
HB2 
HER2OE 
HB2 
HER3OE 
HB2 
HER2/3OE 
M 
M 
M 
c) 
e) 
g) 
a) 
L 
CC 
b) 
CC 
d) 
DC 
DL 
M 
f) 
DL 
CC 
h) 
149 
 
Fig 4.14 Quantification of area, number and lumen formation of HER overexpressing HB2 cell 
units in 3D dual-culture gels with myoepithelial cells from H & E stained sections 
Size, number and lumen formation of wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), 
HER3 overexpressing (HB2 HER3OE) and both HER2 and HER3 overexpressing (HB2 HER2/3OE) 
HB2 cell units cultured with GFP Myo1089 (Myo) was quantified with Aperio Image scope, 
analysed with Graph Pad Prism 6 and normalized to total size of each respective collagen gel 
section. (a) Overexpression of HER2, HER3 and HER2/3 in HB2 cells significantly increased size 
of HB2 units formed. (b) Number of units was only significantly decreased with HER2 and HER3 
overexpression with no significant difference seen with HB2 HER2OE or HB2 HER3OE. (c) 
Overexpression of HER2 only in HB2 cells significantly decreased lumen formation. Bars denote 
a) 
b) 
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mean from three technical replicates and error bars standard error of the mean (SEM). * 
indicates significant difference to HB2 WT + Myo following unpaired t-test (p=<0.01). 
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Fig 4.15 Immunohistochemical labelling of myoepithelial cells in 3D in vitro dual-culture 
model  
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were co-cultured in 3D 
collagen gels with GFP positive myoepithelial cells (GFP Myo1089) for 21 days. 5µm sections of 
gels were stained with anti-tGFP by IHC to visualise distribution of myoepithelial cells within 
gels with representative images from three technical replicates presented. All gels displayed 
positive staining for tGFP in cells distributed around the outer edges of HB2 cell units (arrows, 
a-d). Original magnification 20x, scale bars = 100µm.  
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Fig 4.16 IHC characterisation of 3D in vitro dual-culture models of HER overexpressing HB2 
cells with myoepithelial cells A 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype in 
the presence of GFP Myo1089 cells (M) were characterised by IHC to assess cell adhesion and 
polarisation with representative images from three technical replicates presented. HER2 and 
HER3 overexpression reduced E-Cadherin (E-Cad) expression in HB2 units in the presence of 
GFP Myo1089 cells. HB2 WT units displayed strong expression of E-Cad between cell junctions 
surrounding a central lumen (arrow, b). There was a marked decrease in E-Cad expression in 
HB2 HER2OE, HB2 HER3OE and HB2 HER2/3OE units. HB2 HER3OE and HB2 HER3OE units had 
low levels of E-Cad expression within units (yellow arrows, e & h respectively) while HB2 
HER2/3OE units (k) contain low levels of E-Cad expression both on the edge of units (black 
arrow) and within units (yellow arrow). Strong expression of Epithelial Membrane Antigen 
(EMA) was detected in the centre of HB2 WT units (arrow, c) and was negative for cells on the 
outer edge of the units. Expression of EMA was also detected within the middle of HB2 
HER2OE (arrow, f) and HB2 HER2/3OE (arrow, l) units although this was weaker than in HB2 
WT units.  Strong but less organised EMA expression was detected across HB2 HER3OE units 
(i). Primary antibody was omitted to serve as negative (Neg) controls (a, d, g & j). Original 
magnification b, e, h & k, 40x, scale bars = 50µm. Original magnification of all others, 20x, scale 
bars = 100µm. 
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Fig 4.17 IHC characterisation of 3D in vitro dual-culture models of HER overexpressing HB2 
cells with myoepithelial cells B 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype 
with GFP Myo1089 cells were characterised by IHC to assess proliferation, apoptosis and 
basement membrane production with representative images from three technical replicates 
presented. HB2 WT, HB2 HER2OE and HB2 HER3OE cells expressed Ki67 in patches within units 
(a, d & g respectively) whereas all cells within HB2 HER2/3OE were positive for Ki67 (j). HB2 
WT were largely negative for M30 expression but contained points of positivity within units 
(arrow, b). HB2 HER2OE (e) and HB2 HER3OE (h) units were negative for M30 staining while 
expression was clearly detected within lumens of HB2 HER2/3OE units (arrow, k). Collagen IV 
(Coll IV) expression was detected in all HB2 units with HB2 WT and HB2 HER2OE units showing 
expression on outer edges of units (arrows, c & f respectively), and HB2 HER3OE displaying 
expression in invaginations from the edges of units (arrow, i). HB2 HER2/3OE displayed 
expression within units (arrow l). Original magnification 20x, scale bars = 100µm. 
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4.4.6 The effect of fibroblasts on the morphology and phenotype of wildtype and 
HER overexpressing HB2 cells in 3D in vitro dual-culture  
The determine the effect of fibroblasts on the formation of wildtype and HER overexpressing 
HB2 units, we assessed the morphology of HB2 dual cultures with representative images from 
three technical replicates presented (Fig 4.18) and demonstrated that in the presence of LS11-
083 dsRed Fib, HB2 WT units remained small, rounded and cohesive but with less lumen 
formation than with GFP Myo1089 cells while with HER2 or HER3 overexpression alone, HB2 
units appeared much larger and discohesive with the appearance of spindle-shaped cells 
around edges and no lumens  which were features not observed with mono-, and dual-cultures 
with GFP Myo1089 cells. The effects of LS11-083 dsRed Fibs on HB2 HER2/3OE units were less 
pronounced with elongated and discohesive HB2 units observed which appeared smaller than 
with mono-culture. Quantification of units from three technical replicates (Fig 4.19) supported 
these observations with a significant increase in size of HB2 units with either HER2 or HER3 
overexpression alone (p=<0.05, unpaired t-test). Only overexpression of either HER2 or HER3 
in the presence of LS11-083 dsRed Fibs induced a change in number of units with a significant 
decrease to HB2 WT (p=<0.01, unpaired t-test). Only overexpression of HER2 demonstrated a 
significant loss of lumen formation compared to HB2 WT (p=0.0210, unpaired t-test). 
Analysis by IHC using anti-dsRed (Fig 4.20) showed LS11-083 dsRed Fibs loosely distributed 
throughout collagen gels in HB2 WT and HB2 HER2/3OE gels only with no staining observed in 
HB2 HER2OE and HB2 HER3OE gels. Representative images from three technical replicates are 
presented. This confirmed units observed and quantified by H & E staining consisted 
predominantly of HB2 cells and not LS11-083 dsRed Fibs.  
Characterisation of HB2 unit phenotype by IHC with representative images from three 
technical replicates presented (Fig 4.21 & 4.22) in response to LS11-083 dsRed Fibs 
demonstrated weaker E-cad expression within HB2 WT and HB2 HER3OE units, patchy 
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expression in HB2 HER2OE units and a loss of expression in HB2 HER2/3OE units. LS11-083 
dsRed Fibs altered EMA expression with concentrated expression on the outer edges of HB2 
WT units, and strong cytoplasmic staining observed across entirety of HER overexpressing HB2 
units. Proliferation was increased with LS11-083 dsRed Fibs with strong Ki67 expression 
observed largely across the entirety of all HB2 units. Apoptosis was unaffected by LS11-083 
dsRed Fibs as HB2 WT and HB2 HER2/3OE units were negative for M30 expression but an 
increase of apoptotic cells was detected in HB2 HER2OE and HB2 HER3OE units. Deposition of 
coll IV in all HB2 units was unaffected by LS11-083 dsRed Fibs exhibiting a similar profile to GFP 
Myo1089 dual-cultures.  
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Fig 4.18 H & E staining of 3D in vitro dual-culture models of HER overexpressing HB2 cells 
with fibroblasts 
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were cultured with dsRed 
positive fibroblasts (dsRed fib) in 3D collagen gels for 21 days. 5µm sections of gels were 
stained with H & E with representative images from three technical replicates presented. HB2 
WT cells (a) formed compact, rounded units (RU) containing cohesive cells (CC) with spindle-
shaped fibroblasts (F) loosely distributed throughout the collagen gel. HB2 HER2OE cells (b) 
formed much larger less compact units containing discohesive cells (DC) that featured 
protrusions (PRO) and short spindle-shaped cells (*) loosely associated around the edge of the 
units. Similarly, HB2 HER3OE cells (c) formed large units that featured protrusions and short 
spindle-shaped cells loosely associated around the edge of the units but these were more 
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cohesive than HB2 HER2OE units. These also contained longer spindle-shaped cells (SC) loosely 
distributed around the gels. HB2 HER2/3OE cells (d) formed elongated units (EU) which 
contained discohesive cells but similar to HB2 WT featured fibroblasts loosely distributed 
throughout the collagen gel. Original magnification 20x, scale bars = 100µm. 
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Fig 4.19 Quantification of area, number and lumen formation of HER overexpressing HB2 cell 
units in 3D dual-culture gels with fibroblasts from H & E stained sections 
Size, number and lumen formation of wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), 
HER3 overexpressing (HB2 HER3OE) and both HER2 and HER3 overexpressing (HB2 HER2/3OE) 
HB2 cell units cultured with dsRed Fibs was quantified with Aperio Image scope, analysed with 
a) 
b) 
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Graph Pad Prism 6 and normalized to total size of each respective collagen gel section. (a) 
Overexpression of HER2, HER3 and HER2/3 in HB2 cells significantly increased size of HB2 units 
formed. (b) Unlike other mono- and co-cultures, number of HB2 HER2OE and HB2 HER3OE 
units was significantly decreased with no significant difference seen with HB2 HER2/3OE. (c) 
Overexpression of HER2 only in HB2 cells significantly decreased lumen formation. Bars denote 
mean from three technical replicates and error bars standard error of the mean (SEM). * 
indicates significant difference to HB2 WT following unpaired t-test (p=<0.05). 
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Fig 4.20 IHC labelling of fibroblasts in 3D in vitro dual-culture model  
Wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 HER3OE) 
and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were co-cultured in 3D 
collagen gels with LS11-083 dsRed positive fibroblasts (LS11-083 dsRed Fibs) for 21 days. 5µm 
sections of gels were stained with anti-dsRed by IHC to visualise distribution of fibroblasts 
within gels with representative images from three technical replicates presented. HB2 WT and 
HB2 HER2/3OE gels displayed positive staining for dsRed Fibs. HB2 WT gels showed 
distribution of LS11-083 dsRed Fibs loosely associated with the edges of HB2 WT units (arrow, 
a). HB2 HER2/3OE gels also showed distribution of LS11-083 dsRed Fibs around edges of units 
(black arrow, d) as well as loosely distributed throughout the collagen gel (yellow arrow, d). No 
dsRed staining was observed in HB2 HER2OE (b) or HB2 HER3OE (c) gels. Original magnification 
20x, scale bars = 100µm.
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Fig 4.21 IHC characterisation of 3D in vitro dual-culture models of HER overexpressing HB2 
cells with fibroblasts A 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype 
with LS11-083 dsRed fibs (F) were characterised by IHC to assess cell adhesion and polarisation 
with representative images from three technical replicates presented. While all HB2 units were 
positive for E-Cadherin (E-Cad), E-Cad distribution within units differed upon HER2 and HER3 
expression. HB2 WT cells displayed strong expression of E-Cad localised between cell junctions 
(arrow, b). HB2 HER2OE, HB2 HER3OE and HB2 HER2/3OE cells showed weaker patchy 
distribution of E-Cad staining within units (arrows, e, h & k respectively). Strong Epithelial 
Membrane Antigen (EMA) expression was detected within the whole of HB2 WT units (c). HB2 
HER2OE and HB2 HER3OE units also showed strong expression of EMA throughout the whole 
of the units (f & i respectively). HER2/3OE cell units showed areas of strong EMA staining 
localised within centre of units (arrow, l). Primary antibody was omitted to serve as negative 
(Neg) controls (a, d, g & j). Original magnification b, e, h & k, 40x, scale bars = 50µm. Original 
magnification of all others, 20x, scale bars = 100µm.
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Fig 4.22 IHC characterisation of 3D in vitro dual-culture models of HER overexpressing HB2 
cells with fibroblasts A 
HB2 wildtype (HB2 WT), HB2 HER2 overexpressing (HB2 HER2OE), HB2 HER3 overexpressing 
(HB2 HER3OE) and HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype 
with dsRed Fib (F) were characterised by IHC to assess proliferation, apoptosis and basement 
membrane production with representative images from three technical replicates presented. 
All cells within HB2 WT and HB2 HER2OE units displayed strong Ki67 expression (a & d 
respectively). HB2 HER3OE and HB2 HER2/3OE units also contained areas of Ki67 negativity 
(yellow arrows, g & j). HB2 WT and HB2 HER2/3OE were negative for M30 expression (b & k 
respectively), while HB2 HER2OE and HB2 HER3OE units contained positive areas in their 
centre (arrows, e & h respectively). Collagen IV (Coll IV) expression was detected only on outer 
edges of HB2 WT units (yellow arrow, c), while HB2 HER2OE and HB2 HER3OE units showed 
positive staining in their centres (arrows, f & i respectively). HB2 HER2/3OE units displayed 
Coll4 expression both within and around edges (arrows, l). Original magnification 20x, scale 
bars = 100µm. 
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4.4.7 Comparison of mono-, dual- and tri-cultures of HER protein overexpressing 
HB2 cells 
To assess if the effects of HER protein overexpression in HB2 cells is affected by the 3D in vitro 
culture context, the representative H&E images from the HER overexpressing HB2 mono-, 
dual- and tri-cultures presented and discussed above were compared (Fig 4.23). This 
demonstrated that the co-culture of GFP Myo1089 cells, LS11-083 dsRed Fibs or both affected 
the morphology of HER overexpressing HB2 units. In tri-culture, HER2 overexpression induced 
the largest, most elongated and irregular HB2 unit morphology whereas in mono-culture, 
HER2, HER3 and both HER2 and HER3 overexpression all induced the formation of large, 
elongated, branched and discohesive HB2 units. Dual-culture with GFP Myo1089 cells had an 
organisational effect inducing the formation of rounded and cohesive HB2 units regardless of 
HER2 or HER3 protein overexpression. Dual-culture with LS11-083 dsRed Fibs had opposing 
effects to GFP Myo1089 cells with HB2 HER2OE, HB2 HER3OE and HB2 HER2/3OE units 
appearing much larger, discohesive and disorganised. Quantification of units from three 
technical replicates for each culture condition (Fig 4.24) supported these observations with a 
significant increase in size of HB2 WT, HB2 HER2OE and HB2 HER3OE units in dual-culture with 
LS11-083 dsRed Fibs (p=<0.05, unpaired t-test. The size of HB2 HER2/3OE units remained 
unchanged in mono-culture, dual-culture with LS11-083 dsRed Fibs and in tri-culture but was 
significantly decreased in dual-culture with GFP Myo1089 cells (p=<0.0001, unpaired t-test). 
This demonstrated that the effects of HER protein overexpression is context dependent 
suggesting a tumour suppressive role for GFP Myo1089 cells and a tumour promoting role for 
LS11-083 dsRed Fibs. 
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Fig 4.23 Comparison of the morphological effects of HER protein overexpression on HB2 cells 
in different co-culture contexts  
Representative H&E images from three technical replicates for HB2 WT, HB2 HER2OE, HB2 
HER3OE and HB2 HER2/3OE units in tri-culture, in mono-culture and in dual-culture with either 
GFP Myo1089 cells (Dual-culture- Myo) or LS11-083 dsRed Fibs (Dual-culture- Fibs) are 
presented to compare morphological changes in response to HER overexpression in different 
co-culture contexts. It is apparent that HER overexpression had different effects on HB2 unit 
phenotype dependent on the co-culture context. On the whole, GFP Myo1089 cells had an 
organisational effect on HB2 units inducing formation of rounded and cohesive units 
regardless of HER protein overexpression (i-l). LS11-083 dsRed Fibs had opposing effects on 
HER overexpressing HB2 units as units appeared much larger, discohesive and disorganised (m-
p). While HER2 overexpression appeared to have the most disruptive effects in the tri-culture 
context (a-d), it was HER3 overexpression that had the most effect on HB2 unit morphology in 
mono-cultures (e-h). Abbreviations :- SC = Spindle cell, L = Lumen, DL = Distorted Lumen, CC = 
Cohesive Cells, DC = Discohesive cells, M = Myoepithelial and F = Fibroblast. Original 
magnification, 20x, scale bars = 100µm. 
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Fig 4.24 Quantification of area of HER overexpressing HB2 units in 3D mono-, dual- and tri-
culture gels from H & E stained sections  
Size of wildtype (HB2 WT), HER2 overexpressing (HB2 HER2OE), HER3 overexpressing (HB2 
HER3OE) and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cell units cultured as 
mono-culture (HB2 only), in dual culture with GFP Myo1089 (HB2 + Myo), in dual-culture with 
LS11-083 dsRed Fibs (HB2 + Fib) and in tri-culture with both GFP Myo1089 and LS11-083 dsRed 
Fib (HB2 Tri) was quantified with Aperio Image scope, analysed with Graph Pad Prism 6 and 
normalized to total size of each respective collagen gel section. (a) Dual-culture of HB2 WT 
cells with LS11-083 dsRed Fibs and in tri-culture significantly increased the size of HB2 units 
formed whereas dual-culture with GFP Myo1089 cells had no significant effect compared to 
HB2 WT mono-cultures.  The size of HB2 HER2OE (b) and HB2 HER3OE cells (c) was significantly 
increased in dual-culture with LS11-083 dsRed Fibs only in comparison to mono-cultures. The 
size of HB2 HER2/3OE units (d) remained unchanged in dual-culture with LS11-083 dsRed Fibs 
and in tri-culture whereas dual-culture with GFP Myo1089 cells significantly decreased the size 
of HB2 units formed. Bars denote mean from three technical replicates and error bars 
standard error of the mean (SEM). * indicates significant difference to respective mono-
cultures following unpaired t-test (p=<0.05). 
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4.5 Discussion 
HER2 is a well characterised oncogene thought to be involved in breast tumorigenesis. 
However, despite the wealth of data available on HER2, the mechanisms behind how its 
overexpression affects normal mammary epithelium and breast cancer initiation is unclear. 3D 
models of HER protein overexpression in non-tumorigenic mammary epithelial cells usually 
consist of mono-cultures of MCF10A cells in reconstituted basement membrane preparations. 
These studies demonstrate a role for HER2 and HER3 in lumen filling, akin to features of DCIS, 
and invasion of non-tumorigenic mammary epithelial cells [273-275]. Possibly due to the 
scarcity of available cell lines, there have been few studies validating these features in other 
non-tumorigenic mammary epithelial cell types. Though not using HER2 overexpressing cells, 
the effects of HER2 and HER3 signalling have been investigated using the HB2 cell line cultured 
in collagen. Stimulation of HER2 signalling induced morphological changes such as increased 
branching of HB2 structures as well as increased cell proliferation [271] but lumen filling could 
not be addressed with this model. Though these studies go some way to investigating the 
transforming potential of HER2 and do so in a 3D context, they are still inadequate models of 
normal in vivo breast as they do not contain a stromal component. 
This made HER2 a good candidate to focus on when assessing if the model was amenable to 
genetic manipulation and thus suitable for breast cancer initiation studies. We incorporated 
HER2 and HER3 overexpressing HB2 cells in our 3D tri-culture in vitro model of normal breast, 
providing a more in vivo-like microenvironment. To highlight the importance of culturing cells 
in an appropriate microenvironment, we also cultured HER overexpressing HB2 cells either 
alone, in co-culture with myoepithelial cells only or with fibroblasts only and compared to our 
tri-culture models with the aim of elucidating whether the effects of HER protein on luminal 
epithelial cells were context dependent.   
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4.5.1 The effects of HER protein overexpression in HB2 cells in the 3D tri-culture 
model 
First, we sought to assess the effects of HER2 and HER3 overexpression in the luminal 
epithelium in the tri-culture model of normal breast. Through culture of HB2 WT cells with GFP 
Myo1089 cells and LS11-083 dsRed Fibs, we were able to recapitulate features seen in Chapter 
3 with small rounded units formed containing lumens as well as a similar phenotype upon IHC 
characterisation proving that the model was robust and reproducible. It appeared HER2 
overexpression in HB2 cells alone had the most dramatic effect on the architecture of HB2 
units. HB2 HER2OE units were much larger, more elongated, featured protrusions and were 
remarkably similar to DCIS. We quantified lumen formation within HB2 units and defined a 
lumen as a space within units surrounded by a continuous layer of HB2 cells. We found that 
HER protein overexpression significantly reduced lumen formation within HB2 units. This 
correlated with reports in the literature which suggested HER2 and HER3 protein 
overexpression increased proliferation and lumen filling in MCF10A cells [273-275]. However, 
these features were less pronounced with HER3 overexpression alone or with a combination of 
HER2 and HER3 overexpression suggesting that the HER2-HER3 heterodimer was not the most 
potent inducer of aberrant epithelial architecture in our tri-culture model. This indicated that 
in the tri-culture model, HER2 overexpression elicited a DCIS-like phenotype of HB2 cells 
mediated not through dimerization with HER3 but perhaps with another HER receptor. 
Although this contradicts studies discussed which suggested the HER2-HER3 heterodimer is the 
most mitogenic HER receptor combination, dimerization of HER2 with other HER proteins such 
as EGFR [276] has also been proven to be strongly mitogenic which could account for the 
larger HB2 HER2OE units.  
Another theory is that the larger HB2 HER2OE units were produced via cell migration and then 
subsequent adhesion rather than via increased proliferation. The HER2-EGFR heterodimer can 
drive cell migration in HER2 overexpressing cells [277]. This would account for the appearance 
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of protrusions at the edges of these units as well as the little change observed in Ki67. 
However, loss of E-cad expression is a feature of EMT [278] which was not observed in our 
study. This could be explained by the fact that E-cad can aid HER2-EGFR signalling [279] and 
has been shown to stabilise the HER2-HER3 heterodimer [280] and thus may not be a robust 
marker for EMT in the context of HER protein manipulation. The retention of E-cad in HB2 
units correlates with research by Aceto et al [275] who showed increased migration of 
MCF10A cells upon HER2 overexpression with no change in E-cad expression. This group 
examined markers such as N-Cadherin and Fibronectin-1 which were not analysed in our study 
meaning it is feasible that HER overexpressing HB2 cells in our study did undergo EMT.   
Given that coll IV expression surrounding HB2 units was unchanged by HER overexpression, 
and considering the theory that HER2 overexpression induces larger HB2 units due to cell 
migration, it could be that these structures are formed by groups of cells migrating together 
early on in the culture process and that this migration is enhanced by HER2 overexpression. 
Following a period in culture, GFP Myo1089 cells and LS11-083 dsRed Fibs may induce 
organisation of HB2 units and subsequently stimulate basement membrane production. 
However, the loss of organised EMA staining in these units would indicate that the ability of 
HB2 HER2OE cells to resume normal polarisation and architecture is still impaired. Distribution 
of EMA has been proven to be disrupted via HER2 expression and is thought to contribute to 
increased mitogenic activity [Reviewed in 281] perhaps explaining this aberrant staining 
pattern. While not investigated in our study, analysis of structures formed at earlier time 
points in culture, IHC with specific cell motility markers, and/or time-lapse microscopy could 
determine whether the aberrant architecture of HB2 units upon HER overexpression is due to 
cell migration or other mechanisms.  
It was clear from this experiment that although HER2 overexpression in the tri-culture model 
produced a DCIS-like phenotype, the overexpression of both HER2 and HER3 had less of a 
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detrimental effect on HB2 unit architecture contradicting what has been suggested in the 
literature. One limitation here is that the confirmation of HER2 and HER3 protein 
overexpression was only assessed by western blot and not confirmed by dual-stain 
immunofluorescence for both HER2 and HER3 in HB2 HER2/3OE cells. This coupled with the 
fact that these cells were generated through transduction of HER2 and HER3 genes on two 
separate plasmids on two separate occasions means it is therefore possible that this cell line 
consists of a mixed population of cells that overexpress just HER2 and cells that overexpress 
both HER2 and HER3. This would support the observation of a mixed morphology of HB2 units 
in the tri-culture model. However, this is unlikely due to the fact that the cell line was purified 
by dual-staining FACS to produce cell populations which were over 95% positive for both 
transgenes. In addition, it could be expected that cells containing both transgenes would 
confer a growth advantage over those that express HER2 only due to strong evidence of the 
ability of the HER2-HER3 heterodimer to increase PI3K and MAPK signalling [249-251] and 
would therefore represent the majority of the cell population. Nevertheless, further 
examination of this cell line by dual-stain immunofluorescence for HER2 and HER3 would be 
required to definitively prove this. 
However, since the effects of HER protein overexpression on luminal epithelial architecture 
has not been studied in the presence of both myoepithelial cells and fibroblast before, we 
hypothesised that the unexpected response from HB2 HER2/3OE cells in the tri-culture model 
was due to the difference in the luminal cell microenvironment and that the effects of HER 
overexpression are context dependent. We therefore examined the effects of HER 
overexpression in HB2 cells in different co-culture conditions to address this. 
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4.5.2 The importance of the stromal microenvironment on the effects of HER 
protein overexpression in HB2 cells 
The mono-culture of HER overexpressing cells resulted in different morphologies and 
phenotypes to those observed in tri-culture. We found that HB2 WT units were unable to form 
lumens without myoepithelial cells or fibroblasts. However, interestingly, lumen formation 
increased upon overexpression of HER3 and HER2 and HER3 in HB2 cells. Since HER2-HER3 
heterodimer signalling is proven to increase cell proliferation in HB2 cells [271], a decrease in 
lumen formation in these units might be expected. However, examination of these lumens by 
H & E staining suggests they were a product of necrosis rather than HB2 cell polarisation and 
rearrangement. This is supported by a lack of M30 expression within these units suggesting 
lumens were not formed by programmed cell death. It has been demonstrated that tumours in 
vivo above 200mm3 undergo necrosis in their centres due to lack of nutrient penetration [282]. 
Since HB2 units were much larger upon HER3 and both HER2 and HER3 overexpression, it 
could be reasoned that necrosis was triggered by a lack of nutrient penetration into these 
structures due to their size. However, HB2 HER2OE units were similarly much larger than HB2 
WT units but necrosis was not observed suggesting this is not the case. Central necrosis 
following lumen filling within breast ducts is a feature of high grade DCIS [283]. HER2 
amplification is found in approximately 90% of high grade DCIS lesions [284]. It was surprising 
that in our study, HER3 overexpression seemed to drive development of these DCIS-like 
features as well as increased branching. However, since these features were conserved in HB2 
HER2/3OE units, we can speculate that HER3 effects were dependent on the dimerization with 
HER2. The abundance of HER3 protein in DCIS has not been documented so it is possible that 
HER3 is required for HER2 induced DCIS features in vivo.  
The mono-culture of HER overexpressing HB2 cells produced a phenotype that largely 
correlated with results from tri-culture.  EMA localisation to the centre of HB2 WT units was 
observed and was lost in response to HER2 and HER3 overexpression and all HB2 unit types 
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remained proliferative. One difference observed in all mono-cultures was a lack of strong and 
organised collagen IV staining around the outer edges of the units suggesting inadequate 
formation of a basement membrane. This could be due to a lack of an appropriate 
microenvironment in this system. 
Though HER protein overexpression in HB2 cells in mono-culture better recapitulated features 
seen in the literature than what was observed in the tri-culture model, this agreed with our 
hypothesis that myoepithelial cells and fibroblasts influence the effect of HER protein 
overexpression in HB2 cells. We investigated this further by examining the morphology and 
phenotype of HER protein overexpressing HB2 cells in dual-culture with either GFP Myo1089 
cells or LS11-083 dsRed Fibs. 
4.5.3 Myoepithelial cells suppress the tumorigenic effects of HER overexpression 
in HB2 cells 
Consistent with research by Gudjonsson et al [285] who demonstrated myoepithelial cells have 
the capacity to induce organisation and lumen formation of luminal epithelial cells, co-culture 
with GFP Myo1089 cells induced lumen formation in HB2 WT cells and dramatically altered 
structures of HER overexpressing HB2 units in comparison to mono-cultures. Branching of HER 
overexpressing HB2 units was diminished and these appeared cohesive and rounded akin to 
HB2 WT units. However, overall size did not appear to be affected with no significant 
difference in size demonstrated to mono-cultures apart from with HB2 HER2/3OE units.  
IHC characterisation of the units provided insight into the mechanisms behind the 
“containment” effect of GFP Myo1089 cells. GFP Myo1089 cells appeared to increase 
polarisation of HER overexpressing HB2 units. GFP Myo1089 cells caused increased distribution 
of EMA to the centre of HB2 HER2OE and HB2 HER2/3OE units with less ubiquitous 
cytoplasmic staining as observed in mono-cultures. Since this was not observed in HB2 HER3OE 
cultures, one theory is that HER2 mediates this process as it has been proven to interact with 
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EMA at cell membranes [Reviewed in 281], and that dimerization with another HER partner by 
HER3 interfered with GFP Myo1089 induced polarisation of HB2 cells.  
GFP Myo1089 cells also appeared to have pro-apoptotic effects on HER overexpressing units. 
M30 expression was detected in the centre of HB2 HER2/3OE units suggesting lumens may be 
formed by programmed cell death and was a feature not observed in mono-cultures. 
Myoepithelial cells have been proven to induce apoptosis in tumour cells [286]. However, this 
was not observed in HB2 HER2OE and HB2 HER3OE units. It could be that GFP Myo1089 cells 
have a pro-apoptotic effect on HB2 cells and that this effect is overcome by overexpression of 
HER2 or HER3 alone but not both. It is conceivable that heterodimerisation with other HER 
receptors in HB2 HER2OE and HB2 HER3OE cells triggers a more potent anti-apoptotic 
signalling cascade than the HER2-HER3 heterodimer and that this is more efficient in 
counteracting the pro-apoptotic signals of GFP Myo1089 cells.  
Lack of organised staining of collagen IV around edges of HB2 HER2OE, HER3OE and HER2/3OE 
units suggests that the “containment” effect of GFP Myo1089 cells have on these structures is 
not mediated by laying down a collagen IV-rich basement membrane protein layer. While coll 
IV is a major component of basement membrane [287], it is feasible that the containment 
effect of GFP Myo1089 cells is mediated by production of other basement membrane proteins. 
For example, myoepithelial cells secrete Laminin-1 which induces organisation of luminal 
epithelial cells in culture [71] and could be expressed in our dual-culture model. Myoepithelial 
cells also release a variety of paracrine factors such as TIMP-1, Protease Nexin 2, alpha-1 
antitrypsin and Maspin [288] that reduce tumour cell invasion and could also account for the 
containment effect of HB2 cells in the model.  
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4.5.4 Fibroblasts promote the tumorigenic effects of HER overexpression in HB2 
cells 
Co-culture of HER overexpressing HB2 cells with LS11-083 dsRed Fibs had dramatically 
different effects compared to mono-culture, tri-culture or co-culture with myoepithelial cells. 
Consistent with evidence that CAFs promote proliferation and invasion of tumour epithelial 
cells through paracrine factors [Reviewed in 33, 289, 290] and that CAFs have no [291] or little 
effect [292] on the proliferation on normal MCF10A epithelial cells, LS11-083 dsRed Fibs had 
little morphological effect on HB2 WT units but dramatically disrupted the architecture of HB2 
HER2OE and HB2 HER3OE units. These were over 13 times larger and consisted of discohesive 
spindle-shaped cells.  
IHC characterisation did not show any change in Ki67 staining which suggested that LS11-083 
dsRed Fibs did not mediate their effects via increasing proliferation of HB2 cells. This is despite 
evidence that fibroblasts can stimulate epithelial cell proliferation [293] via release of HGF 
[294] and cause a DCIS-like phenotype in 3D culture  [295].  However, a loss of E-cad 
expression in HB2 HER3OE and HB2 HER2/3OE was observed so it is possible that LS11-083 
dsRed Fibs mediated their effects through promoting an EMT transition in these cells. Since 
this was only evident upon HER3 overexpression, it is conceivable that this was facilitated 
through production of the HER2-HER3 ligand heregulin which has been reported to be 
secreted by fibroblasts [296] and stimulates the PI3K-Akt pathway, down-regulating E-cad 
[297].  An increase in cell migration could explain the increase in size of these units perhaps 
indicating HB2 cells moved together to form large structures perhaps accounting for the 
significant reduction in number of units observed. However, E-cad expression was not lost in 
HB2 HER2OE units meaning LS11-083 dsRed Fibs must mediate the same effects on these cells 
via a different unknown mechanism.  
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This theory of an increased invasive phenotype is also supported by the loss of coll IV 
surrounding HER overexpressing HB2 units [298, 299] which could be explained by the capacity 
of fibroblasts to not only secrete growth and pro-migratory factors, but also their ability to 
secrete collagenase IV [300]. Although the production of coll IV in HB2 WT cultures is indicative 
that these cells had a less invasive phenotype as expected, it was surprising that this was not 
evident in dual-culture with GFP Myo1089 cells. While fibroblasts are known to produce 
collagen I [301], the literature states it is myoepithelial cells that produce coll IV [71]. The 
production of coll IV by fibroblasts in breast has not been documented. Since in breast, coll IV 
is secreted by myoepithelial cells, perhaps in this situation LS11-083 dsRed Fibs stimulate HB2 
cells to become myoepithelial-like which is a process proven possible in the literature [302] via 
EMT through expression of CXCL12 [303]. It is possible HB2 cells produced coll IV themselves 
through release of TGF-β by LS11-083 dsRed Fibs [304] which is known to induce coll IV 
production by epithelial cells in other tissue types [305]. Since myoepithelial cells in other 
tissues produce coll IV in response to TGF-β signalling [306], it is feasible that GFP Myo1089 
cells in our system need growth factors produced by LS11-083 dsRed Fibs to lay down 
basement membrane proteins, which is supported by the detection of collagen IV in our tri-
culture model. TGF-β signalling in mammary epithelia is complex however; it is proven that 
TGF-β is tumour suppressive in normal mammary epithelia but tumour promoting in mammary 
epithelia that have undergone an oncogenic event [307]. It is conceivable that in our system, 
LS11-083 dsRed Fibs secrete TGF-β which promotes coll IV production by normal HB2 cells but 
invasion and migration of HB2 HER2OE and HER3OE cells.  
Given the disruption caused by the addition of LS11-083 dsRed Fibs to the HB2 unit 
architecture, it was surprising that IHC with anti-dsRed demonstrated a loss of fibroblasts in 
these cultures. This could be explained by a “Reverse Warburg” effect. It is documented that 
breast cancer cells can induce aerobic glycolysis in neighbouring fibroblast cells [308]. It is 
therefore plausible that in our study, HER2 or HER3 overexpression induces a tumorigenic 
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phenotype in HB2 cells; these subsequently induce aerobic glycolysis and thus mitochondrial 
dysfunction in the LS11-083 dsRed Fibs which “feeds” the HB2 cells and leads to increased 
proliferation or motility but ultimately resulting in LS11-083 dsRed Fib death. Although not 
examined in our study, this could be confirmed by IHC for monocarboxylate transporter-1 and 
monocarboxylate transporter-4 thereby monitoring lactate influx and efflux in these cells 
[309]. 
4.5.5 Summary  
Through the overexpression of HER proteins within HB2 cells in our study, we have 
demonstrated that the model is amenable to genetic manipulation and thus suitable for cancer 
initiation studies in a more in-vivo like context. By recapitulating features from Chapter 3, we 
have also proved the model is robust, is quantifiable and can be easily analysed through 
standard laboratory techniques such as IHC. Furthermore, we have proved through 
overexpression of HER2 that formation of structures that accurately reflect DCIS in vivo can be 
achieved (confirmed by a consultant breast pathologist, Dr Rebecca Millican-Slater) further 
validating the suitability of the model for cancer initiation studies.  
In addition, we have provided evidence that the ability of HER2 and HER3 overexpression to 
induce changes in HB2 luminal epithelial architecture is altered in the presence of both 
myoepithelial cells and fibroblasts. It was clear that unlike the mono-cultures, the effects of 
HER overexpression in the tri-cultures were not consistent with studies in the literature. It is 
probable that co-culture of luminal cells with myoepithelial cells or fibroblasts changes the 
ligand availability to HER receptors and can therefore influence which heterodimers are 
formed, which in turn affects downstream signalling and phenotype of these cells. Wolf-Yadlin 
and colleagues [276] found that regardless of HER2 overexpression, it is the ligand that 
determines HER heterodimerisation and thus signalling outcome of epithelial cells.  Since 
heregulin stimulates the HER2-HER3 heterodimer, a deficiency in heregulin upon co-culture 
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with GFP Myo1089 cells and LS11-083 dsRed Fibs could explain the lack of a significant 
response upon HER2 and HER3 overexpression together in the dual- and tri-culture models. 
This will be addressed in Chapter 5. It is apparent that the stroma influences the potency of 
oncogenic events in the luminal epithelium and perhaps caution should be taken when 
interpreting results from studies that lack these components.  
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5  Chapter 5: Effect of Heregulin on normal and HER 
overexpressing tri-culture models  
5.1 Introduction 
While Chapter 4 proved that overexpression of HER2 and HER3 proteins together in HB2 cells 
increased the size and disrupted the shape of HB2 WT units in 3D tri-culture, these changes 
appeared less pronounced than with either HER2 or HER3 overexpression alone. This 
contradicted the notion in the literature whereby the HER2-HER3 heterodimer is considered 
the most potent [310, 311]. We therefore sought to prove HB2 HER2/3OE cells were able to 
respond to HER2-HER3 ligand by examining the morphological effects of ligand stimulation in 
3D tri-culture as well as the capacity to stimulate known downstream signalling proteins 
intracellularly. We hypothesised that HB2 HER2/3OE cells had the capacity to induce the 
morphological features described in the literature as well as those seen in Chapter 4 with HER2 
or HER3 overexpression alone but that in the 3D novel tri-culture environment, the 
endogenous levels of the HER2-HER3 ligand were not sufficient to facilitate this and that the 
HB2 HER2/3OE cells were not deficient in their HER2-HER3 signalling capacity. 
5.1.1 HER ligands: Neuregulins 
Neuregulins (also known as Heregulins) are a family of structurally related proteins that 
mediate intercellular signalling interactions. The neuregulin gene family consists of four 
members, NRG1, NRG2, NRG3 and NRG4 (also known as HRG1-4). Less is known about the 
functions of NRG2-4 with NRG1 receiving the most research attention over the last few 
decades [312]. Through post-transcriptional modification, over 15 different precursor isoforms 
are synthesised from the NRG1 gene [313]. These isoforms are classified as Type I, Type II or 
Type III determined by their differing N-terminal sequences. The structure of neuregulin-1 
isoforms are show in Fig 5.1. Type I and II neuregulins contain immunoglobulin-like domains (Ig 
domains) and only differ in their N-terminal sequences whereas Type III neuregulins do not 
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contain Ig domains but do contain cysteine-rich domains within their N-terminal sequences.  
All bioactive neuregulins contain either an α or β EGF-like domain which alone has proved 
sufficient to activate HER receptor dimers [314]. Type I precursors contain hydrophobic 
transmembrane spanning domains and thus are expressed at cell membranes. As shown in Fig 
5.2, these are orientated with N-terminal region, Ig-domains and EGF-like domains situated 
extracellularly and cytoplasmic tail situated intracellularly. Extracellular cleavage of 
proproteins via ADAM17 and ADAM 19 [315, 316] at the stalk region releases an ectodomain 
fragment that is bioactive serving as a ligand for HER dimers in a paracrine manner.  
5.1.2 Heregulin 
Heregulin (HRG) is a type I NRG and is further sub classified as HRG-α and HRG-β dependent on 
the nature of the EGF-like domain [314]. Both these HRG isoforms are proven to have the 
same binding specificity to HER2/HER3 and HER2/HER4 heterodimers [317-319]. HRG-α has 
been demonstrated to be the dominant isoform in regulating breast development and ductal 
branching in pre-clinical mouse models [320]. However, other reports have suggested HRG-β 
can elicit these same effects in a context dependent manner requiring the presence of 
estradiol and progesterone [321]. It remains unclear why HRG-α has proven more critical for 
breast development. Most studies using human breast cells in vitro and biochemical assays 
have reported HRG-β to be up to 100 times more potent than HRG-α in the binding affinity for 
HER receptors [317, 319, 322] making HRG-β the preferred isoform for subsequent in vitro 
studies. These conflicting results could be attributed to the difference in physiology between 
mice and humans as there is no data available on the expression of HRG isoforms in during 
human development.  
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Fig 5.1 Schematic representation of the structures of neuregulin-1 isoforms 
Neuregulin-1 isoforms differ in their N-terminal sequences (green) due to initiation from different promoters generating Type I, Type II and Type III NRG1. 
Type I, II and III NRG1 all contain an EGF-like domain (yellow) which differs following alternative splicing to give α, β or γ variants (*). Only Type I and II NRG1 
contain an immunoglobulin-like domain (Ig-like domain, light blue). Domains specific to Type I NRG1 include: Spacer sequences containing glycosylation 
sites (pink, 1 & 2), a juxtamembrane stalk region which differs following alternative splicing to give 1, 2, 3, 4 or 5 variants (**) and that provides a cleavage 
site (dark blue), a transmembrane spanning domain (red) and an intracellular cytoplasmic tail (lilac) which differs following alternative splicing to give a, b or 
c variants (***). Type I NRG1 is the only isoform of NRG1 capable of existing as a transmembrane spanning protein due to it being the only NRG1 with a 
transmembrane spanning domain. 
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Fig 5.2 Schematic representation of proteolytic processing of Type I NRG1.   
Type I NRG1 precursors are localised to the plasma membrane (PM) and cleaved in the stalk 
region (dashed line) by matrix metalloproteinases (MMPs). This releases an extracellular N-
terminal fragment (NTF) and an inactive intracellular C-terminal fragment (CTF). The NTF 
contains the EGF-like domain which is bioactive and serves as a ligand both in an autocrine and 
paracrine manner. Type specific N-terminal sequence (green), Ig-like domain (light blue), 
spacer sequences (pink), EGF-like domain (yellow), stalk region (dark blue), transmembrane 
spanning domain (red) and cytoplasmic tail (lilac).   
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5.1.3 Function of Heregulin 
Increasing evidence suggests a role for HRG in breast cancer progression. Pre-clinical in vivo 
studies have reported HRG-β overexpression is sufficient for mammary tumorigenesis [323, 
324] and can do so independent of estradiol stimulation [325]. In addition, in vitro studies have 
demonstrated HRG to be a potent mitogenic factor in a variety of different sub-types of breast 
cancer cell lines with or without HER2 overexpression [314, 326-328]. Several studies have 
investigated the expression of HRG in human breast cancer samples. Possibly due to lack of 
sufficiently characterised antibodies, a variety of different levels of HRG have been reported in 
human breast cancers with specific isoform data not readily available. These are summarised 
in Table 5.1. However, it is clear that HRG was expressed in at least 25% of breast cancers 
regardless of the sub-group and sample size examined further indicating the prominent role 
HRG plays in the progression of human breast tumours.  
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Type of breast 
sample              
(if specified) 
Type of assay used Sample size % HRG 
expression 
Reference 
Invasive 
carcinomas 
Immunohistochemistry 189 30 [329] 
Early stage and 
metastatic  
carcinomas 
Immunohistochemistry 151 50 [330] 
Carcinomas Western Blotting 60 25 [331] 
Stage II primary 
carcinomas 
Immunohistochemistry 35 48 [332] 
Ductal 
carcinoma in 
situ (various 
grades) 
Immunohistochemistry 60 60-95 [333] 
HER2 
low/negative 
carcinomas 
Immunohistochemistry 171 25 [334] 
Invasive ductal 
and lobular 
carcinomas of 
varying grades 
Immunohistochemistry 201 47  HRG-α 
63  HRG-β 
[335] 
Table 5.1 Summary of heregulin expression in breast tumours 
5.1.4 Signal transduction by Heregulin 
Three major “hallmarks” of tumorigenesis and cancer progression are increased cellular 
proliferation, avoidance of apoptosis and tumour cell invasion [336], all of which are induced 
by HRG via the HER2/HER3 heterodimer. Binding of HRG to HER3 causes heterodimerization 
with HER2 and initiates autophosphorylation of specific tyrosine residues activating a variety of 
key signalling cascades (summarised in Figure 5.3). Upon activation from HRG, HER2 provides 
docking sites for proteins such as Grb2 and Shc [337] which activates Ras via Sos stimulating a 
linear signalling cascade culminating in MAPK/Erk activation. Erk activates transcription factors 
such as Jun/Fos and Myc resulting in cell cycle progression via Cyclin D1 [338]. Simultaneously, 
activated HER3 is a potent activator for PI3K. HER3 provides six docking sites for the p85 
subunit of PI3K [248] which leads to activation of PI3K resulting in the production of 
phosphatidylinositol-3,4,5-triphosphate (PIP3). This leads to Akt phosphorylation by PDK1 and 
initiates pro-survival and anti-apoptotic signalling through inhibition of proteins such as GSK3 
and Bad [339]. In addition, activated HER2/HER3 heterodimers stimulate phospholipase-Cγ 
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(PLCγ) signalling [340, 341] which can also activate Jun/Fos, as well as Janus kinase-STAT (Jak-
STAT) pathways [342] both of which regulate cell cycle progression. HRG signalling through 
HER2/HER3 is proven to enhance cell motility and invasion of cells through various 
mechanisms. HRG is proven to increase motility of breast cancer cell lines through the 
activation of rac signalling [343] and regulation of factors such as autocrine motility factor 
[344], G-protein couple receptor 30 [345] and fibroblast growth factor inducible 14 [346]. HRG 
is demonstrated to regulate focal adhesion formation via paxillin [347, 348], lamellipodia and 
filopodia formation [349] and also proved to increase expression of matrix metalloproteinases 
[350]. Activated HER2/HER3 heterodimers also contributed to tumour cell invasion and 
metastasis in vivo [351] further validating the clinical relevance and potency of HRG as an 
oncoprotein.  
The majority of in vitro studies into the effects of HRG and HER2/HER3 signalling in the breast 
to date have been conducted with breast cancer cell lines with little research using normal 
breast epithelia in the context of surrounding stromal cells. 
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Fig 5.3 Schematic of major signalling pathways stimulated by heregulin and HER2-HER3 heterodimers 
Activation of the HER2-HER3 heterodimer by heregulin (HRG) at the plasma membrane initiates downstream signalling of several major pathways resulting 
in increased cell proliferation and survival. Binding of adaptor proteins such as GRB2 and SHC or kinases such as PLCγ to HER2 activates downstream Ras-
Erk1/2 and PKC effectors leading to activation of nuclear transcription factors such as Myc and Jun-Fos. This leads to an increase in Cyclin D1 levels and 
therefore increases proliferation. Binding of PI3K to HER3 stimulates the Akt pathway inhibiting GSK3 and Bad resulting in antiapoptotic signalling. HER2-
HER3 heterodimers also have the capacity to activate JAK-STAT pathways which further enhance cell proliferation through increased transcription. 
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5.2 Aims 
The aim of this series of experiments was to investigate whether HB2 HER2/3OE cells had the 
capacity to respond to heregulin stimulation in both 3D tri-culture and intracellularly in a 
manner that reflected studies in the literature. The morphology and phenotype of HB2 
HER2/3OE 3D tri-cultures in response to heregulin was assessed and the efficiency of heregulin 
stimulated intracellular signalling in 2D was examined with a view to elucidating the reasons 
for the unexpected similar morphology and phenotype of HB2 wildtype and HB2 HER2 and 
HER3 overexpressing 3D structures observed in Chapter 4. This was addressed by :- 
 Comparing the morphology of wildtype and both HER2 and HER3 overexpressing HB2 
cells in 3D tri-culture in vitro models in response to heregulin stimulation 
 Quantifying differences in morphology of HB2 units by assessing area, number and 
lumen formation from H & E stained gel sections  
 Characterising the phenotype of structures by IHC  
 Investigating the intracellular signalling pathways within wildtype and both HER2 and 
HER3 overexpressing HB2 cells in response to heregulin in 2D monolayer using a 
Proteome ProfilerTM human phospho-kinase array 
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5.3 Materials and Methods 
5.3.1 Heregulin stimulation of 3D in vitro tri-cultures 
3D tri-cultures with HB2 WT and HB2 HER2/3OE cells were prepared as per Chapter 2. For 
heregulin stimulation, at the time of set up, 3D gels were submerged in media containing 
10ng/mL heregulin β1 (Sigma) and control gels in normal heregulin-free media. Thereafter, 
media was changed twice weekly for the duration of culture with media containing 10ng/mL 
heregulin β1 for heregulin stimulated gels and normal media for control gels.  
5.3.2 Analysis of intracellular signalling pathways induced by heregulin 
The intracellular signalling pathways activated by heregulin were analysed using Proteome 
ProfilerTM human phospho-kinase arrays (R & D Systems) according to manufacturer’s 
instructions. Briefly, HB2 WT and HB2 HER2/3OE cells were seeded into 25cm3 vented cap 
culture flasks (Corning) at a seeding density of 2 x 107 cells per flask. Media was replaced with 
serum-free media 2 hours prior to stimulation experiments. Heregulin β1 (10ng/mL) was 
added dropwise onto cells and cells were incubated at 37oC and 5% CO2 for 15mins. Serum 
free media was added to separate flasks to serve as negative controls. Working on ice, cells 
were lysed and protein extracted using lysis buffer provided. Protein concentrations were 
determined using a DC protein assay (BioRad) as per section 2.11. Protein samples were 
diluted in assay buffer provided and 300µg of protein sample incubated on each array 
membrane as per manufacturer’s instructions. Membranes were developed using ECL 
solutions provided and visualised using a ChemiDoc® MP imaging system (BioRad). 
Densitometry analysis was performed using BioRad Image Lab 4.1 software by overlaying an 
image of the array template (provided in kit) onto array membrane image and manually 
annotating each spot to take a pixel intensity reading. Mean pixel intensity for duplicate pairs 
of antibody spots was calculated using Microsoft Excel. Background intensity readings taken 
from PBS negative control spots were subtracted from these means. Mean pixel intensity for 
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each antibody on the array was then normalised to the internal positive reference control 
spots to allow separate arrays to be compared.  
In order to assess the activation of phospho-kinases specifically in response to heregulin 
stimulation, mean pixel intensity of phospho-kinases from heregulin stimulated membranes 
were compared to their respective controls and fold difference calculated using GraphPad 
Prism 6 software. Where biological replicate experiments were performed, the mean fold 
difference and SEM were calculated using GraphPad Prism 6 software. In order to focus on 
phospho-kinases that were considerably differentially activated, a threshold of ≥2-fold 
difference was set and all phospho-kinases that were <2-fold differentially expressed were not 
considered. 
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5.4 Results 
5.4.1 Morphology of HER protein overexpressing HB2 cells in 3D in vitro tri-
culture model in response to heregulin stimulation 
Due to the unexpected similarities between the morphology and phenotype of HB2 WT and 
HB2 HER2/3OE tri-cultures in Chapter 4, HB2 HER2/3OE tri-cultures were stimulated with the 
heregulin ligand for the HER2/3 heterodimer in order to see if HB2 HER2/3OE cells had the 
capacity to respond to ligand and disrupt the epithelial architecture in tri-culture and whether 
these responded in a different manner to HB2 WT cells. The morphology of HB2 WT and HB2 
HER2/3OE tri-cultures were assessed in response to stimulation with 10ng/ml heregulin with 
representative images from three technical replicates presented (Fig 5.4). This demonstrated 
that in the presence of heregulin, HB2 WT cells formed larger and more elongated units 
compared to the small rounded units with clear lumen formation without heregulin. HB2 
HER2/3OE cells formed much larger, elongated units which featured discohesive cells and 
distorted lumens in response to heregulin. HB2 HER2/3OE units also presented protrusions 
from outer edges of units.  Quantification of these structures (Fig 5.5) supported these 
observations. A significant increase in size of HB2 units was demonstrated upon heregulin 
stimulation with HB2 WT, and HB2 HER2/3OE cells (p=<0.05, unpaired t-test). No significant 
difference was observed in the number of units formed upon heregulin stimulation but there 
was a significant decrease in lumen formation of HB2 WT units (p=0.001, unpaired t-test). No 
significant difference in lumen formation was demonstrated in HB2 HER2/3OE units (p=0.197, 
unpaired t-test).  
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Fig 5.4 H & E staining of 3D in vitro tri-culture models containing HER protein overexpressing 
HB2 cells with or without heregulin  
Wildtype (HB2 WT) and both HER2 and HER3 overexpressing (HB2 HER2/3OE) HB2 cells were 
co-cultured in 3D collagen gels with GFP positive myoepithelial cells (GFP Myo1089) and dsRed 
positive fibroblast cells (dsRed Fib) for 21 days. These were cultured in the presence or 
absence of 10ng/ml of heregulin-β1 and 5µm sections of gels H & E stained with 
representative images from three technical replicates presented. HB2 WT control cells (a) 
formed cohesive rounded units (RU) with appearance of lumens (L) but formed a mixture of 
larger more elongated units (EU) and rounded units (RU) in response to heregulin (b). HB2 
HER2/3OE cells formed much larger structures with the appearance of protrusions (PRO) from 
the outer edges of structures, distorted lumens (DL) and consisted of discohesive cells (DC) in 
response to heregulin (d) when compared to HB2 HER2/3OE control cells (c). Original 
magnification 20x, scale bars = 100µm. 
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Fig 5.5 Quantification of area, number and lumen formation of HER protein overexpressing 
HB2 units in 3D tri-culture gels in response to heregulin from H & E stained sections 
Size (a), number (b) and lumen formation (c) of wildtype (HB2 WT) and both HER2 and HER3 
overexpressing (HB2 HER2/3OE) HB2 cell units in response to 10ng/ml heregulin stimulation 
a) 
b) 
c) 
* * 
* 
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was quantified with Aperio Image scope, analysed with Graph Pad Prism 6 and normalized to 
total size of each respective collagen gel section. (a) Stimulation with heregulin significantly 
increased the size of HB2 WT and HB2 HER2/3OE units. (b) No significant difference was 
observed with the number of HB2 WT and HB2 HER2/3OE units in response to heregulin. (c) 
Stimulation with heregulin significantly decreased lumen formation in HB2 WT only while no 
significant difference was observed with HB2 HER2/3OE units. Bars denote mean from three 
technical replicates and error bars standard error of the mean (SEM). * indicates significant 
difference to HB2 controls following unpaired t-test (p=<0.05). 
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5.4.2 Phenotype of HB2 wildtype cells in 3D in vitro tri-culture model in response 
to heregulin stimulation 
Characterisation of HB2 WT 3D tri-cultures by IHC with or without heregulin stimulation 
demonstrated that despite lack of HER protein overexpression, the phenotype of HB2 WT units 
in is altered in response to heregulin. Representative images from three technical replicates 
are presented (Fig 5.6 & 5.7). While little difference was observed in the membranous pattern 
of E-Cad expression in response to heregulin, EMA expression was disrupted in response to 
heregulin as HB2 WT control units showed strong expression concentrated to the apical-lumen 
interface in the centre of units while ubiquitous cytoplasmic staining was observed in HB2 WT 
units with heregulin. Strong Ki67 expression was observed across all HB2 WT units regardless 
of heregulin stimulation confirming the presence of proliferative HB2 cells while apoptosis 
demonstrated by M30 staining was only detected in the centre of HB2 WT control units and 
was absent in HB2 WT units + heregulin. Disruption of basement membrane protein 
production was also observed in response to heregulin as HB2 WT control units displayed 
strong Coll IV expression neatly distributed around their outer edges while this was lost in HB2 
WT units + heregulin. The distribution of GFP Myo1089 cells and LS11-083 dsRed Fibs 
remained unchanged with tGFP staining detected in rounded cells associated around outer 
edges of units and dsRed staining detected in long spindle-shaped cells loosely distributed 
throughout the collagen gels regardless of heregulin stimulation.   
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Fig 5.6 Immunohistochemical characterisation of 3D in vitro tri-culture models of HB2 WT 
cells in response to heregulin A 
HB2 wildtype (HB2 WT) cell unit phenotype within tri-cultures in response to 10ng/ml 
heregulin was characterised by IHC to assess cell adhesion, polarisation and proliferation. 
Representative images from three technical replicates presented. HB2 units were positive for 
E-cadherin (E-Cad) staining localised between HB2 cell junctions without and with heregulin 
stimulation (arrows, c & d respectively). Epithelial Membrane Antigen (EMA) staining was 
concentrated at the apical-lumen interface of cells in the centre of units (yellow arrow, e) but 
was ubiquitous throughout the cytoplasm of cells in response to heregulin (f). Strong Ki67 
staining was observed in all cells of HB2 WT units both without (g) and with heregulin 
stimulation (h). Primary antibody was omitted to serve as negative (Neg) controls (a & b). 
Original magnification 20x, scale bars = 100µm.  
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Fig 5.7 Immunohistochemical characterisation of 3D in vitro tri-culture models of HB2 WT 
cells in response to heregulin B 
HB2 wildtype (HB2 WT) unit phenotype within tri-cultures in response to 10ng/ml heregulin 
was characterised by IHC to assess apoptosis and basement membrane production. 
Representative images from three technical replicates presented. M30 staining was visible in 
the central lumens of control units (arrow, a) but was absent upon stimulation with heregulin 
(b). Collagen IV (Coll IV) expression was neatly distributed around outer edges of control units 
(yellow arrow, c) but was disorganised in response to heregulin stimulation with a lack of 
concentrated staining around the outer edges of units (d). Both control and heregulin 
stimulated tri-cultures showed positive staining for tGFP in cells distributed around the outer 
edges of units (arrows, e & f) and positive staining for dsRed in cells loosely distributed 
throughout the collagen gel (arrows, g & h). Original magnification 20x, scale bars = 100µm. 
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5.4.3 Phenotype of HER2 and HER3 overexpressing HB2 cells in 3D in vitro tri-
culture model in response to heregulin stimulation 
Characterisation of HB2 HER2/3OE 3D tri-cultures by IHC with or without heregulin stimulation 
demonstrated differences in phenotype of HB2 units in response to heregulin suggesting a 
response from HB2 HER2/3OE cells in 3D tri-culture. Representative images from three 
technical replicates presented (Fig 5.8 & 5.9). Little difference was observed in the 
membranous pattern of E-Cad expression, the strong ubiquitous cytoplasmic expression of 
EMA and strong Ki67 expression across all HB2 HER2/3OE units in response to heregulin 
stimulation. Apoptotic cells were detected via M30 staining in the centre of HB2 HER2/3OE 
units regardless of heregulin stimulation. Basement membrane protein production was altered 
in response to heregulin as HB2 HER2/3OE control units displayed Coll IV expression 
distributed around their outer edges as well as in their centre while Coll IV was only detected 
in the centre of HB2 HER2/3OE units + heregulin. The distribution of GFP Myo1089 cells and 
LS11-083 dsRed Fibs remained unchanged with tGFP staining detected in rounded cells 
associated around outer edges of units, and dsRed staining detected in long spindle-shaped 
cells loosely distributed throughout the collagen gels regardless of heregulin stimulation.  
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Fig 5.8 Immunohistochemical characterisation of 3D in vitro tri-culture models of both HER2 
and HER3 overexpressing HB2 cells in response to heregulin 
HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) cell unit phenotype within tri-cultures in 
response to 10ng/ml heregulin was characterised by IHC to assess cell adhesion, polarisation 
and proliferation. Representative images from three technical replicates presented. E-cadherin 
(E-Cad) staining was localised between HB2 cell junctions in control and heregulin stimulated 
units (c & d respectively). Epithelial Membrane Antigen (EMA) staining was ubiquitous 
throughout the cytoplasm of HB2 cells in controls (e) and heregulin stimulated HB2 units (f). 
Strong Ki67 staining was observed in all cells of HB2 control (g) and heregulin stimulated (h) 
units. Primary antibody was omitted to serve as negative (Neg) controls (a & b). Original 
magnification 20x, scale bars = 100µm. 
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Fig 5.9 Immunohistochemical characterisation of 3D in vitro tri-culture models of both HER2 
and HER3 overexpressing HB2 cells in response to heregulin 
HB2 HER2 and HER3 overexpressing (HB2 HER2/3OE) unit phenotype within tri-cultures in 
response to 10ng/ml heregulin was characterised by IHC to assess apoptosis and basement 
membrane production. Representative images from three technical replicates presented. M30 
staining was detected in central areas of both HB2 HER2/3OE control (arrow, a) and heregulin 
stimulated units (arrow, b). Collagen IV (Coll IV) expression was detected both around outer 
edges and within control units (arrows, c) but was detected in the centre of heregulin 
stimulated units only (arrow, d). Both control and heregulin stimulated tri-cultures showed 
positive staining for tGFP in cells distributed around the outer edges of units (arrows, e & f) 
and positive staining for dsRed in cells loosely distributed throughout the collagen gel (arrows, 
g & h). Original magnification 20x, scale bars = 100µm. 
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5.4.4 Analysis of intracellular signalling pathway activation by heregulin in 
wildtype and HER2 and HER3 overexpressing HB2 cells using a human 
phospho-kinase Proteome ProfilerTM array 
In order to further investigate whether HB2 HER2/3OE cells had the capacity to respond to 
heregulin stimulation in a manner indicated in the literature, the intracellular signalling 
mechanisms stimulated by heregulin were examined and compared to HB2 WT control cells. 
This was assessed by comparing HB2 WT and HB2 HER2/3OE control cells to cells stimulated 
for 15 mins  with 10ng/ml heregulin using Proteome ProfilerTM human phospho-kinase arrays 
(R&D Systems) which allowed comparison of activation of 46 different human phospho-
kinases. Arrays for HB2 WT control cells and HB2 WT cells + heregulin were compared (Fig 
5.10, results from one biological replicate and no technical replicates) and arrays for HB2 
HER2/3OE control cells and HB2 HER2/3OE cells + heregulin were compared (Fig 5.11, results 
from two biological replicates) in order to determine the effect of HER2 and HER3 
overexpression in HB2 cells in the presence of heregulin. A subset of phospho-kinases whose 
phosphorylation were at least two-fold increased or decreased in comparison to control cells 
were identified for both HB2 WT and HB2 HER2/3OE cells. In the presence of heregulin, 
expression of phospho-kinases Erk1/2, GSK-3α/β, Akt, PRAS40 and WNK1 were increased and 
Lck and PDGFRβ decreased in HB2 WT cells (results from one biological replicate). In the 
presence of heregulin, expression of phospho-kinases Erk1/2, GSK-3α/β, Akt, PRAS40 were 
also increased and Lck also decreased in HB2 HER2/3OE cells, however, a subset of phospho-
kinases were identified which were either increased or decreased in HB2 HER2/3OE which 
were not identified in HB2 WT cells in response to heregulin. These included an increase in 
expression of the phospho-kinases Fyn, Hck and FAK and a decrease in expression of eNOS, 
PLCγ1 and Pyk2. In addition, while WNK1 was increased and PDGFRβ decreased in HB2 WT 
cells in response to heregulin, these kinases were not differentially expressed in response to 
heregulin in HB2 HER2/3OE cells.  
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It was noted that expression of some of the phospho-kinases identified to be at least two-fold 
increased or decreased following densitometry analysis were not visible on the array 
membranes following developing. This indicated a need for further validation of phospho-
kinase expression in these cells.  
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Fig 5.10 Human phospho kinase array analysis of signalling downstream of heregulin in HB2 
wildtype cells  
a) Human phospho kinase arrays, probed with 46 different phospho-kinase antibodies in 
duplicate with internal controls, were incubated with lysates from HB2 wildtype cells (HB2 WT) 
and HB2 WT cells stimulated with 10ng/ml heregulin for 15 minutes (HB2 WT + HRG) and 
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1  2 
3  
4  
5
6  
7  
1  
2  
3  
4  5 
6 7 
a) 
b) 
 
  
 
  
  
206 
 
developed for three minutes. Following heregulin stimulation, specific spots appeared more 
intense or fainter than HB2 WT controls.  
b) Histogram shows quantification of expression of a subset of phospho kinases following 
densitometry analysis using BioRad Image Lab 4.1 software. Phospho kinase expression was 
calculated as fold difference to HB2 WT after normalisation to internal positive reference 
controls (red boxes, a). Phopsho kinases which were differentially expressed by two-fold in 
comparison to HB2 WT are shown and labelled numbers 1-7 on arrays (a) and histogram (b).  
Results from one biological replicate with no technical replicates.  
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Fig 5.11 Human phospho kinase array analysis of signalling downstream of heregulin in HER2 
and HER3 overexpressing HB2 cells  
a) Human phospho kinase arrays, probed with 46 different phospho kinase antibodies in 
duplicate with internal controls, were incubated with lysates from HER2 and HER3 
overexpressing HB2 cells (HB2 HER2/3OE control) and HB2 HER2/3OE cells stimulated with 
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10ng/ml heregulin for 15 minutes (HB2 HER2/3OE + HRG) and developed for three minutes. 
Representative images of two replicate experiments shown. Following heregulin stimulation, 
specific spots appeared more intense or fainter than HB2 HER2/3OE controls.  
b) Histogram shows quantification of expression of a subset of phospho kinases following 
densitometry analysis using BioRad Image Lab 4.1 software. Bars denote mean from two 
biological replicate experiments and error bars standard error of the mean (SEM).Phospho 
kinase expression was calculated as fold difference to HB2 HER2/3OE controls after 
normalisation to internal positive reference controls (red boxes, a). Phopsho kinases which 
were differentially expressed by two-fold in comparison to HB2 HER2/3OE and did so in both 
replicate experiments are shown and labelled numbers 1-11 on arrays (a) and histogram (b).  
Results from two biological replicate experiments.  
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5.4.5 Validation of the differential expression of both visible and non-visible 
phospho-kinases identified via Proteome ProfilerTM human phospho-kinase 
arrays in HB2 wildtype and HER2 and HER3 overexpressing HB2 cells by 
western blot  
Phospho-Akt was selected as a representative phospho-kinase clearly visible and phospho-
PLCγ1 selected as a representative phospho-kinase not clearly visible on human phospho-
kinase array membranes. Protein samples extracted previously for phospho-kinase array 
analysis were used for western blot analysis of expression of phospho-Akt (Fig 5.12) and 
phospho-PLCγ1 (Fig 5.13) in HB2 WT and HER2/3OE control and heregulin stimulated cells. 
Images and results for each antibody presented are from a single experiment run. This 
confirmed an increase in Akt activation in response to HRG stimulation in both cell lines and 
that PLCγ1 is only activated in HB2 HER2/3OE control cells and is deactivated in response to 
HRG in these cells.   
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Fig 5.12 Western blots for phospho-Akt in HB2 WT and HB2 HER2/3OE cells stimulated with 
heregulin. 
a) Anti-phospho-Akt IgG was used to detect activated Akt protein in HB2 wildtype cells (HB2 
WT) and HB2 cells overexpressing both HER2 and HER3 (HB2 HER2/3OE) in response to 
stimulation with 10ng/ml heregulin-β1 (HRG). A band of ~60kDa was observed in HB2 WT+HRG 
and HB2 HER2/3OE+HRG cells. No band was detected in HB2 WT and HB2 HER2/3OE control 
cells. Anti-β-Actin IgG was used as a loading control for which bands were observed in all 
samples at ~42kDa.  
b) Histogram shows quantification of phospho-Akt expression following densitometry analysis 
using BioRad Image Lab 4.1 software. Phospho-Akt expression was calculated as fold 
difference to HB2 control cells after normalization to β-Actin for heregulin stimulated HB2 
cells. 
Results presented from a single experimental run. 
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Fig 5.13 Western blots for phospho-PLCγ1 in HB2 WT and HB2 HER2/3OE cells stimulated 
with heregulin. 
a) Anti-phospho-PLCγ1 IgG was used to detect activated PLCγ1 protein in HB2 wildtype cells 
(HB2 WT) and HB2 cells overexpressing both HER2 and HER3 (HB2 HER2/3OE) in response to 
stimulation with 10ng/ml heregulin-β1 (HRG). A band of ~155kDa was observed in HB2 
HER2/3OE control cells. No band was detected in HB2 WT control, HB2 WT+HRG and HB2 
HER2/3OE+HRG cells. Anti-β-Actin IgG was used as a loading control for which bands were 
observed in all samples at ~42kDa.  
b) Histogram shows quantification of phospho-PLCγ1 expression following densitometry 
analysis using BioRad Image Lab 4.1 software. Phospho-Akt expression was calculated as fold 
difference to HB2 controls after normalization to β-Actin for heregulin stimulated HB2 cells. 
Results presented from a single experimental run. 
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5.5 Discussion 
It has been reported that regardless of HER protein overexpression, it is the stimulation from 
HER ligands that determines HER receptor heterodimerisation and governs the signalling 
outcome downstream of HER receptors in epithelial cells [276]. Since HER2-HER3 
overexpression in HB2 cells did not affect the structures formed in the tri-culture model in 
Chapter 4 as expected, we hypothesised that HB2 HER2/3OE cells had the capacity to induce 
the morphological features described in the literature and were not deficient in their HER2-
HER3 signalling capacity but that there were insufficient endogenous levels of the HER2-HER3 
heterodimer ligand heregulin in the novel 3D tri-culture system to facilitate a response. We 
aimed to test this theory by stimulating 3D tri-cultures with heregulin with a view to inducing a 
morphology and phenotype characteristic of early breast cancer lesions and to validate that 
the HB2 HER2/3OE cells activate known downstream HER2-HER3 signalling mechanisms 
intracellularly. 
5.5.1 Comparison of wildtype and HER2 and HER3 overexpressing HB2 cell 3D in 
vitro tri-cultures in response to heregulin stimulation 
10ng/ml of heregulin-β1 was selected as an appropriate isoform and concentration for HER 
signalling activation for our experiments as this is considered physiologically relevant and has 
been widely adopted in the majority of heregulin stimulation studies [352-354]. This has also 
been validated in studies using HB2 cells [271, 355, 356].  
Stimulation of HB2 HER2/3OE tri-cultures with heregulin-β1 induced a morphology and 
phenotype analogous to HB2 HER2OE tri-cultures observed in Chapter 4. Larger, more 
branching HB2 units were produced which featured protrusions in comparison to HB2 
HER2/3OE control units. This suggested that in 3D tri-culture, HB2 HER2/3OE cells do have the 
capacity to disrupt normal architecture provided the HER2-HER3 ligand heregulin is present. It 
was clear that heregulin stimulation of HB2 HER2/3OE cells in the 3D tri-culture context 
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produced a more tumorigenic phenotype akin to results seen with [276]. However, we also 
observed that heregulin induced a similar morphology in HB2 WT cells with larger and more 
elongated units observed and lumen formation significantly decreased. Furthermore, both HB2 
WT and HB2 HER2/3OE tri-cultures in response to heregulin exhibited the same phenotype 
upon examination by IHC. It was expected that an excess of HER2 and HER3 protein expression 
would dramatically increase the sensitivity of HB2 cells to heregulin ligand stimulation. In these 
experiments the quantification of the size of HB2 units in response to heregulin-β1 was the 
same regardless of HER2 and HER3 protein overexpression and these had the same phenotype 
when analysed by IHC. Analysis of levels of HER2 and HER3 protein expression via western blot 
demonstrated that HER2 and HER3 proteins were at least 13-fold overexpressed in HB2 
HER2/3OE cells in comparison to HB2 WT cells (see Chapter 4). This confirmed that these 
observations were not due to deficient HER protein overexpression. 
This suggested that heregulin stimulation of both HB2 WT and HB2 HER2/3OE cells in 3D tri-
culture was sufficient to promote a pro-tumorigenic phenotype regardless of HER2-HER3 
overexpression. This correlates with work by Baeckstrӧm et al [271] who reported mitogenic 
effects and increased branching of HB2 WT structures in response to heregulin stimulation in 
collagen gels without HER2 and HER3 protein overexpression.  
Therefore, while we had partly proved our hypothesis in that HB2 HER2/3OE cells have the 
capacity to induce a pro-tumorigenic morphology as reported in the literature [276] and akin 
to results with HB2 HER2OE in Chapter 4 in response to heregulin, it was still unclear whether 
HB2 HER2/3OE cells differed in their HER2-HER3 signalling capacity due to the similar results 
obtained with HB2 WT cells.  
We then sought to investigate which intracellular signalling pathways were activated 
downstream of heregulin in the HB2 HER2/3OE cells to determine whether observations in our 
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cultures were due to deficient intracellular signalling processes downstream of the HER2-HER3 
heterodimer.  
5.5.2 Comparison of intracellular signalling pathway activation by heregulin in 
HB2 wildtype and HER2 and HER3 overexpressing cells 
A time point of 15 minutes for stimulation with heregulin-β1 was selected as an appropriate 
time point for our experiments as this has been proven to be sufficient for activation of 
downstream heregulin signalling [325, 357] which has also proven valid for HB2 cells [356]. 
Heregulin has been reported in multiple studies to induce phosphorylation of Akt [339, 358, 
359], GSK3 [360, 361] and Erk1/2 [362-364] in a variety of tissue types. In concordance with 
these studies, stimulation of HB2 WT and HB2 HER2/3OE cells with heregulin-β1 caused an 
increase in the levels phospho-Akt, phospho-GSK3α/β and phospho-Erk1/2 when analysed 
using human phospho-kinase arrays. This provided confidence that the concentration and time 
point of heregulin stimulation in our experiments was sufficient for downstream heregulin 
signalling pathway activation. In order to determine if there were any differences between the 
intracellular signalling pathways of HB2 WT and HB2 HER2/3OE cells in response to heregulin 
signalling, we first compared HB2 WT control to HB2 WT heregulin stimulated arrays and then 
HB2 HER2/3OE control to HB2 HER2/3OE heregulin stimulated arrays. We examined which 
kinases were differentially activated by at least two-fold in response to heregulin signalling for 
HB2 WT cells and then for HB2 HER2/3OE cells and determined whether there were any 
differences in the patterns of activation between the two cell types. This was in order to assess 
whether overexpression of the HER2-HER3 heterodimer caused HB2 cells to respond 
differently to heregulin stimulation or whether they responded the same therefore explaining 
the similarity in morphology and phenotype of these cells in the 3D tri-culture system. We 
identified a subset of kinases differentially activated in both HB2 WT and HER2/3OE cells, some 
by HB2 WT only, and some in HB2 HER2/3OE cells only. These are summarised in Table 5.2. We 
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further validated our quantification methods of these arrays by selecting two kinases, one 
which was easily visible on array membranes and one which was not easily visible and 
confirmed their expression patterns by western blot.  
Kinases 
phosphorylated 
in both cell 
types 
Increased or 
decreased? 
Kinases 
phosphorylated 
in HB2 WT only 
Increased or 
decreased? 
Kinases 
phosphorylated 
in HB2 
HER2/3OE only 
Increased or 
decreased? 
Erk1/2 Increased WNK1 Increased Fyn Increased 
GSK3α/β Increased PDGFRβ Decreased Hck Increased 
Akt Increased   FAK Increased 
PRAS40 Increased   eNOS Decreased 
Lck Decreased   PLCγ1 Decreased 
    Pyk2 Decreased 
Table 5.2 Summary of differentially activated kinases between HB2 WT cells and HB2 
HER2/3OE cells in response to heregulin stimulation 
The increase of phosphorylation of Akt and GSK3α/β suggested that in both cell types, 
heregulin-β1 stimulated activation of PI3K-Akt signalling. This correlated with the increase in 
PRAS40 phosphorylation which is a known substrate for activated Akt [365]. Phosphorylation 
of PRAS40 by Akt relieves inhibition of mTORC1 allowing cell growth through activation of S6K1 
[366]. The increase in Erk1/2 phosphorylation suggested that heregulin-β1 also stimulated 
activation of Ras-Erk signalling in both cell types. The combined effect of this suggests an 
increase in proliferation, survival and protein translation of these cells in response to heregulin 
stimulation. Since Lck is a Src family kinase proven to stimulate Ras-Erk pathway [367, 368], 
the decreased Lck activation in these cells was unexpected. The majority of data available on 
Lck has been conducted in T cells with few studies addressing Lck function in breast cells and 
no data available on the effects of heregulin on Lck activation. High levels of Lck expression has 
been linked to both increased survival of breast cancer patients and increased breast cancer 
invasiveness [369] making it difficult to speculate the reasons for the decreased activation of 
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this protein. One theory is that this is attributed to active Syk signalling which is known to 
inhibit Lck activation in normal breast epithelium [370] but why this would be stimulated by 
heregulin is not known.  
Increased activation of WNK1 protein was specific to HB2 WT cells in response to heregulin. 
The increased activation of WNK1 can be expected upon increased PI3K-Akt signalling as 
WNK1 is a substrate for Akt [371].  WNK1 is a serine-threonine kinase which can stimulate Erk5 
mediated cell proliferation [372] and is a negative regulator of insulin-stimulated cell 
proliferation [371]. The reason for lack of increased activation of WNK1 in HB2 HER2/3OE cells 
is unknown. One theory is that since HER2-HER3 heterodimers are known to co-operate with 
insulin and insulin-like growth factor signalling [276], HER2-HER3 overexpression enhances 
insulin-stimulated proliferation thereby overcoming the inhibitory effects of WNK1 in these 
cells. Little connection could be found between heregulin signalling and PDGFR signalling. 
However, it has been documented that PDGFR is downregulated by mTOR [373] and since it is 
likely mTOR is increased in response to heregulin in HB2 WT cells due to the increase in Akt 
and PRAS40 phosphorylation, this could provide an explanation for PDGFR depletion. 
However, the reason why this is not the same for HB2 HER2/3OE cells is unknown.   
It is clear from these results that despite the lack of HER2 and HER3 protein expression 
detected by western blot in HB2 WT cells in our study, heregulin had the capacity to induce 
several of the same major proliferative and anti-apoptotic signalling cascades as HB2 
HER2/3OE cells perhaps explaining the similar morphology of these two cell types in response 
to heregulin in 3D tri-culture. It is likely that HB2 WT cells do indeed express HER2 and HER3 
protein which would correlate with findings from the Berditchevski laboratory (personal 
communication, Dr Fedor Berditchevski). It is feasible that our western blot detection method 
was not sensitive enough to capture endogenous HER2 and HER3 expression or required 
prolonged exposure. Since heregulin is specific to HER2/HER3 or HER2/HER4 heterodimers 
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[317-319], it would be reasonable to suggest that at least HER2 was present in these cells but 
would need further optimisation of our western blot technique to confirm both this and the 
expression of HER3 in these cells. 
The increase in kinases such as FAK and Fyn in HB2 HER2/3OE cells could be suggestive of 
increased migratory potential of these cells in response to heregulin. Heregulin has been 
reported to enhance the formation of filopodia, lamellipodia and increase migration of non-
invasive breast cells [267]. Heregulin has the potential to recruit FAK to HER2-HER3 
heterodimers [374] and induce its phosphorylation and activation [375]. FAK is well 
acknowledged as a major regulator of cell migration [376] and is stimulated by 
phosphorylation by Src kinases such as Fyn [377]. Fyn is reported to be required for cell 
migration [378] with a capacity to induce actin rearrangement [379]. Both Fyn [380] and FAK 
[381, 382] are reported to be involved in integrin signalling. Heregulin is also proven to 
mediate integrin signalling [383] suggesting a possible integrin-HER2-HER3 heterodimer 
complex formation with activation of FAK and Src downstream effectors in response to 
heregulin in these cells. The decreased activation of Pyk2 in these cells could be attributed to 
multiple events in these cells. Increased activation of FAK can downregulate Pyk2 [384]. The 
recruitment of Fyn to integrin-HER2-HER3 complexes could be competitively inhibiting Fyn 
association with Pyk2 and the reduction of Lck could cause loss of Pyk2 activation [385].  
Though the increased activation of PLCγ in HB2 HER2/3OE control compared with HB2 WT cells 
was expected as PLCγ1 has been proven to be activated by HER2-HER3 heterodimers [340, 
341] the loss of PLCγ1 signalling in HB2 HER2/3OE cells upon heregulin stimulation was 
unexpected given that heregulin activates the HER2-HER3 heterodimer. However, there is 
some evidence to suggest that activation of PLCγ1 can be reliant upon kinases such as Fyn and 
Lck [386, 387]. The recruitment of Fyn to other signalling complexes and the downregulation of 
Lck in these cells could account for this downregulation of PLCγ1.  The reduction in eNOS could 
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be explained by the reduction in PLCγ1 activity as PLCγ1 can indirectly activate eNOS through 
increasing intracellular calcium levels [388, 389] and thereby increasing Calmodulin activity 
[390]. Calmodulin is proven to activate eNOS [391] therefore providing an explanation of loss 
of eNOS in these cells upon lack of PLCγ1.  Another theory is that there is an increase in 
Caveolin-1 activity in these cells which has been shown to inhibit eNOS [392]. Interestingly, 
caveolin-1 has also been demonstrated to interact and mobilize Fyn to integrin complexes 
[380] and could therefore be influencing multiple signalling processes in these cells.  
Combined, this suggests that HB2 HER2/3OE cells do have the capacity to respond to heregulin 
stimulation as expected by up regulating kinases such as Akt and PRAS40 and thus proves our 
hypothesis that these cells are not deficient in their HER2-HER3 signalling capacity. In addition, 
the differential activation of kinases such as FAK and Fyn to HB2 WT cells may be indicative of 
different adhesion and migration properties of these cells.  
However, intracellular signalling processes are incredibly complex with a high degree of 
crosstalk and overlap. Many of the signalling processes highlighted above are clearly context 
dependent with many of the studies described undertaken in other cell and tissue types to 
breast. A major limitation of our experimentation here is that the intracellular signalling 
processes were studied in 2D rather than 3D culture. It is plausible that these effects would 
not be conserved in 3D and that our observations in 3D were induced by different mechanisms 
due to different intercellular signalling mechanisms and ligand availability.  Therefore, not only 
are conclusions drawn here based on speculation from crude experimentation, but an 
inappropriate model system was employed. Further investigation and validation is needed to 
confirm these theories using appropriate model systems. 
Nevertheless, these experiments have confirmed that in 2D monolayer culture, the 
overexpression of HER2 and HER3 in HB2 cells altered the activation of a subset of phospho-
kinases in response to heregulin verifying that HER2 and HER3 overexpression altered 
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intracellular signalling mechanisms in these cells. This indicated that the lack of a highly 
mitogenic and migratory morphology and phenotype of HB2 HER2/3OE in comparison to HB2 
WT cells was not due to deficient expression, functionality and downstream signalling of the 
HER2 and HER3 heterodimer from heregulin in these cells but may be due to the external 
influences of surrounding stromal cells and the microenvironment. This too would require 
further experimentation in 3D cultures to confirm this theory. 
  
220 
 
6 Chapter 6: Assessing the suitability of the in vitro model to 
study the role of the stroma on cancer initiation  
6.1 Introduction 
Over the last few years it has become increasingly apparent that the tumour stroma is not just 
a passive bystander in the progression of breast tumours. Work by Finak et al [53] proposed 
that the stromal gene expression signature can be used as a powerful prognostic indicator of 
clinical outcome of breast cancer patients. However, little is known about how changes in gene 
expression of stromal cells affect the morphology and phenotype of the normal luminal 
epithelium and whether these changes are attributed to the initiation of tumorigenesis. 
Our tri-culture model included both a fibroblast and a myoepithelial component and validation 
experiments earlier in this thesis showed that the model was representative of normal breast 
in vivo. To determine whether it had potential to be used as a tool to study the role of gene 
expression changes in stromal cells on cancer initiation, we selected two protein candidates to 
knockdown in our fibroblasts and myoepithelial cells and investigated the effect on normal 
epithelial architecture. These were Dedicator of Cytokinesis 4 (DOCK4) and Estrogen Receptor 
β1 (ERβ1). These were chosen in concordance with local research interests, the rationales for 
which are discussed below.  
6.1.1 DOCK proteins 
Over 60 guanine nucleotide exchange factors (GEFs) have been identified in the human 
genome. GEFs are a family of proteins which function to activate Rho GTPases [393]. 
Therefore, through downstream signalling to Rho GTPases, GEFs play a role in regulating 
cytoskeletal remodelling and thus several key cell functions such as maintaining cell polarity 
[394], cell migration [395] and even cell proliferation [396]. 
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One family of GEFs identified are the DOCK family proteins. To date, 11 members of the DOCK 
family have been identified [397]. All DOCK proteins contain a DOCK homology region 1 
domain (DHR1) which binds PIP3 [398] and a bioactive DOCK homology region 2 domain 
(DHR2) which catalyses the conversion of GDP to GTP [399].  
DOCK4 is a member of the DOCK protein family. In addition to containing DHR1 and DHR2 
domains, DOCK4 also contains an SH3 domain at its N-terminus and a proline rich motif at its 
C-terminus contributing to its quaternary structure and aiding inter-molecular protein 
interactions [400]. Though extensive functional data for the DOCK4 protein is lacking, DOCK4 
has been linked to tumorigenesis through its interaction with downstream protein targets such 
as Rap GTPase  regulating cell junction assembly and also metastasis through its role in 
lymphatic/haematogenous spread [401]. It is also reported that protein complexes containing 
DOCK4 can increase cell migration and invasion in breast cancer [402]. DOCK4 is a GEF for Rac1 
[403]. Rac1 is a Rho GTPase with well documented roles in cancer initiation and progression. 
Rac1 is commonly overexpressed in breast cancers [404] where it mediates increased 
migration, invasiveness and anchorage-independent growth of MCF-7 cells via Pak1 activation 
[405], as well as cyclin D1 induction by heregulin [362]. Currently there is no extensive data 
available on the abundance and function of DOCK4 in breast tumour cells and fibroblasts. 
Preliminary work in our group has demonstrated variable DOCK4 expression in fibroblasts in 
both breast carcinoma samples (Fig 6.1) and in reduction mammoplasty samples (Fig 6.3, 
section 6.3). The significance of this is currently unknown. 
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Fig 6.1 Expression of DOCK4 in breast carcinoma samples  
Examples of breast carcinoma samples representing weak (a), moderate (b) and strong (c) 
DOCK4 expression in tumour epithelial cells (TE). In all cases, intensity of DOCK4 expression in 
fibroblasts varied with each sample regardless of levels in tumour epithelium. Each contained 
examples of weak DOCK4 expression (WF) and strong expression (SF) in fibroblasts.  
Images courtesy of Dr Renu Gahlaut and Dr Georgia Mavria (Leeds Institute of Cancer and 
Pathology).  
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6.1.2 ERβ1  
In 1986, the first gene encoding a protein receptor responsible for binding 17β estradiol was 
cloned (now known as ERα) and was long believed to be the only mediator of estrogen 
signalling [406, 407].  However, a decade later, a second estrogen receptor was identified, first 
in rat [408], and then in humans [409] and was denoted ERβ. ERβ is expressed in a variety of 
tissue types and is the major form of ER in the normal adult breast with expression observed in 
luminal epithelium, myoepithelium and stromal cells [410]. ERβ belongs to the nuclear 
hormone receptor (NHR) family of proteins which feature common structural compositions. 
ERβ contains an AF1 domain at its N-terminus which activates transcription irrespective of 
ligand binding, a DNA binding domain (DBD), an AF2 domain which activates transcription in 
response to ligand binding and an estrogen ligand binding domain (LBD) [411, 412].  Several 
isoforms of ERβ have been identified which arise through alternative splicing and differ in their 
last coding exon [413]. ERβ1 was the first ERβ isoform to be resolved [408] and has since been 
proven to be the only ligand binding ERβ isoform [414]. Upon activation, ERβ1 can either 
homodimerise, or form heterodimers with other ERβ isoforms [415] or with ERα [416].  
Like other NHRs, the classical ERβ signalling pathway involves the binding of a ligand to ERβ 
dimers in the cytoplasm causing activation and translocation into the nucleus. Once in the 
nucleus, ERβ binds DNA via its DNA binding domain to estrogen response elements [417] or 
serves as a co-regulator for other transcription factors such as AP-1 [418]. Roles for ERβ have 
also been reported in the mitochondria [419] and in signalling cascades from the plasma 
membrane [420].  
Perhaps due to lack of sufficiently well characterised antibodies, conflicting roles for ERβ have 
been reported in breast cancer. However, the majority of both clinical and in vitro studies to 
date have reported a tumour suppressive role for ERβ. Several clinical studies have reported a 
correlation with ERβ expression and increased patient survival [421-423]. In addition, several in 
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vitro studies have reported an anti-proliferative effect of ERβ in breast cancer cells [424-426] 
as well as decreased cell invasion [427] and increased apoptosis [428].  
Given the putative tumour suppressive nature of ERβ in breast cancer as well as the reported 
tumour suppressive nature of myoepithelial cells [429], it could be proposed that the tumour 
suppressive role of myoepithelial cells is mediated by ERβ. The loss of both ERβ [430] and 
myoepithelial cells [431] in the transition from DCIS to invasive cancer may strengthen this 
proposal.  
6.1.3 CAFs and cancer initiation 
As a follow up to previous chapters, we were also interested in whether activation of normal 
fibroblasts can alter the morphology of the normal luminal epithelium further exploring the 
theory that changes in stromal cell activity can initiate tumorigenesis. Therefore, the effect of 
pre-exposing our normal fibroblasts to the well characterised HER2 overexpressing tumour cell 
line SkBr3 on the normal architecture of our model was investigated. 
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6.2 Aims 
In order to determine if the 3D in vitro tri-culture model could be used to study the role of 
gene expression changes in stromal cells on cancer initiation, the effect of DOCK4 protein 
knockdown in fibroblasts and ERβ1 knockdown in myoepithelial cells on the morphology and 
phenotype of normal HB2 cells in 3D tri-culture models of normal breast was investigated. In 
keeping with the theme from previous chapters, the effect of exposing of normal fibroblasts to 
the conditioned medium of the HER2 overexpressing breast tumour cell line SkBr3 was 
investigated in an attempt to elucidate whether tumour cells “activate” normal fibroblasts and 
whether these activated fibroblasts have the capacity to disrupt normal luminal cell 
architecture. This was addressed by :- 
 Induction of stable knockdown of DOCK4 in LS11-045 hTERT immortalised fibroblasts 
using lentiviral shRNAs and comparison of the morphology and phenotype of HB2 cells 
in 3D tri-culture in vitro models with fibroblasts deficient in DOCK4 and respective 
controls 
 Induction of knockdown of ERβ1 in GFP Myo1089 cells using siRNA and comparison of 
the morphology and phenotype of HB2 cells in 3D tri-culture in vitro models with ERβ1 
siRNA GFP Myo1089 cells and respective controls 
 Pre-culturing LS11-083 dsRed fibroblasts in SkBr3 conditioned medium and 
comparison of the morphology and phenotype of HB2 cells in 3D tri-culture in vitro 
models with LS11-083 dsRed fibroblasts pre-conditioned to SkBr3 cells  
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6.3 Materials and Methods 
6.3.1 Downregulation of DOCK4 in LS11-045 hTERT fibroblasts by shRNA 
transduction 
Lentiviral transduction was carried out as per Chapter 2. In order to produce LS11-045 hTERT 
fibroblasts with stable knockdown of DOCK4 protein, two pGIPZ-tGFP vectors containing 
shRNA sequences against DOCK4 were used (see Fig 6.2, Thermo Scientific) with the pGIPZ-
tGFP empty vector used as a control (see Chapter 3). The shRNA sequences used were as 
follows:-  
 5’- CTCAGTATTTGCAGATATA - 3’ (referred to as DOCK4 shRNA 1) 
 5’- CGCAAGGTCTCTCAGTTAT -3’ (referred to as DOCK4 shRNA 2) 
Fig 6.2 Simplified plasmid map of pGIPZ shRNA lentiviral expression plasmid 
Diagram represents key elements contained within the expression plasmid used to lentivirally 
transduce cells with DOCK4 shRNA. Key elements are as follows:- Human Cytomegalovirus 
promoter (hCMV), TurboGFP gene (tGFP), internal ribosome entry site (IRES), Puromycin 
resistance gene (PuroR), short hairpin RNA sequence against DOCK4 (DOCK4 shRNA), 
Woodchuck hepatitis virus post-transcription regulatory element (WPRE), 3’- self inactivating 
long terminal repeat (3’-SIN LTR), Simian Vacuolating Virus 40 origin of replication (SV40 Ori), 
pUC origin of replication (pUC), Ampicillin resistance gene (AmpR), 5’-LTR, psi packaging 
sequence (ψ) and Rev Response Element (RRE).  
Adapted from [http://www.thermoscientificbio.com/shrna/gipz-lentiviral-shrna/].  
pGIPZ shRNA 
plasmid 
DOCK4 
shRNA 
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6.3.2 Lentiviral Transduction for cell tracking  
Lentiviral transduction was carried out as per Chapter 2. In order to produce Myo1089 cells 
that stably expressed dsRed fluorescent protein, the pFURW empty lentiviral expression vector 
was used (see Chapter 3, Fig 3.2 for a plasmid map of the pFURW vector). 
6.3.3 Downregulation of ERβ1 in GFP Myo1089 cells 
siRNA transfection 
Transfection of siRNAs against ERβ1 in GFP Myo1089 cells was performed according to a 
method previously optimised by Dr Euan Baxter (Leeds Institute of Cancer and Pathology) 
shown to give >70% downregulation of ERβ1 in MCF-7 cells (unpublished). ERβ1 siRNA 
oligonucleotides were supplied lyophilised (Sigma) and were re-suspended in 1x siRNA Buffer 
(Dharmacon; 20mM KCl, 6mM HEPES-pH 7.5, 0.2mM MgCl2) to obtain standard stock 
concentrations of 10µM. ERβ1 siRNA sequences used were as follows:- 
 5’- GGGCTTCATCTTTCTGCTG- 3’ 
 5’- GGGCATGGAACATCTGCTCAACA -3’ 
A negative control with a siRNA pool of non-targeting sequences was obtained (Dharmacon 
#D-001206-13) and is termed scrambled control. 
GFP Myo1089 cells were seeded into a 6-well plate and left to adhere for 24 hours ensuring 
60% confluency. Cell media was replaced prior to the transfection procedure. Transient 
transfection was performed using Lipofectamine® RNAiMAX reagent (Invitrogen) according to 
manufacturer’s instructions for a 6-well plate. The final concentration of siRNA in each 
reaction was 100pmol for both ERβ1 siRNA and scrambled control. In the case of ERβ1, the two 
different siRNA sequences above were pooled to give a total concentration of 100pmol. 
Solutions containing siRNA-Lipofectamine® RNAiMAX complexes were added dropwise to GFP 
Myo1089 cells (250µl per well) and cells left to recover for 72 hours before assessing 
knockdown efficiency by qPCR. 
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RNA extraction from cells cultured in 2D 
Total RNA was extracted from cells using a Qiagen RNA Easy Plus Mini Kit (Qiagen) according to 
manufacturer’s instructions. Briefly, cells were lysed in situ with lysis buffer containing RNase I. 
Genomic DNA was removed via gDNA eliminator columns (supplied) before lysate was applied 
to columns that contain a membrane filter that binds RNA. Total RNA was eluted from the 
column with 30µl nuclease-free water (supplied). RNA was analysed using a Nanodrop ND-
1000 spectrophotometer reading at an optical density of 260nm and 280nm to determine 
concentration and purity.   
RNA Extraction from cells contained in 3D collagen gels 
Total RNA was extracted from GFP Myo1089 mono-culture gels as previously described [432]. 
Briefly, GFP Myo1089 cells were cultured as mono-cultures in 3D collagen gels as per Chapter 2 
to give a final cell density of 4x105 cells per mL of gel. After 21 days in culture, the medium was 
removed from the top and bottom of three replicate gels and gels rinsed twice with ice cold 
DPBS. Working on ice, collagen gels were removed from inserts using a pre-chilled truncated 
P1000 pipette tip (Gilson) and transferred into pre-chilled sterile eppendorf tubes. After a soft 
centrifugation step (1 min, 7500rpm), residual medium supernatant (that had been retained by 
the collagen gel) as well as collagen overlaying the cell pellet was removed by pipetting. Cell 
pellet was then lysed immediately and RNA extraction carried out as for cells cultured in 2D 
(above). 
DNase Treatment and cDNA synthesis 
RNA (10µg) was treated with DNase using a TURBO DNase kit (Ambion) according to 
manufacturer’s instructions. A total reaction volume of 50µl was used. cDNA was synthesised 
using a Superscript II kit (Invitrogen).  Briefly, 100ng of DNase treated RNA was added to a tube 
placed on ice, 1μl mixed deoxyribonucleotide triphosphate (dNTPs, 10mM, Promega) and 1μl 
oligo dT (250ng/μl) (supplied) were added and the volume made up to 12μl with nuclease-free 
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water (Ambion). Solution was incubated at 65°C for 5 mins and replaced on ice. To this, 1μl 
RNase (RNase Out), 2μl (0.1M) dithiothreitol  and 5μl of 10 x buffer (all supplied) were added. 
Solution was incubated at 42oC for 2 mins before adding 1μl of Superscript II reverse 
transcriptase (supplied).  Reaction mixture was then incubated for 50 minutes at 42°C and then 
15 minutes at 70oC.  The cDNA was stored at -20°C until required.   
qPCR 
The downregulation of ERβ1 was assessed by qPCR. This was performed using Taqman® gene 
expression assays (Life technologies). All reactions performed in a hood which was UV 
irradiated prior to use. Total volume of each reaction was 20µl comprising of 2µl of the cDNA 
template, 1µl of Taqman gene expression assay, 10µl of TaqMan® Gene Expression Master Mix 
and made up to 20 µl with nuclease free water (all Applied Biosytems). Two types of controls 
were employed for each gene expression assay, one with cDNA template omitted and one 
minus RT control per cell type lysed. For each reaction, 20 µl was transferred to a MicroAmp® 
optical 96-well plate (Applied Biosytems) and plate sealed with optical tape. Reactions were 
amplified on an ABI 7700 machine (Applied Biosystems) with the following thermocycling 
parameters: 2 mins 50oC, 10 mins 95oC, and then 40 cycles of 15 secs 95oC and 1 min 60oC. All 
reactions were performed in triplicate. Relative quantification of ERβ1 mRNA was calculated in 
relation to the RPLP0 housekeeping gene [433]. The ΔCt was calculated [434] in comparison to 
RPLP0 and the fold difference to scrambled control calculated to determine efficiency of ERβ1 
downregulation. 
6.3.4 Pre-conditioning of LS11-083 dsRed Fibs to SkBr3 cells 
Conditioned medium from SkBr3 cells was prepared as per Chapter 2. LS11-083 dsRed Fibs 
were cultured under normal conditions in vented cap cell culture flasks (Corning) until 50% 
confluency was reached. Cells were rinsed in DPBS and medium replaced with SkBr3 cell 
conditioned medium either neat or diluted in 1:2 DMEM-GlutaMAXTM-I + 10% HI-FCS to give 
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50% and 100% SkBr3 conditioned medium. Media of control flasks were replaced with fresh 
DMEM-GlutaMAXTM-I + 10% HI-FCS. LS11-083 dsRed Fibs were then incubated for 24 hours 
prior to incorporation into 3D tri-culture as per Chapter 2.  
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6.4 Results 
6.4.1 Confirmation of DOCK4 expression in fibroblasts from the LS11-045 normal 
breast reduction mammoplasty sample 
DOCK4 protein expression was examined in the normal breast reduction mammoplasty sample 
denoted LS11-045 by IHC (Fig 6.3). DOCK4 staining was detected in both the normal breast 
epithelium and in the majority of surrounding stromal fibroblasts confirming that DOCK4 
protein was expressed in original fibroblasts in vivo prior to in vitro culture. Representative 
image from three technical replicates presented. 
6.4.2 Knockdown of DOCK4 in hTERT fibroblasts 
In order to determine the effect of knocking down DOCK4 protein in fibroblasts, LS11-045 
hTERT fibroblasts were transduced with lentiviruses harbouring two different shRNA 
sequences for DOCK4 (DOCK4 shRNA 1 and DOCK4 shRNA 2) or empty vector control (EV) in 
addition to tGFP. Three fibroblast populations were produced which all retained an elongated 
spindle-shaped morphology following transduction and with over 95% of cells positive for tGFP 
(Fig 6.4). Given that with the method of FACS, a population of 95-100% of tGFP positive cells 
would be considered very high purity [435], and that >95%  of our cells were positive for tGFP 
upon visual inspection without sorting, it was deemed unnecessary to enrich for a tGFP 
positive cell population any further by FACS sorting.  
DOCK4 protein expression was assessed by western blot in untreated LS11-045 hTERT 
fibroblasts and compared to EV fibroblasts. This not only confirmed that DOCK4 protein 
expression was retained in fibroblasts following isolation from the original breast reduction 
mammoplasty specimen and subsequent hTERT transduction, but also that expression was not 
altered by transduction with the control lentivirus, EV. Representative image from three 
independent western blots presented. DOCK4 protein expression was then assessed to 
determine the effectiveness of each shRNA in the knockdown of DOCK4. Fig 6.5 depicts a 
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decrease in expression of total DOCK4 protein upon treatment with both DOCK4 shRNA 
plasmids in comparison to EV control fibroblasts. However, a fainter band was observed upon 
treatment with DOCK4 shRNA 2 than DOCK4 shRNA 1 plasmid. Representative image from 
three independent western blots presented. Quantification data are presented as expression 
fold difference to EV controls and confirmed a 2-fold decrease in expression of DOCK4 protein 
with DOCK4 shRNA 1 and a 7-fold decrease with DOCK4 shRNA 2. This suggested a more 
efficient knockdown of DOCK4 protein in LS11-045 hTERT fibroblasts transduced with DOCK4 
shRNA 2 than DOCK4 shRNA 1. Therefore, hTERT fibroblasts containing DOCK4 shRNA 2 were 
used for subsequent experimentation and are referred to as DOCK4 shRNA fib and empty 
vector control fibroblasts referred to as EV fib from here in.   
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Fig 6.3 Expression of DOCK4 in normal breast tissue 
Anti-DOCK4 IgG was used to detect DOCK4 protein expression in LS11-045 normal breast 
reduction mammoplasty sample by IHC. In addition to the strong DOCK4 staining in the normal 
breast epithelium (E), DOCK4 was detected in the majority of the surrounding stromal 
fibroblasts (F +ve). Fibroblasts were also observed which were negative for DOCK4 staining (F –
ve) but these were fewer in number than DOCK4 positive fibroblasts. Original magnification 
20x, scale bar = 100µm. Representative image from three technical replicates presented. 
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Fig 6.4 Lentiviral transduction of hTERT fibroblasts with DOCK4 shRNA 
Phase contrast microscopy of hTERT fibroblasts prior to lentiviral transduction showed a mono 
layer of dispersed cells (a, original magnification 4x) with elongated spindle-shaped 
morphology (b, original magnification 10x). hTERT fibroblasts were lentivirally transduced tGFP 
lentivirus harbouring empty vector (c & d) or tGFP lentiviruses harbouring two different shRNA 
sequences for the protein DOCK4 labelled here as DOCK4 shRNA 1 (e & f) and DOCK4 shRNA 2 
(g & h). Phase contrast microscopy demonstrated that hTERT fibroblasts maintained an 
elongated spindle-shaped morphology following lentiviral transduction (c, e and g). 
Fluorescence microscopy for all lentiviral vectors confirmed that over 95% of the cells were 
positive for the GFP reporter (d, f & h). Original magnification for c-h, 10x. Images acquired 
with an EVOS fl microscope. 
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Fig 6.5 Western blot for DOCK4 in fibroblasts transduced with lentiviruses harbouring two 
DOCK4 shRNAs in comparison to fibroblasts with control lentiviral transduction (EV)  
a) Anti-DOCK4 was used to detect total DOCK4 protein in untreated hTERT fibroblasts 
(untreated) and in empty vector fibroblasts (EV). Bands of ~225kDa were observed in both. 
Anti-β-Actin IgG was used as a loading control for which bands were observed in both samples 
at ~42kDa. Representative image from three independent western blots. b) Anti-DOCK4 IgG 
was used to detect total DOCK4 protein in EV and fibroblasts transduced with lentiviruses 
harbouring two different DOCK4 shRNAs (DOCK4 shRNA 1 & DOCK4 shRNA 2). Bands of 
~255kDa were observed in EV and DOCK4 shRNA 1 cells with EV displaying a more intense 
band than DOCK4 shRNA 1. No band was detected in DOCK4 shRNA 2. Anti-β-Actin IgG was 
used as a loading control for which bands were observed in all samples at ~42kDa. 
Representative image from three independent western blots. Histogram shows quantification 
of DOCK4 expression following densitometry analysis using the BioRad Image Lab 4.1 software. 
DOCK4 expression was calculated as fold difference to EV after normalization to β-Actin for 
each sample. Bars denote mean from three independent western blots and error bars 
standard error of the mean (SEM).  
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6.4.3 Production and characterisation of a dsRed positive myoepithelial cell line 
Due to the tGFP reporter present in our fibroblasts, to enable the tracking of Myo1089 cells in 
3D tri-culture, Myo1089 cells were lentivirally transduced with a lentivirus harbouring the 
pFURW-dsRed empty vector plasmid. FACS yielded a Myo1089 cell population which was >99% 
positive for dsRed and retained a stellate-shaped morphology (Fig 6.6). These are referred to 
as dsRed Myo1089 cells from here in.  
6.4.4 Morphology and phenotype of 3D in vitro tri-culture models containing 
fibroblasts with or without DOCK4 protein expression 
In order to determine any potential effects of knocking down DOCK4 protein in fibroblasts on 
epithelial architecture, HB2 WT and dsRed Myo1089 cells were co-cultured with EV fibs or 
DOCK4 shRNA fibs in the 3D tri-culture system and the morphology of the cultures assessed. 
Visualisation by H & E demonstrated that in the presence of either EV fibs or DOCK4 shRNA 
fibs, HB2 WT cells formed small rounded units which consisted of cohesive cells with lumen 
formation in their centres as per results in previous chapters (Fig 6.7). Representative images 
from three technical replicates presented. This suggested that knockdown of DOCK4 protein in 
fibroblasts had no effect on the morphology of HB2 cell architecture.  
Similarly, characterisation by IHC showed little difference in the phenotype of HB2 units 
cultured with EV fibs and DOCK4 shRNA fibs (Fig 6.8 and 6.9, representative images from three 
technical replicates presented). HB2 unit phenotype was comparable to results from previous 
chapters whereby E-Cad was observed between HB2 cell junctions and EMA concentrated at 
the apical-lumen interface with both types of fibroblasts. Ki67 was equally strong and 
abundant in HB2 cells and M30 staining negligible regardless of fibroblasts used. Basement 
membrane production was evident with both types of fibroblast with areas of Coll IV staining 
observed around outer edges of HB2 units. Both EV Fibs and DOCK4 shRNA fibs showed similar 
distribution within gels with tGFP staining detected both loosely associated with outer edges 
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of HB2 units and distributed throughout the collagen gel matrix. dsRed Myo1089 cells were 
also found associated with outer edges of HB2 units in both contexts. 
This suggested that knockdown of DOCK4 protein in fibroblasts does not affect the 
morphology and phenotype of normal mammary epithelial architecture in the 3D in vitro tri-
culture model of breast. 
Fig 6.6 Lentiviral transduction of Myo1089 cells with dsRed fluorescent protein 
Phase contrast microscopy of Myo1089 cells prior to lentiviral transduction showed a 
cobblestone monolayer of cohesive cells (a, original magnification 4x) which consisted of an 
elongated stellate-shaped morphology (b, original magnification 10x). Myo1089 cells were 
lentivirally transduced with pFURW-dsRed vector. Phase contrast microscopy demonstrated 
that Myo1089 cells maintained an elongated stellate-shaped morphology following lentiviral 
transduction (c). Fluorescence microscopy demonstrated over 95% of the cells were positive 
for the dsRed fluorescent reporter (d). Original magnification for c & d, 10x. Images (a) and (b) 
acquired using an Olympus CKK41 microscope with an Olympus Camedia C-7070 camera 
attached. Images (c) and (d) acquired using an EVOS fl microscope. 
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Fig 6.7 Representative H & E staining of 3D in vitro tri-culture models containing fibroblasts 
with or without DOCK4 protein expression  
Empty vector control fibroblasts (EV Fibs) and fibroblasts with knockdown of DOCK4 (DOCK4 
shRNA Fibs) were co-cultured in 3D collagen gels with dsRed Myo1089 and HB2 wildtype cells 
for 21 days and 5µm sections of gels were H & E stained. Little difference was observed with  
knockdown of DOCK4 protein in fibroblasts on the morphology of HB2 units. HB2 cells formed 
cohesive rounded units (RU) with appearance of lumens (L) both in the presence of EV Fibs (a 
& b) and DOCK4 shRNA Fibs (c & d). Original magnification 20x, scale bars = 100µm. 
Representative images from three technical replicates presented. 
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Fig 6.8 IHC characterisation of 3D in vitro tri-culture models containing fibroblasts with or 
without DOCK4 protein expression A 
3D in vitro tri-culture model containing empty vector control fibroblasts (EV Fibs) and 
fibroblasts with knockdown of DOCK4 (DOCK4 shRNA Fibs) with HB2 cells and dsRed Myo1089 
cells were characterised by IHC. Little difference was observed with the knockdown of DOCK4 
protein in fibroblasts on the phenotype of HB2 units. Primary antibody was omitted to serve as 
a negative control (a & b). E-cadherin (E-Cad) was expressed by HB2 cells at cell-cell junctions 
(arrow, c) in the presence of EV Fibs (arrow, c) and DOCK4 shRNA Fibs (arrow, d).  Strong 
staining was observed in HB2 cells with both types of fibroblasts (e & f). HB2 cells were positive 
for Ki67 regardless of fibroblast type (g & h).  Original magnification 20x, scale bars = 100µm. 
Representative images from three technical replicates presented.  
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Fig 6.9 IHC characterisation of 3D in vitro tri-culture models containing fibroblasts with or 
without DOCK4 protein expression B 
3D in vitro tri-culture model containing empty vector control fibroblasts (EV Fibs) and 
fibroblasts with knockdown of DOCK4 (DOCK4 shRNA Fibs) with HB2 cells and dsRed Myo1089 
cells were characterised by IHC. Little difference was observed with the knockdown of DOCK4 
protein in fibroblasts on the phenotype of HB2 units. M30 staining was largely negative in 
cultures containing EV Fibs with a small amount observed in cells on the outer periphery of 
HB2 units (arrow, a). No M30 was detected with DOCK4 shRNA Fibs (b). Collagen IV (Coll IV) 
was detected surrounding the outer edges of HB2 units with EV Fibs (arrow, c) while with 
DOCK4 shRNA Fibs, Coll IV was only detected in small points around the outside of HB2 units 
(arrows, d). Both EV Fib and DOCK4 shRNA Fib containing tri-cultures showed positive staining 
for tGFP in cells loosely distributed throughout the collagen gel (arrows, e & f), and dsRed in 
rounded cells around the outer edges of HB2 units (arrows g & h).  Original magnification 20x, 
scale bars = 100µm. Representative images from three technical replicates presented.  
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6.4.5 Confirmation of ER expression in GFP Myo1089 cells 
In order to assess ER status in GFP Myo1089 cells, immunofluorescence was carried out using 
antibodies against ERα and ERβ1 (Fig 6.10). This demonstrated that GFP Myo1089 cells are 
negative for ERα but positive for ERβ1. ERβ1 staining was detected in the cytoplasm of all cells 
and in speckles in the nuclei of ~25% of cells. This confirmed that GFP Myo1089 cells ERβ1 in 
2D. Representative images from three technical replicates presented. 
ERβ1 mRNA expression was also assessed in GFP Myo1089 cells using qPCR both in a 2D 
monolayer and a 3D mono-culture to confirm that expression of ERβ1 was retained in 3D 
culture. Results from three biological replicates presented. This demonstrated expression of 
ERβ1 in GFP Myo1089 cells when cultured in both 2D and 3D but showed a 10-fold increase in 
levels of expression when cultured in a 3D setting. This confirmed that GFP Myo1089 cells 
expressed ERβ1 in both 2D and 3D and were therefore suitable for subsequent ERβ1 
knockdown experiments. 
6.4.6 Knockdown of ERβ1 in myoepithelial cells 
GFP Myo1089 cells were treated with ERβ1 siRNA in 2D culture in order to knockdown ERβ1 
expression (Fig 6.11). Results from three biological replicates presented. Treatment with ERβ1 
siRNA caused an 8-fold decrease in the expression of ERβ1 mRNA in comparison to treatment 
with scrambled control. This confirmed the effectiveness of siRNA treatment in knocking down 
ERβ1 in these cells.  
6.4.7 Morphology and phenotype of 3D in vitro tri-culture models containing 
myoepithelial cells with or without ERβ1 expression 
In order to determine the effect of knocking down ERβ1 in myoepithelial cells on epithelial 
architecture, HB2 WT and LS11-083 dsRed Fibs were co-cultured with GFP Myo1089 cells 
treated with scrambled control (Control) or GFP Myo1089 cells treated with ERβ1 siRNA (ERβ1 
siRNA) and morphology assessed. Visualisation by H & E staining demonstrated that in the 
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presence of control or ERβ1 siRNA GFP Myo1089 cells, HB2 WT cells formed rounded units 
which consisted of cohesive cells with lumen formation in their centres (Fig 6.12). 
Representative images from three technical replicates presented. This suggested the 
knockdown of ERβ1 with siRNA in GFP Myo1089 cells had no effect on the morphology of HB2 
cell architecture.  
Similar to DOCK4 knockdown experiments, characterisation by IHC showed little difference in 
the phenotype of HB2 units cultured with control and ERβ1 siRNA GFP Myo1089 cells (Fig 6.13 
& 6.14, representative images from three technical replicates presented). With both types of 
GFP Myo1089 cells, HB2 units displayed E-Cad staining between cell junctions, EMA at apical-
lumen interface and strong Ki67 staining within HB2 cell nuclei. M30 staining was observed in 
cells around outer edges of HB2 units with both control and ERβ1 siRNA GFP Myo1089 cells 
and in the centres of units with ERβ1 siRNA GFP Myo1089 cells. Coll IV and tGFP staining was 
distributed around outer edges of HB2 units confirming basement membrane production and 
association of GFP Myo1089 cells with HB2 units. dsRed staining was observed in cells loosely 
distributed throughout the collagen gel.  
This suggested that knockdown of ERβ1 in GFP Myo1089 cells does not affect the morphology 
and phenotype of normal mammary epithelial architecture in the 3D in vitro tri-culture model 
of normal breast. 
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Fig 6.10 Confirmation of ERβ1 expression in GFP Myo1089 cells in 2D by 
immunofluorescence and comparison to expression in 3D by qPCR 
i) The ER status of GFP Myo1089 cells was analysed by immunofluorescence staining and 
visualised using Texas Red (red) with nuclei visualised using DAPI (blue). Representative images 
from three biological replicates presented. Primary antibody was omitted to serve as a 
negative control (a). All cells were negative for ERα (b) but positive for ERβ1 with staining 
observed both in the cytoplasm of all cells (green arrow, c) and in speckles in the nuclei of 
~25% of cells (inset, yellow arrow, c). Original magnification, 63x.  
ii) Taqman qPCR was used to detect ERβ1 mRNA expression in GFP Myo1089 cells cultured as a 
2D monolayer (Myo 2D) and in 3D as a mono-culture in collagen I (Myo 3D) to confirm 
expression of ERβ1. Data presented as relative expression and normalised to RPLP0 reference 
gene. Expression of ERβ1 in GFP Myo1089 cells was significantly higher upon culture in 3D in 
comparison to 2D with 3D cultures expressing 10x more ERβ1 than 2D cultures. Bars denote 
mean from three independent experiments and error bars standard error of the mean (SEM). * 
indicates significant difference following unpaired t-test (p=<0.01) 
  
i) 
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Fig 6.11 Analysis of downregulation of ERβ1 in GFP Myo1089 cells cultured in 2D by qPCR  
Taqman qPCR was used to detect ERβ1 mRNA expression in GFP Myo1089 cells cultured in 2D 
treated with a scrambled control (Myo control) and with ERβ1 siRNA (Myo ERβ1 siRNA) to 
confirm downregulation of ERβ1. Data presented as expression fold difference to scrambled 
control and normalised to RPLP0 reference gene. Expression of ERβ1 was significantly lower in 
GFP Myo1089 cells treated with ERβ1 siRNA and confirmed an 80% downregulation of ERβ1. 
Bars denote mean from three independent experiments and error bars standard error of the 
mean (SEM). * indicates significant difference following unpaired t-test (p=<0.01) 
  
* 
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Fig 6.12 Representative H & E staining of 3D in vitro tri-culture models containing 
myoepithelial cells with or without ERβ1 protein expression  
Control GFP Myo1089 cells (Control) and GFP Myo1089 cells containing ERβ1 siRNA (ERβ1 
siRNA) were co-cultured in 3D collagen gels with dsRed positive fibroblasts (dsRed Fib) and 
HB2 wildtype cells for 21 days and 5µm sections of gels H & E stained. Representative images 
from three technical replicates presented. Little difference was observed with the knockdown 
of ERβ1 protein in GFP Myo1089 cells on the morphology of HB2 units. HB2 cells formed 
cohesive rounded units (RU) with appearance of lumens (L) both in the presence of control 
GFP Myo1089 cells (a & b) and ERβ1 siRNA GFP Myo1089 cells (c & d). Original magnification 
20x, scale bars = 100µm.  
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Fig 6.13 IHC characterisation of 3D in vitro tri-culture models containing myoepithelial cells 
with or without ERβ1 protein expression A 
3D in vitro tri-culture model containing control GFP Myo1089 cells (Control) and GFP Myo1089 
cells containing ERβ1 siRNA (ERβ1 siRNA) with HB2 cells and dsRed Fibs were characterised by 
IHC. Representative images from three technical replicates presented. Little difference was 
observed with the knockdown of ERβ1 protein in GFP Myo1089 cells on the phenotype of HB2 
units. Primary antibody was omitted to serve as a negative control (a & b). E-cadherin (E-Cad) 
was expressed by HB2 cells at cell-cell junctions (arrow, c) in the presence of control (arrow, c) 
and ERβ1 siRNA GFP Myo1089 cells (arrow, d).  Strong epithelial membrane antigen (EMA) 
staining was concentrated at the apical-lumen interface in HB2 cells with both types of GFP 
Myo1089 cells (yellow arrows, e & f). HB2 cells were positive for Ki67 regardless of type of GFP 
Myo1089 cells (g & h).  Original magnification 20x, scale bars = 100µm.   
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Fig 6.14 IHC characterisation of 3D in vitro tri-culture models containing myoepithelial cells 
with or without ERβ1 protein expression B 
3D in vitro tri-culture model containing control GFP Myo1089 cells (Control) and GFP Myo1089 
cells containing ERβ1 siRNA (ERβ1 siRNA) with HB2 cells and dsRed Fibs were characterised by 
IHC. Representative images from three technical replicates presented. Little difference was 
observed with the knockdown of ERβ1 protein in GFP Myo1089 cells on the phenotype of HB2 
units. M30 staining was present on the outer periphery of HB2 units with control and ERβ1 
siRNA GFP Myo1089 cells (arrows, a & b) as well as in the centre of units containing ERβ1 
siRNA GFP Myo1089 cells (arrow, b). Collagen IV (Coll IV) was detected surrounding outer 
edges of HB2 units with control and ERβ1 siRNA GFP Myo1089 cells (arrows, c & d). Both 
control and ERβ1 siRNA GFP Myo1089 containing tri-cultures showed positive staining for tGFP 
in rounded cells around the outer edges of HB2 units (arrows, e & f), and dsRed in cells loosely 
distributed throughout the collagen gel (arrows g & h).  Original magnification 20x, scale bars = 
100µm.   
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6.4.8 Morphology of HER overexpressing HB2 cells in 3D tri-culture with 
fibroblasts pre-conditioned to SkBr3 cells 
In order to investigate whether HER2 positive tumour cells had the capacity to influence 
normal fibroblast behaviour and produce a HER2 CAF-like fibroblast population and 
subsequently disrupt epithelial architecture, attempts were made to pre-condition LS11-083 
dsRed Fibs to SkBr3 cells with the aim of inducing a HER2 CAF-like phenotype. LS11-083 dsRed 
Fibs were cultured in a range of dilutions of SkBr3 conditioned medium (from 0% to 100%) 
prior to tri-culture with HB2 WT or HB2 HER2/3OE cells (Fig 6.15). This did not affect the cell 
morphology of either HB2 WT units or HB2 HER2/3OE units in 3D tri-cultures. As per previous 
chapters, HB2 WT units retained a rounded morphology containing lumens and HB2 HER2/3OE 
units a larger, elongated morphology regardless of condition of LS11-083 dsRed Fibs used. This 
suggested that LS11-083 dsRed Fibs previously exposed to SkBr3 cells did not have the capacity 
to disrupt normal cell architecture or enhance to tumorigenicity of HER2/3 overexpressing HB2 
cells in the 3D tri-culture model.  
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Fig 6.15 Representative H & E staining of 3D in vitro tri-culture models containing HER 
protein overexpressing HB2 cells with fibroblasts with exposed to SkBr3 cell conditioned 
medium 
HB2 wildtype (HB2 WT) and HER2 and HER3 overexpressing HB2 cells (HB2 HER2/3OE) were 
co-cultured in 3D collagen gels with GFP positive Myo1089 cells (GFP Myo1089) and LS11-083 
dsRed positive fibroblasts (LS11-083 dsRed Fibs) which had been exposed to normal media 
conditions (Con), 50% SkBr3 conditioned medium (50%) or 100% SkBr3 conditioned medium 
(100%). These were cultured for 21 days and 5µm sections of gels and H & E stained. Little 
difference was observed with the prior exposure of LS11-083 dsRed Fibs to 50% and 100% 
SkBr3 conditioned medium on the morphology of HB2 units. HB2 WT cells formed cohesive 
rounded units in all fibroblast conditions (a, c & e). HB2 HER2/3OE cells formed larger more 
elongated units to HB2 WT units but these remained unchanged in the presence of fibroblasts 
exposed to SkBr3 medium (b, d & f). Original magnification 20x, scale bars = 100µm. 
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6.5 Discussion 
Having produced a novel 3D in vitro tri-culture model of normal breast that includes both a 
myoepithelial and fibroblast component, it seemed fitting that this model would be suited to 
investigating the influence of stromal cells on luminal epithelial architecture. Thus far we had 
proven the capacity of this model for cancer initiation studies in the luminal epithelium but 
stromal influence had not been addressed.  
6.5.1 The effect of DOCK4 deficient fibroblasts on 3D tri-cultures of normal breast 
We first focussed on the fibroblast component of our tri-culture model. Little is known about 
the function of DOCK4 in the breast. However, DOCK proteins are well known to influence cell 
migration [395] and since fibroblasts are highly migratory in nature [436-439] we hypothesised 
that DOCK4 deficient fibroblasts would differ in their ability to interact with the breast 
epithelium and may induce changes in breast epithelial architecture in our model.  
RNA interference (RNAi) is a widely accepted tool to downregulate proteins of interest within a 
cell. By delivering double stranded RNA sequences identical to the RNA sequence of a target 
protein, target mRNA is degraded by RISC complexes preventing translation of target mRNA 
and downregulating the protein [440]. Two RNAi approaches can be taken: siRNAs into the 
cytoplasm or, for stable downregulation, transduction of the cell with a virus containing a 
target shRNA which is synthesised by the cell and processed in the cytoplasm providing a 
continuous source of siRNAs against a target [441]. 
First we confirmed the expression of DOCK4 in the majority of fibroblasts in the original tissue 
specimen. Following confirmation that our control empty vector lentivirus had no effect on the 
levels of DOCK4 expression in our fibroblasts in culture, we applied the concept of shRNA-
mediated knockdown of DOCK4 in our LS11-045 hTERT fibroblasts via stable transduction with 
lentiviral vectors containing two different shRNA sequences. We successfully identified an 
effective shRNA construct against DOCK4 and produced a LS11-045 hTERT fibroblast cell 
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population with a significantly reduced level of DOCK4 protein expression as assessed by 
western blot. In addition, the pGIPZ lentiviral vectors (as described in Chapter 3) contained a 
tGFP fluorescent reporter allowing us to track these DOCK4 shRNA fibroblasts in culture. In 
order to distinguish these from Myo1089 cells and HB2 cells in the 3D tri-culture model, 
Myo1089 cells were transduced with pFURW-dsRed virus.  
Incorporation of DOCK4 shRNA fibroblasts into our 3D tri-culture model did not affect the 
normal architecture of HB2 cells and dsRed Myo1089 cells. Morphology of HB2 units 
demonstrated retention of a rounded shape with clear lumen formation regardless of DOCK4 
knockdown in fibroblasts. This was reflected in their characterisation whereby both these tri-
cultures exhibited the same phenotype analogous to the normal HB2 tri-culture phenotype 
observed in previous chapters when examined by IHC.  
DOCK4 functions by activating the Rho GTPase Rac1 and inducing migration through the 
formation of actin stress fibres and lamellipodia. Knockdown of DOCK4 in NIH3T3 fibroblasts 
caused a reduction in migration [403]. The lack of altered phenotype of HB2 units in our 
culture system with DOCK4 shRNA fibroblasts may suggest that cell migration of fibroblasts is 
not required to mediate their effects on the epithelium.  It is feasible that the production of 
growth factors and paracrine signalling by fibroblasts is not affected by their ability to migrate. 
It has been reported that fibroblast conditioned media can substitute for the use of fibroblasts 
in culture [219] supporting the theory that fibroblasts regulate epithelial cell behaviour via 
paracrine signalling as opposed to cell-cell contact. In addition, little cell contact was observed 
between fibroblasts and epithelial units within all our tri-cultures which could support this 
theory.  
Another possible explanation for the lack of effect of DOCK4 knockdown in fibroblasts on 
epithelial cell behaviour is that cell migration was not affected.  Despite work by Hiramoto et al 
[403] showing a reduction of cell migration in NIH3T3 fibroblasts, it is possible that migration 
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of our fibroblasts was not affected by knockdown of DOCK4. Recent work by Petrie et al [442] 
has demonstrated that human foetal fibroblasts do not require downstream Rac and Cdc42 to 
migrate. In this study, fibroblasts migrated via novel lobopodia structures which did not 
accumulate active Rac and Cdc42. Interestingly, these lobopodia structures were the 
predominant protrusion structure in fibroblasts cultured in 3D collagen matrix whereas the 
more commonly reported lamellipodia were predominant in 2D culture. This could offer an 
explanation for the lack of response to DOCK4 knockdown in our fibroblasts but would need 
further experimentation to validate this theory. The work by Petrie et al was carried out in 
human foetal fibroblasts and which had been exposed to a mouse dermal microenvironment 
so may not be applicable to breast. Nevertheless, a difference in behaviour of fibroblasts in 3D 
opposed to 2D culture could account for the lack of phenotype observed in our experiments. 
Though not here, the migratory capacity of these fibroblasts in 2D and 3D culture via real-time 
imaging and the examination of the growth factors they produce via proteomic techniques 
could provide answers to these questions.  
6.5.2 The effect of ERβ1 deficient myoepithelial cells on 3D tri-cultures of normal 
breast 
We then focussed on the myoepithelial component of our model. As discussed previously, 
both myoepithelial cells and ERβ have a suspected tumour suppressor role in breast cancer 
due to their loss in the transition from DCIS to invasive cancer. We therefore postulated that 
the tumour suppressive nature of myoepithelial cells is reliant on ERβ expression.  
To address this, ERβ1 was chosen as a representative of ERβ activity in these cells. ERβ1 is the 
only ERβ isoform capable of binding ligand [414]. Since we demonstrated that GFP Myo1089 
cells are ERα negative, we reasoned that ERβ could not heterodimerise with ERα. Therefore, 
ERβ signalling would be reliant on heterodimerization with ERβ1 [415]. Consequently, by 
removing ERβ1 expression, the overall effects of ERβ would be downregulated. Due to the fact 
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that this cell line was immortalised with vectors containing resistance genes for hygromycin 
and neomycin [181] and also contain an empty vector containing puromycin resistance gene 
[personal communication, Dr Mike Allen, Barts Cancer Institute] as well as our tGFP 
fluorescence reporter gene, we reasoned that stable knockdown of ERβ1 with a virus vector 
would not have been easily achieved due to inability to select positive clones. We therefore 
applied the concept of siRNA mediated knockdown of ERβ1 in GFP Myo1089 cells. After 
confirming the expression of ERβ1 in GFP Myo1089 cells in both 2D and 3D, using a pool of two 
different siRNA sequence oligonucleotides against ERβ1, we successfully downregulated ERβ1 
expression by ~80% as assessed by qPCR.  
Similar to results using DOCK4 shRNA fibroblasts, incorporation of ERβ1 siRNA GFP Myo1089 
cells into our 3D tri-culture model did not affect the normal architecture of HB2 cells cultured 
with dsRed fibroblasts. Rounded HB2 units with lumen formation were retained regardless of 
ERβ1 siRNA. Characterisation of both tri-cultures demonstrated no change in phenotype of 
HB2 units when examined by IHC. In addition, downregulation of ERβ1 did not appear to 
change the apoptotic or proliferative nature of GFP Myo1089 cells or their localisation around 
the outside of HB2 units.  
Though it could be construed from these results that ERβ1 is not required for normal GFP 
Myo1089 activity in our tri-culture model, there were caveats with this experiment.  Perhaps 
the major limitation was the use of siRNAs for this experiment. Knockdown of a target using 
siRNAs is a transient process with a maximum duration of silencing of 10 days [443]. Given that 
the 3D tri-culture models were analysed after 21 days in culture, it is possible that ERβ1 
signalling gradually resumed following 10 days in culture and resulted in no alterations of 
epithelial architecture observed at time of analysis. The appearance of rounded HB2 structures 
following seven days in culture [see chapter 3] suggests that epithelial structures are formed in 
the early stages of 3D culture and then retained. This indicates that these structures are not 
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the result of a dynamic rearrangement of cells throughout the length of time in culture. For 
this reason, it is likely that the knockdown of ERβ1 in GFP Myo1089 cells coincided with the 
arrangement of epithelial structures in the early stages of culture. This suggests that ERβ1 did 
not impair the ability of GFP Myo1089 cells in regulating luminal epithelial cell arrangement. 
However, examination of these structures via real-time imaging would be required to confirm 
this theory.  
Another caveat with this experiment is that we could not confirm a knockdown of ERβ1 
protein expression. Though we showed an 80% knockdown of ERβ1 mRNA expression in GFP 
Myo1089 cells by qPCR,  the method of qPCR does not directly correlate with protein 
expression and only accounts for gene expression [444]. Knockdown of ERβ1 protein 
expression could not be confirmed due to lack of antibodies suitable for western blotting. In 
addition, since we demonstrated a 10-fold increase in ERβ1 expression in 3D culture compared 
to 2D it is possible that the siRNAs which proved adequate for the knockdown of ERβ1 in 2D 
were not sufficient to knockdown ERβ1 in 3D culture. For both these reasons it is therefore 
conceivable that there was insufficient knockdown of ERβ1 protein expression in GFP 
Myo1089 cells when cultured in 3D.  
6.5.3 The effect of pre-conditioning normal fibroblasts to SkBr3 cells on 3D tri-
cultures of normal breast 
The cross-talk between stromal fibroblasts and tumour epithelial cells is a well-documented 
and widely accepted concept [445, 446]. However, the origin of CAFs is poorly understood. It is 
currently unknown whether a) established tumour cells signal to normal stromal cells and 
induce activation of the stroma, or b) stromal cells first undergo changes in phenotype which 
subsequently trigger pro-tumorigenic responses in the epithelium.  
As a follow up to previous chapters, we attempted to investigate whether HER2 positive 
tumour cells had the capacity to influence normal fibroblast behaviour and produce a HER2 
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CAF-like fibroblast population. Since CAFs are proven to induce EMT in normal and tumorigenic 
breast epithelium [303], we predicted that if we were successful in inducing a HER2 CAF-like 
phenotype in our normal fibroblasts, that these would alter epithelial cell architecture in our 
normal 3D tri-culture model.  
SkBr3 cells are a breast cancer cell line proven to overexpress HER2 protein and are therefore 
commonly used as a representative of the HER2 sub-group of breast cancers [135]. As 
mentioned, conditioned media is used as a substitute for direct cell culture in vitro [447].  In an 
attempt to produce a HER2 CAF-like population, we cultured LS11-083 dsRed Fibs in SkBr3 
conditioned medium prior to incorporation into our 3D tri-culture models. Different dilutions 
of SkBr3 conditioned medium were used ranging from 0% (normal medium) to 100%. The 
morphology of both HB2 WT and HB2 HER2/3OE tri-culture models were unchanged upon 
culture with LS11-083 dsRed Fibs pre-exposed to all concentrations of SkBr3 conditioned 
medium.  
It is tempting to conclude that SkBr3 cells were incapable of altering the phenotype of normal 
fibroblasts and that these were therefore unable to disrupt luminal epithelial architecture. 
However, like the ERβ1 siRNA experiments, there were several limitations with this 
experiment. 
Since signal transduction via growth factors is known to be a rapid process, in this study 
fibroblasts were pre-cultured in SkBr3 medium for 24 hours prior to incorporation into 3D 
culture. It is possible that 24 hours in conditioned medium was not sufficient to induce any 
lasting changes in our normal fibroblasts. This also assumed that all proteins released by SkBr3 
cells likely to induce changes in our fibroblasts were growth factors. Several non-growth factor 
proteins have been identified through cancer cell secretome studies which may affect 
fibroblast behaviour [448, 449]. These require prolonged culture to elicit their effects. In 
addition, although morphology of the fibroblasts was assessed and found to be unaltered, 
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phenotype was not characterised following pre-culture in SkBr3 conditioned medium and prior 
to 3D culture. For this reason we cannot establish whether a different phenotype was induced 
by culture in SkBr3 conditioned medium.  
Since the conditioned medium produced from SkBr3 cells was not analysed proteomically, we 
also cannot be certain that there were sufficient proteins and factors present in the medium to 
induce a change or, if they were present, whether they correlated with known factors secreted 
by HER2 tumour cells [275, 450, 451].  
This experiment also assumed that the tumour cells are solely responsible for inducing an 
activated phenotype of fibroblasts. Since inflammatory cells are a critical component of 
tumour progression not accounted for in our study [452], it is likely that this is not the case and 
that a more complex environment is required for normal fibroblast activation. It is clear that 
conclusions cannot be made from this investigation. One way to overcome this would be to 
use fibroblasts originally isolated from HER2 overexpressing patient tumours.  
6.5.4 Summary 
Despite the lack of success in producing a different phenotype of HB2 cells in the 3D tri-
cultures with these experiments, we have established that the model shows great promise in 
the study of stromal components of the normal breast. We have shown that in addition to 
luminal epithelial cells, the stromal cells in this model are amenable to genetic engineering and 
given the right application, could help elucidate the role of stromal cells in cancer initiation.  
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7 Chapter 7: Final Discussion 
7.1 Thesis Summary 
Current available 3D in vitro models of normal breast tissue lack key components that 
contribute to normal breast architecture and function such as collagen I ECM and 
myoepithelial cells. These typically contain either one or at most two different cell types and 
although show some similarity to normal breast acini, do not accurately reflect normal in vivo 
breast architecture. 
The aim of this thesis was to address this by developing a new organotypic 3D in vitro model of 
normal breast tissue that contained three of the major functional cell types of the mammary 
gland, luminal epithelium, myoepithelium and stromal fibroblasts, in a physiologically relevant 
collagen I matrix. In Chapter 3, we first attempted to achieve this with the commonly used 
MCF10A cell line as a representative of luminal epithelium. Despite the success of other 
researchers in producing acini-like structures with these cells in both Matrigel and collagen 
matrices [154, 190, 201], we found that in culture with our myoepithelial cell representative 
(Myo1089) in collagen I that MCF10A cells had a mixed luminal/basal phenotype. This has been 
reported in 2D culture [180, 220, 221] and we therefore deemed these cells unsuitable for this 
purpose. However, following a series of optimisation steps, we were successful in producing a 
3D in vitro model using HB2 cells as the representative luminal epithelium. This model 
contained HB2 cells with Myo1089 cells and normal breast reduction mammoplasty fibroblasts 
(isolated and transduced with hTERT in house) and was therefore the first model of its kind to 
include all three of these components in collagen I. We found that this model accurately 
reflected acini in vivo in both morphology and phenotype when we compared to a breast 
reduction mammoplasty specimen. Through experiments in subsequent chapters, we 
demonstrated that these morphological and phenotypical features were reproducible proving 
that the model is not only representative of normal breast, but is robust. This robustness 
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coupled with the proven ability to track different cell types by standard histological techniques 
and quantify any observations and changes in architecture means this model may prove a 
valuable tool to other researchers.  
In order to prove whether our model was suitable for use as a tool to study cancer initiation, in 
Chapter 4 we selected the protein HER2 as a candidate to test this theory. HER2 is 
overexpressed in the luminal epithelium of approximately 16% of breast cancers [260] and 
approximately 50% of cases of DCIS [262]. The stable overexpression of HER2 within HB2 cells 
of our model resulted in dramatic disruption of the normal architecture with increased 
branching and protrusions, discohesive HB2 cells and loss of lumen formation. These also 
showed remarkable resemblance to DCIS in vivo validating that our model was indeed suitable 
for cancer initiation studies and capable of mimicking early lesions of breast in a physiologically 
relevant context.  
In order to reinforce the importance of including myoepithelial cells and fibroblasts in the 
study of cancer initiation and that the effects of oncogenic events are context dependent, we 
also set up 3D models of HER overexpressing HB2 cells in mono-culture, in dual-culture with 
myoepithelial cells or dual culture with fibroblasts. We found that our HER overexpressing 
mono-culture model correlated with MCF10A and HB2 mono-culture models reported in the 
literature [274-276], with the HER2-HER3 heterodimer having the most disruptive effect [453]. 
However, culture of these same cells with myoepithelial cells resulted in the formation of very 
different structures with myoepithelial cells having a “containment” or tumour suppressive 
effect. In contrast, dual-culture with fibroblasts had the opposite effect with structures 
appearing much larger and disordered. These experiments emphasised luminal epithelial 
organisation is maintained by a delicate balance between the opposing functions of fibroblasts 
and myoepithelial cells and that the presence of both is vital when interpreting the effects of a 
genetic insult or oncogenic event on luminal cell transformation.  
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One unexpected finding from these experiments was that overexpression of both HER2 and 
HER3 in our tri-culture model did not have the most disruptive effect on normal architecture. 
As mentioned, reports in the literature suggest that the HER2-HER3 heterodimer is the most 
potent heterodimer of the HER family [453]. To determine if our observations were due to a 
deficiency in endogenous heregulin ligand in our cultures or if our HB2 cells did not respond to 
HER2-HER3 overexpression as expected, in Chapter 5 we conducted stimulation experiments 
with heregulin and assessed the effects on our tri-culture model and the intracellular signalling 
pathways activated within these cells. We found that heregulin caused increased disruption of 
the architecture of our model. In addition, we demonstrated that HER2-HER3 overexpressing 
HB2 cells had increased activation of Akt and MAPK pathways as well as a subset of phospho-
kinases related to cell adhesion/migration which was increased in response to heregulin 
correlating with published data [339, 362]. Therefore, HER2-HER3 overexpression in our HB2 
cells was effective and caused activation of reported downstream signalling pathways. We 
concluded that the lack of the expected morphology of these cells in our 3D model is likely due 
to the culture context explaining why these results did not correlate mono-culture models 
published in the literature. Perhaps in a more physiologically relevant context, HER2-HER3 
overexpression alone is not sufficient to completely transform/induce aberrant architecture of 
luminal epithelium and requires an excess of ligand. This further stressed the importance of an 
appropriate microenvironment  
However, one of the biggest strengths of a tri-culture model such as this is the ability to study 
the role of stromal cells on cancer initiation. In Chapter 6, we attempted to prove this by 
selecting DOCK4 and ERβ1 to study in the fibroblasts and myoepithelial cells (respectively) and 
examining their effect on luminal epithelial architecture/phenotype. The function of DOCK4 is 
currently unknown in fibroblasts of both the normal breast and breast cancer but has been 
linked to invasion and migration in breast cancer [402]. Unpublished preliminary work by our 
collaborators has shown that DOCK4 expression is heterogeneous and may be linked to 
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increased acquisition of ECM. ERβ1 is reported to be a tumour suppressor [424, 425, 427, 428, 
454]. Like myoepithelial cells [431] it is lost in the transition from DCIS to invasive breast 
cancer [430] but whether these two events are connected and influence tumorigenesis are 
unclear. Neither the downregulation of DOCK4 in fibroblasts or ERβ1 in myoepithelial cells of 
our model had any effect on the morphology and phenotype of the luminal epithelium 
indicating that these proteins do not play a role in breast cancer initiation at least under the 
conditions of these experiments. In addition, we wanted to assess whether paracrine factors 
released from established HER2 overexpressing tumour cells had the power to alter normal 
fibroblast phenotype. To see if these fibroblasts could then go on to influence the normal 
epithelium and initiate transformation, fibroblasts were “conditioned” to SkBr3 media prior to 
culture in the normal 3D model. We also found this had no effect on the morphology and 
phenotype of the luminal epithelium indicating that paracrine factors from SkBr3 cells did not 
modify fibroblasts and if they did, were not potent enough to change their behaviour in our 
normal 3D model.  
Nevertheless, the work from this thesis addresses topical areas in the breast cancer field. A 
recent review was undertaken by more than 100 internationally recognised breast cancer 
scientists, clinicians and healthcare professionals to identify current gaps in knowledge in 
breast cancer research. Two of the key areas recognised were; the need to better understand 
the changes that occur in the normal breast that result in tumorigenesis and, the need to 
develop better 3D culture models that incorporate stromal components, are heterotypic and 
that accurately reflect physiological in vivo conditions [167]. This thesis has addressed both 
these concepts. 
7.2 Comparison of the model to other pre-clinical models of breast 
Due to the complexity and heterogeneity of breast tissue and breast cancer there is no single 
model that can fully recapitulate all aspects of the breast microenvironment. The model 
261 
 
presented in this thesis offers an improvement to 2D in vitro culture providing a more 
biologically relevant in vivo-like 3D environment. 2D in vitro cultures lack appropriate polarity 
and extracellular cues that regulate in vivo architecture [136]. This novel 3D model also allows 
the interaction between three different cell types to be studied which cannot be achieved in 
2D culture. However, 3D culture in this manner does not allow for easy dissection of complex 
intracellular signalling pathways and molecular biological processes which can be easily 
achieved with 2D cultures.  
It is clear that the inclusion of myoepithelial cells and the use of collagen I in this model offer 
an improvement to current 3D in vitro models of normal breast as it is more reminiscent of in 
vivo breast. In addition, this model, like others, demonstrated lumen and basement membrane 
formation and polarisation. It was also proven that the structures formed could be quantified 
and phenotype analysed easily by IHC. However, unlike other models, due to the use of 
collagen I, the multicellular structures cannot be analysed easily by immunofluorescence 
techniques, nor can they be subjected to biochemical analysis using subsequent RNA, DNA, 
protein extraction easily as mono-culture spheroids/3D in vitro models can [455].  
Until the advent of 3D in vitro culture, animal models, typically mouse xenograft or genetically 
engineered mice (GEM), were the only method available to study cell interactions and 
behaviour in an in vivo environment. These have been vital in the discovery and development 
of new drug therapies [456-459]. However, it has been reported that mouse and human 
physiology differ [460] with the tumours produced in GEM models often not representative of 
human breast tumours [255]. In addition, mouse models are expensive, labour intensive and 
time consuming to produce. The 3D model presented here offers an alternative with the ability 
to study cell interactions and behaviour in a human in vivo-like environment. The model has 
the potential to study tumour progression akin to xenograft models by incorporating tumour 
epithelial cells as well as cancer initiation via oncogene manipulation similar to GEM models. 
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What’s more, this model is inexpensive, easy to set up and to genetically manipulate and 
requires no specialist equipment or expertise while maintaining a degree of multicellularity 
and in vivo architecture. However, unlike mouse models, our model does not incorporate a 
blood supply [461], adipose tissue [462, 463], or an immune system [464, 465] which are all 
factors known to influence tumour progression and metastasis.  
The model presented in this thesis offers an improvement on current 2D and 3D in vitro 
models of normal breast in that it is more representative of human breast tissue and can 
recapitulate the morphological and phenotypical features achieved with other available in vitro 
models. Also, this model may offer an alternative to the use of expensive and time-consuming 
mouse models in the study of breast cancer initiation and progression in an in vivo-like 
environment. However, this model cannot be used to address all scientific questions such as 
the influence of vascularisation, adipose tissue and an immune system on tumour initiation 
and progression nor can it be used to dissect intricate intracellular events in these processes. 
Therefore, it is clear that while this model can be used to address a number of scientific 
questions, a variety of different pre-clinical models still need to be adopted to fully understand 
breast tumours and their heterogeneity.   
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7.3 Limitations and solutions  
7.3.1 The 3D model 
Although our model is an improvement on the current normal in vitro models of breast 
available, it still does not fully recapitulate in vivo stromal architecture. Recent studies have 
proposed that adipocytes (referred to as cancer associated adipocytes) have the capacity to 
induce breast tumour development and progression through reverting back to a fibroblast-like 
phenotype and releasing proteases, MMPs and cytokines [239, 466]. In addition, immune cells 
[237] and vascular endothelial cells [234, 467] have long been acknowledged to induce breast 
tumour development and progression. Although adipocytes [212] and endothelial cells [468, 
469] have been included in normal MCF10A 3D cultures by other researchers, these have 
generally omitted myoepithelial cells which we have proven play an integral role in 
maintaining epithelial architecture. Inclusion of one or both of these cell types in our model 
would further capture the complexity of in vivo breast and provide a more accurate platform 
for cancer initiation studies. However, optimising culture conditions to retain in vivo-like 
characteristics of each cell type in such a model would be challenging. Tracking each of these 
cell types in culture would be difficult due to limited colours of fluorescent proteins available 
and difficulties in imaging discussed in Chapter 1.  
The expression of fluorescent proteins by the cells in our model gives the opportunity to 
observe how cells migrate within these gels and how they interact with each other and may be 
useful for comparative analysis in addition to quantification of structures. This was not 
addressed in our study but would require sophisticated equipment to allow live cell real time 
imaging for up to three weeks. Issues with background fluorescence of collagen would also 
need to be overcome [170]. Use of a well-equipped multiphoton microscope could aid in this 
process [171].  
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Although we have produced a 3D model of normal breast tissue in this study, the methods of 
analysis have not allowed visualisation of the model in 3D. For example, it would be useful to 
determine if the structures in the model are a branching network of duct-like structures which 
could be an indicator of how well these structures represent normal ductal/acini epithelium. 
This could be achieved through digital reconstruction of H & E stained serial sections of our 
gels, an area which our department has expertise and which is currently being investigated 
[470]. Previous work in our group has demonstrated the value of 3D reconstructions of DCIS in 
vivo breast tissue [paper in preparation by Booth et al], and is a method which could be 
applied to the model. 
7.3.2 Analysis of cancer initiation 
Another area of this work that could be improved is the analysis of epithelial structures 
following genetic manipulation. Following overexpression of HER proteins in the model, 
although morphological changes indicative of increased cell migration/invasion were observed, 
with the exception of E-cadherin, specific markers for these processes were not examined by 
IHC. Although loss of E-cadherin has been associated with EMT and invasion in breast cancer 
[471, 472], this was not observed in this study, however, it has recently been proposed that 
this may not be vital for EMT [473]. This same study highlighted caveolin-1 as an excellent 
marker for EMT. In addition, markers such as N-cadherin and fibronectin-1 have proven 
successful in identifying cells undergoing EMT for other researchers using 3D-cultures [276] 
and may prove better markers for analysing the models.  
In addition, throughout this study, EMA was used as a marker of “polarity” due to its 
localisation at the apical membrane of luminal epithelial cells in normal breast tissue. 
However, EMA is not a specific marker of polarity and proved difficult to interpret due to its 
strong staining in HER overexpressing cultures. Desmosomal and tight junction proteins may 
prove more suitable markers of epithelial cell polarity [16, 474].  
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One limitation of the model is that biochemical analysis is challenging making quantification of 
gene/protein expression difficult. Separating cells from the surrounding ECM is problematic 
[168]. Enzymatic digestion using collagenase is an option but could be damaging to cells and 
induce changes in phenotype [432]. Although IHC quantification could offer an alternative, this 
introduces variability in staining intensity both intra- and inter-laboratory as well as between 
specimens [475]. This could be overcome to some extent by using laser capture 
microdissection. This would allow changes in gene expression to be detected and quantified 
[476]. However, this could not be applied to protein expression due to protein degradation 
through fixing and H & E staining of gel sections. 
Although heregulin signalling experiments in Chapter 5 suggested that HER2-HER3 
overexpression activates signalling pathways involved in cell migration, these experiments 
were crude as they were performed in 2D rather than 3D with an insufficient number of 
biological replicates. As discussed in Chapter 1, the phenotype of cells cultured in 2D may 
differ from those in 3D. We were also unable to validate the activation of these kinases with 
subsequent biological replicates and western blotting to determine if migration was affected. 
Activation of these kinases would need to be examined by IHC in our 3D tri-culture model to 
determine if they are conserved in a physiologically relevant context. Live real-time cell 
imaging could prove beneficial in clarifying this. 
7.4 Role of stromal cells on cancer initiation 
Despite the obvious advantages of having both myoepithelial cells and fibroblasts in our 
model, we could not definitively conclude that the model can be used to study the role of 
stroma in cancer initiation. As mentioned above, Caveolin-1 is a robust marker for EMT and 
has also been shown in our laboratory as well as by other research groups to be lost in the 
transition from normal to invasive breast cancer [477-479]. However, the effect of 
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downregulation on normal epithelial architecture and breast cancer initiation is unknown and 
may prove a better candidate than DOCK4 to focus on in the fibroblasts of our model.  
However, interesting findings were observed in Chapter 4 whereby HER overexpressing HB2 
cells were dual-cultured with normal fibroblasts. We demonstrated a loss of fibroblasts upon 
co-culture with HER2 or HER3 overexpressing HB2 cells coupled with a dramatic increase in 
size and change in morphology of HB2 cell units. This may correlate with findings by Professor 
Michael Lisanti’s group who found that tumour epithelial cells have the capacity to induce 
aerobic glycolysis and ultimately cell death of fibroblasts, referred to as the “Reverse Warburg” 
effect [294]. The use of markers such as MCT4 [309] at various time points over three weeks 
may prove valuable in elucidating if this  occurs in our model.  
As discussed in Chapter 6, the use of siRNA to downregulate ERβ1 in myoepithelial cells was 
not an appropriate technique for our model as siRNAs are only effective for a maximum of 10 
days and our model is cultured for three weeks. The use of stable shRNA vectors against ERβ1 
would be a more appropriate method of downregulation and may help determine if there is a 
link between the tumour suppressive functions of ERβ1 and myoepithelial cells. Recently, α5β6 
integrin has been identified to be upregulated in DCIS which could prove a successful 
alternative protein candidate to study in our myoepithelial cells [480].  
Due to lack of available HER2 positive breast tumour tissue samples, we were unable to culture 
HER2 CAFs in the model which would have been the ideal alternative to our experiments using 
fibroblasts conditioned with SkBr3 conditioned media. Experiments examining the effects of 
CAFs on normal mammary epithelia have so far been conducted in simple mono- or dual 
cultures. Our model would provide an ideal platform for these experiments and may help 
determine what are the initiating steps in tumorigenesis, changes in fibroblasts that signal to 
normal epithelium resulting in cell transformation, or established transformed epithelial cells 
induce changes in the fibroblasts that feed the epithelium and promote tumorigenesis.  
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7.5 Future Work 
This series of experiments has demonstrated that accurate models of normal breast tissue in 
3D can be achieved in the laboratory without the need for complex equipment or expensive 
reagents. This work could lead to patient benefit through various mechanisms and may not be 
restricted to breast cancer research.  
Current UK government initiatives such as the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (NC3Rs) aims to drive innovation of new 
techniques that will lead to the reduction or replacement of using animals in research [481]. 
Given that the work in this thesis offers a new model that accurately recapitulates the in vivo 
breast environment, this could go some way to reducing the amount of mouse models needed 
for research.  Many of the genetic, protein and drug compound candidates for cancer research 
are discovered through experimentation in 2D in vitro environment that does not accurately 
reflect human tissue, excluding important surrounding cell types. Subsequently, these 
candidates are applied to mouse models with many proving unsuccessful in generating viable 
drug therapies for patient benefit. Models such as the one developed here could provide an 
intermediate to test the effectiveness and appropriate targeting of drugs saving unnecessary 
use of animals and expenditure.  
The model also has the potential for incorporating primary patient cells. This could prove 
valuable for both scientific research and understanding of biological processes, as well as 
direct patient benefit. The study of normal human breast at different developmental and 
hormonal stages is currently unexplored. By incorporating primary cells from breast reduction 
mammoplasties taken from patients of different age and status, we could gain a better 
understanding of the biological processes that occur in normal breast which may prove key in 
the understanding of cancer initiation. This coupled with use of primary patient cells extracted 
from a variety of different tumour types could further understanding of the heterogeneity of 
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both normal breast tissue and breast tumours. The availability of good quality normal [482] 
and breast tumour [483] tissues from specialist breast tissue banks can facilitate this process. 
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